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The work described in this dissertation was initiated in 2008, shortly after the discovery 
of Merkel cell polyomavirus (MCV). MCV was discovered as clonally integrated in 80% 
of Merkel cell carcinoma (MCC) and tumor-derived viral genomes were found to harbor 
individual large T antigen (LT) truncating deletions. The work presented in this thesis 
focuses on two main features associated with MCV cell biology: (1) Viral replication 
requirements that promote viral origin replication in the context of full length MCV LT 
(chapter 3) and (2) cellular targets that enhance human fibroblast proliferation in the 
presence of tumor-derived full length LT (chapter 4). As part of these studies, the novel 
MCV-positive MCC cell line MS-1 was generated, and its cellular and viral features are 
presented here (chapter 2). MCC cell lines are useful tools that can be used to study 
MCV biology, and test therapeutic compounds in vitro, as well as in a xenograft setting 
in vivo as described in the appendix of this thesis. Within the past 6 years, 8 new human 
polyomaviruses have been identified through basic biological approaches, highlighting 
the possibility that other human malignancies may be associated with polyomaviral 
infections. The identification of MCV in association with an aggressive human cancer 
also underscores the relevance of basic research in understanding human disease. 
 
 
IN VITRO ANALYSES OF MERKEL CELL POLYOMAVIRUS CELL BIOLOGY 
Anna Guastafierro 
University of Pittsburgh, 2013
 
 v 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS .............................................................................................. XVI 
1.0 INTRODUCTION ..................................................................................................... 1 
1.1 VIRUSES AND CANCER ................................................................................ 1 
1.1.1 History of tumor viruses ..................................................................... 1 
1.1.2 Viruses and human cancer ................................................................. 2 
1.2 POLYOMAVIRUS BIOLOGY ......................................................................... 11 
1.2.1 History and phylogeny ...................................................................... 11 
1.2.2 Association with human cancer ....................................................... 12 
1.2.3 Human polyomaviruses .................................................................... 13 
1.2.4 Genome organization ........................................................................ 19 
1.2.5 Viral life cycle ..................................................................................... 21 
1.2.6 Permissive vs. non-permissive infection ........................................ 23 
1.2.7 Cell transformation assays ............................................................... 25 
1.2.7.1 Loss of contact inhibition ...................................................... 26 
1.2.7.2 Immortalization ........................................................................ 26 
1.2.7.3 Anchorage-independent growth ............................................ 27 
1.2.7.4 Growth under nutrient deprivation ........................................ 27 
1.2.7.5 Tumor formation in animal hosts .......................................... 27 
 vi 
1.3 SV40 EARLY REGION .................................................................................. 29 
1.3.1 SV40 T antigen interactions with cellular proteins ......................... 29 
1.3.1.1 SV40 LT interaction with Rb family ....................................... 29 
1.3.1.2 SV40 LT interaction with p53 ................................................. 30 
1.3.1.3 Other SV40 LT cellular targets ............................................... 33 
1.3.1.4 SV40 sT .................................................................................... 38 
1.3.2 SV40 transgenic mouse models ....................................................... 40 
1.4 MERKEL CELL CARCINOMA ...................................................................... 43 
1.4.1 Origin and pathology ......................................................................... 43 
1.4.2 Incidence and clinical manifestation ............................................... 44 
1.4.3 Treatment ........................................................................................... 46 
1.4.4 Molecular features ............................................................................. 46 
1.5 MERKEL CELL POLYOMAVIRUS ................................................................ 49 
1.5.1 Discovery of MCV .............................................................................. 49 
1.5.2 MCV genome organization ................................................................ 51 
1.5.3 Large T antigen truncations in MCC tumors ................................... 53 
1.5.4 MCV genome copy number and integration ................................... 55 
1.5.5 MCV Serology and transmission ...................................................... 56 
1.5.6 T antigen expression in MCC ........................................................... 58 
1.5.7 MCV T antigen interactions with cellular proteins ......................... 59 
1.5.8 Cellular transformation by MCV T antigens .................................... 61 
1.5.9 Evidence for causality ....................................................................... 63 
 vii 
2.0 CHARACTERIZATION OF AN EARLY PASSAGE MERKEL CELL 
POLYOMAVIRUS-POSITIVE MERKEL CELL CARCINOMA CELL LINE, MS-1, AND 
ITS GROWTH IN NOD SCID GAMMA MICE ................................................................ 65 
2.1 INTRODUCTION ............................................................................................ 67 
2.2 MATERIALS AND METHODS ....................................................................... 69 
2.2.1 Preparation of tumor biopsy and cell culture conditions .............. 69 
2.2.2 Real time quantitative PCR ............................................................... 69 
2.2.3 MCV genome sequencing ................................................................. 70 
2.2.4 Phage library screen of MCV integration site ................................. 71 
2.2.5 RACE analysis ................................................................................... 71 
2.2.6 Southern blot ..................................................................................... 72 
2.2.7 Immunoblotting .................................................................................. 72 
2.2.8 Xenograft model ................................................................................ 73 
2.2.9 Immunohistochemistry ..................................................................... 73 
2.3 RESULTS ....................................................................................................... 75 
2.3.1 MS-1 cell culture morphology and immunohistochemistry .......... 75 
2.3.2 MCV status ......................................................................................... 77 
2.3.3 T antigen truncations and corresponding protein sizes ................ 79 
2.3.4 Viral genome integration site ........................................................... 82 
2.3.5 Tumorigenicity of MS-1 cells in vivo ................................................ 83 
2.4 DISCUSSION ................................................................................................. 85 
 viii 
3.0 THE MINIMUM REPLICATION ORIGIN OF MERKEL CELL POLYOMAVIRUS 
HAS A UNIQUE LARGE T-ANTIGEN LOADING ARCHITECTURE AND REQUIRES 
SMALL T-ANTIGEN EXPRESSION FOR OPTIMAL REPLICATION ........................... 91 
3.1 INTRODUCTION ............................................................................................ 93 
3.2 MATERIALS AND METHODS ....................................................................... 96 
3.2.1 Plasmids ............................................................................................. 96 
3.2.2 Generation of Antibodies .................................................................. 97 
3.2.3 MCV origin replication assay ............................................................ 97 
3.2.4 Immunoprecipitation ......................................................................... 98 
3.2.5 shRNA knockdown ............................................................................ 99 
3.2.6 Chromatin immunoprecipitation (ChIP) ........................................... 99 
3.2.7 Molecular modeling ......................................................................... 100 
3.3 RESULTS ..................................................................................................... 101 
3.3.1 The minimum MCV replication origin is defined by a 71 nucleotide 
genomic region ............................................................................................ 101 
3.3.2 Pentanucleotide requirements for MCV replication. .................... 105 
3.3.3 Effects of Tumor-derived LT mutations on origin binding and 
replication .................................................................................................... 109 
Other factors influencing MCV replication ............................................... 110 
3.4 DISCUSSION ............................................................................................... 115 
 
 
 ix 
4.0 MERKEL CELL CARCINOMA-DERIVED MERKEL CELL POLYOMAVIRUS T 
ANTIGEN INDUCES HUMAN CELL PROLIFERATION THROUGH ITS RB 
TARGETING DOMAIN BUT IS INSUFFICIENT TO TRANSFORM HUMAN 
FIBROBLASTS ............................................................................................................ 119 
4.1 INTRODUCTION .......................................................................................... 120 
4.2 MATERIALS AND METHODS ..................................................................... 123 
4.2.1 Cell culture ....................................................................................... 123 
4.2.2 Generation of stable cell lines ........................................................ 123 
4.2.3 Lentivirus production ...................................................................... 123 
4.2.4 Overexpression and short hairpin RNA (shRNA) constructs ...... 124 
4.2.5 Cell counting and doubling time determination ........................... 124 
4.2.6 Immunoblotting ................................................................................ 124 
4.2.7 Semi quantitative RT-PCR .............................................................. 126 
4.2.8 Soft agar assay ................................................................................ 126 
4.2.9 Microarray ........................................................................................ 126 
4.3 RESULTS ..................................................................................................... 128 
4.3.1 The effect of MCV T antigens on BJ-hTERT proliferation ............ 128 
4.3.2 Transformation assays ................................................................... 129 
4.3.3 Microarray gene expression profile in BJ-TERT cells expressing 
MCV T antigens ........................................................................................... 133 
4.3.4 Confirmation of LXCXE-motif dependent up-regulation of cyclin E 
and CDK2 transcript levels ......................................................................... 139 
 x 
4.3.5 Validation of increased Cyclin E and CDK2 protein expression in 
BJ-hTERT ..................................................................................................... 140 
4.3.6 Cell cycle analysis of BJ-hTERT stable cells ................................ 143 
4.4 DISCUSSION ............................................................................................... 144 
5.0 CONCLUSIONS AND PERSPECTIVES ............................................................. 148 
5.1 MS-1 CELL LINE ......................................................................................... 148 
5.2 MCV ORIGIN REPLICATION ...................................................................... 148 
5.3 PROLIFERATION AND TRANSFORMATION STUDIES ........................... 150 
APPENDIX A................................................................................................................ 154 
APPENDIX B ................................................................................................................ 160 
APPENDIX C ................................................................................................................ 187 
BIBLIOGRAPHY .......................................................................................................... 208 
 xi 
 LIST OF TABLES 
 
Table 1. Human tumor viruses ......................................................................................... 6 
Table 2. Immunohistochemical features of MCC cell lines ............................................. 76 
Table 3. MCV genome copy number and viral RNA expression .................................... 77 
Table 4. Chromosomal integration sites in MCC ............................................................ 82 
Table 5. Biological functions affected by 339LT expression in BJ-hTERT ................... 137 
Table 6. Cell cycle regulatory genes differentially regulated by 339LT ........................ 138 
Table 7. Microarray analysis of p53 transcriptional targets .......................................... 158 
Table 8. EC50 (µM) concentrations for MCC cell lines .................................................. 180 
Table 9. Average tumor growth kinetics ....................................................................... 198 
 xii 
LIST OF FIGURES 
 
Figure 1. MCV, JCV, BKV , and SV40 T antigen splice isoforms ................................... 19 
Figure 2. The polyomavirus lifecycle .............................................................................. 22 
Figure 3. Possible outcomes of SV40 infection in different cell types ............................ 24 
Figure 4. Targeting of the Rb-E2F and p53 pathways by SV40 LT ................................ 31 
Figure 5. SV40 LT domains and cellular interactors ...................................................... 33 
Figure 6. SV40 sT domains and cellular interactors ....................................................... 38 
Figure 7. Location of Merkel cells ................................................................................... 44 
Figure 8. Pathology and clinical manifestation of MCC .................................................. 45 
Figure 9. Digital transcriptome subtraction ..................................................................... 50 
Figure 10. MCV 350 prototype genome organization ..................................................... 51 
Figure 11. MCV T antigen locus ..................................................................................... 54 
Figure 12. MCV Seroprevalence .................................................................................... 57 
Figure 13. MCV T antigen expression in MCC ............................................................... 58 
Figure 14. Morphological features of MCC cell lines ...................................................... 75 
Figure 15. MS-1 harbors clonally integrated MCV and expresses viral T antigens ........ 79 
Figure 16. MCV genome comparison ............................................................................. 81 
Figure 17. MS-1 xenograft model ................................................................................... 83 
 xiii 
Figure 18. Mapping  of the MCV core origin ................................................................. 103 
Figure 19. Definition of the minimal MCV core origin ................................................... 104 
Figure 20. Pentanucleotide requirements .................................................................... 105 
Figure 21. Single base pair mutational analysis of pentanucleotides ........................... 107 
Figure 22. Reconstitution of pentanucleotide sequence to GAGGC ............................ 108 
Figure 23. Chromatin immunoprecipitation (ChIP) analysis ......................................... 110 
Figure 24. Other factors influencing MCV replication ................................................... 112 
Figure 25. MCV origin replication assay with TAg mutants in DnaJ domain and PP2A 
binding site ................................................................................................................... 114 
Figure 26. Model of the MCV OBDs on the MCV origin ............................................... 116 
Figure 27. Tumor-derived MCV LT promotes human fibroblast proliferation through it 
LXCXE RB targeting domain ........................................................................................ 129 
Figure 28. Generation of BJ-hTERT stable cell lines for transformation assays .......... 130 
Figure 29. BJ-hTERT SV40ER and hRas stable cell line soft agar positive control ..... 131 
Figure 30. BJ-hTERT stable cells soft agar colony formation result ............................ 132 
Figure 31. Microarray gene expression profile of E2F targets ..................................... 133 
Figure 32. Transcriptome modulation by 339LT ........................................................... 134 
Figure 33. Heatmap of cell proliferation related genes ................................................. 135 
Figure 34. Semi quantitative RT-PCR analysis confirms up-regulation of cyclin E and 
CDK2 transcripts by tumor-derived LTs ....................................................................... 140 
Figure 35. Cyclin E and CDK2 protein levels are preferentially up-regulated by tumor-
derived MCV LT ........................................................................................................... 141 
 xiv 
Figure 36. BJ-hTERT 339LT expressing cells show a greater percentage of cells 
entering the cell cycle ................................................................................................... 143 
Figure 37. Endogenous Ras protein levels are decreased in the presence of 339LT .. 155 
Figure 38. MCV LT stabilizes p53 protein levels resulting in p21 induction ................. 157 
Figure 39. Survivin oncoprotein mRNA expression is increased in MCV-positive MCC
 ...................................................................................................................................... 172 
Figure 40. MCV sT knockdown in MCC cell lines does not affect survivin expression 173 
Figure 41. MCV LT induces survivin oncoprotein expression in primary BJ cells through 
its RB targeting domain ................................................................................................ 175 
Figure 42. The survivin promoter inhibitor YM155 inhibits MCV-positive MCC cell growth
 ...................................................................................................................................... 176 
Figure 43. Cell death phenotype of MCV-positive MCC cells treated with YM155 ...... 178 
Figure 44. YM155 inhibits growth of MKL-1 xenografts in NSG mice .......................... 183 
Figure 45. MCC mouse xenograft treatment groups and experimental outline ............ 194 
Figure 46. Mouse weights on saline and YM155 treatment groups ............................. 195 
Figure 47. Survival of various MCC xenograft models on different treatments ............ 197 
Figure 48. Tumor volume response to YM155 is dose, duration, and cell line dependent
 ...................................................................................................................................... 199 
Figure 49. Immunohistochemistry of MCV LT in a MKL-1 xenograft tumor and liver 
metastasis .................................................................................................................... 202 
Figure 50. Immunohistochemistry of MCV LT in various MCC xenograft tumors and 
metastases ................................................................................................................... 203 
 xv 
Figure 51. Various chemotherapeutics induce MCC cell death in an additive, but not 
synergistic manner, when combined with YM155 in vitro ............................................. 205 
 xvi 
ACKNOWLEDGMENTS 
First and foremost, I would like to thank my mentors Dr. Patrick Moore and Dr. Yuan 
Chang. I am in deep gratitude to you for providing me with the opportunity to grow in my 
profession and establish myself as an independent scientist in your lab. I appreciate 
your patience and insightful advice on scientific matters. My graduate student 
experience in your lab has been invaluable for my future career. Thank you! 
Next, I want to thank the current and past members of the Chang-Moore lab, who 
have provided me not only with a professional environment that was very supportive in 
my development as a scientist, but also have become a family away from home. I 
appreciate your guidance and will cherish memories of our times together in and outside 
of the lab for the rest of my life. I especially want to thank Masa for being a great mentor 
to me. I have learned so much from you.  
I would like to thank my thesis committee members for your valuable advice 
throughout the past years. I have benefited from your scientific expertise, and I 
appreciate the time you have taken out of your busy schedules to serve on my thesis 
committee. 
Last but not least, I would like to thank family and friends who have been a 
strong support of mine throughout the years. I want to thank my parents, Lena, Ciro, 
Luisa and Kensington for always believing in me and supporting me in whatever I 
 xvii 
decided to do. You are my foundation in life, without which I could not have done any of 
this. I love you guys! Thank you Gene for being my best friend and confidant 
extraordinaire. You keep my spirits lifted and I appreciate every minute we spend 
together. I will miss you, but I know this is not the end of the road for us. You have a 
friend in me for life. I would like to thank Alex, Nathalie and Sarah for being my friends 
throughout the years and keeping in touch even when we are far away from each other. 
I also want to thank my PIMB friends, for a great graduate school experience. I 
especially want to thank Jelena and Reety for being awesome friends during my stay in 
Pittsburgh. I could not have made it without your advice and friendship. I will miss you! 
 1 
1.0  INTRODUCTION 
1.1 VIRUSES AND CANCER 
1.1.1 History of tumor viruses 
The field of tumor virology dates back to the 1911 discovery of the Avian Rous sarcoma 
virus (RSV) by Francis Peyton Rous (1, 2). Rous discovered that a chicken sarcoma 
could be transmitted from one chicken to another using a filtered cell-free tumor extract 
(3). This novel finding of an infectious agent that induces cancer represented an 
unrecognized concept in the field of cancer research at the time. Even though it was 
known since the 19th century that cancer was a cellular disease, its specific etiology was 
still unclear. The theory of an infectious cause was disregarded for over fifty years due 
to a failure to experimentally verify microbial pathogens as cancer causing agents. Even 
after Rous reported his findings of RSV-induced sarcomas in chickens, the scientific 
community at the time was not convinced that tumor viruses existed, or that they 
represented the causative agent for a number of human cancers. Opponents of this 
theory claimed that the cell-free extracts used by Rous to transmit sarcomas in 
chickens, were in fact not cell-free, or that chickens are not an appropriate model 
system to study human cancer.  
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However, Ludwik Gross’ discoveries of the acutely transforming mouse leukemia 
retrovirus and the mouse polyomavirus (PyV), which causes many (poly) tumors (oma) 
in newborn mice (4, 5), lead to wider acceptance of the concept of viral tumorigenesis in 
the 1950s. In 1966 Rous finally received recognition for his groundbreaking work, and 
was awarded the Nobel Prize. Since then, studies centered around RSV and PyV, as 
well as other subsequently discovered tumor viruses, have contributed to major 
scientific advances including the discoveries of reverse transcriptase, as well as a 
number of cellular oncogenes and tumor suppressors. 
1.1.2 Viruses and human cancer 
Since the 1911 discovery of the avian tumor virus RSV, a total of seven tumor viruses 
have been discovered to cause human cancer. Viruses cause a total of 10-15% of 
cancers worldwide, including cancers of diverse cellular origins. Viral etiology of a 
cancer provides the unique opportunity to develop preventative, diagnostic and 
therapeutic tools that target viral proteins specifically. This has been utilized in 
developing vaccines against hepatitis B virus (HBV) and human papillomavirus (HPV) 
infections, resulting in a decrease of respective liver and cervical tumor incidents. 
Anthony Epstein, Yvonne Barr, and Bert Anchong discovered the first human tumor 
virus called Epstein-Barr virus (EBV) in 1964 (6). EBV is a herpesvirus found by 
electron microscopy of cell lines derived from Burkitt’s lymphoma (Table 1). Burkitt’s 
lymphoma is a cancer which predominately affects children from equatorial Africa and it 
is more common in immunosuppression, which is often related to malaria in this 
geographically confined area. Subsequent serological studies revealed the seemingly 
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contradictory fact that persistent EBV infection is ubiquitous, yet asymptomatic in adults 
worldwide. This posed the question of how such a common viral infection could cause a 
rare, geographically confined cancer (7, 8). In addition, a small number of Burkitt’s 
lymphoma arising in developed countries are not associated with EBV (9). Shortly after 
its discovery, the research team surrounding Gertrude and Werner Henle demonstrated 
that EBV is capable of transforming primary B-cells (10). Nevertheless, it was not until 
1997 that the International Agency for Research on Cancer (IARC) officially declared 
EBV as a human carcinogen (7). To understand the debate that resulted in a 30-year 
time delay until EBV was finally recognized as a human carcinogen, one must 
understand which criteria are used in order to demonstrate disease association.  
 To evaluate causality of an infectious agent in the context of a disease state, 
there are several standards that are used to examine the evidence at hand. These 
include Koch’s postulates published in 1890 as well as Hill’s criteria published in the 
1960’s. Koch’s postulates originate from his work on bacterial pathogens including 
anthrax and tuberculosis (11). They include the following requirements: 1) The 
infectious agent has to occur in every case of the disease, 2) it does not occur in any 
other disease, and 3) it can be isolated as pure cultures in vitro, and when re-introduced 
into susceptible laboratory animals results in the same disease outcome (11). Koch’s 
postulates cannot be applied in the case of EBV or other tumor viruses, since it is not 
always possible to isolate them as pure cultures or introduce them into experimental 
animals and always observe the same disease state. Hill’s criteria to evaluate the 
observed association of a pathogen with a disease state include 1) strength, 2) 
consistency, 3) specificity, 4) temporality, 5) biological gradient, 6) plausibility, 7) 
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coherence, and 8) experimental evidence of association (12). Hill’s criteria were 
established to evaluate the relationship between smoking cigarettes and lung cancer, 
but in the field of tumor virology some aspects are not applicable.  
 With our current knowledge of cancer being a multi-step disease that results from 
a combination of cellular changes and environmental factors, we can explain how a 
common viral infection may cause a rare cancer in a subset of individuals. In the case of 
EBV and other tumor viruses, the immune status of the infected individual plays a major 
role in determining disease state. In immunocompetent individuals, the viral infection is 
contained and regulated by the immune cells. However, in the case of 
immunosuppression, as seen in elderly people, as well as transplant and AIDS patients, 
the virus is able to re-emerge, and viral protein expression may lead to cell 
transformation and consequent tumorigenesis.   
As more human tumor viruses were discovered over time (Table 1), it became 
apparent that tumor viruses usually do not replicate as virions within the tumor cells, but 
instead exist either as latent episomes or integrate into the host cell genome. To date, 7 
human tumor viruses have been identified using different experimental techniques 
(Table 1). They belong to different classes of viruses, and cause tumors in a number of 
different cell types (Table 1). The following paragraphs will provide a brief description of 
each tumor virus discovered subsequent to EBV. 
 Shortly after the discovery of EBV, Blumberg and colleagues identified a new 
antigen named Australia (Au) antigen in the serum of an Australian aborigine (13). They 
found the Au antigen to be present in the sera of patients with acute or chronic hepatitis 
(14), and in 1968 Alfred Prince demonstrated that Au is the surface antigen of HBV (15), 
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the virus that causes serum hepatitis. Due to persistent, yet asymptomatic HBV 
infection in healthy individuals, linking HBV infection to hepatocellular carcinoma (HCC) 
proved to be difficult once again. In 1975 Blumberg and colleagues described a link  
between HBV infection and HCC development, and proposed vaccination against HBV 
using the Au antigen (16). Merck eventually started producing an HBV vaccine 
commercially using recombinant Au subunit produced in yeast, which is still used today. 
Vaccination efforts worldwide have reduced HBV-induced acute and chronic hepatitis, 
as well as HCC incidents (17, 18). HBV-induced liver disease causes > 300,000 deaths 
each year, but expanding routine vaccination regimens during early childhood 
worldwide will likely reduce this death toll further in the future. Previous to the 
identification of HBV, Feinstone and colleagues identified the picornavirus hepatitis A 
virus (HAV) in 1973 as an infectious agent that induces acute hepatitis (19). However, in 
contrast to HBV, HAV infection is not persistent, and not involved in HCC (20).  
 The mechanism by which HBV contributes to HCC is not exactly clear. Lack of 
an appropriate experimental model system that mimics the human host has hindered 
research progression in this field. However, it is well known that chronic viral infection 
with HBV leads to active viral replication in liver cells and viremia. The production of 
viral proteins in chronically infected hepatocytes leads to a persistent immune response 
and destruction of these cells. This leads to a much more rapid turnover of liver cells, 
which are usually long-lived with half-lives of 6-12 months (21). Some studies have 
indicated the HBV protein HBx as a potential viral oncogene, but studies utilizing 
different experimental systems have failed to yield reproducible results (21, 22).  
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Yet another hypothesis that could explain HCC development in the context of HCV 
infection is the presence of harmful environmental co-factors such as aflatoxin, which 
may result in G-to-T transversions. In 80-90% of HCC that have mutated p53 (~50%) 
residue 249 is changed from G to T (21, 23, 24). 
In 1989, Choo et al. found that in addition to HBV and HAV associated hepatitis, 
they were able to distinguish a third form, non-A, non-B hepatitis (NANBH) (25). They 
screened a cDNA library from chimpanzee serum containing the NANBH agent with 
serum from a patient diagnosed with NANBH, and they were able to identify an 
unknown antigen belonging to a new RNA flavivirus, which was named hepatitis C virus 
(HCV) (Table 1). Subsequently, HCV was established as a causal agent in chronic 
hepatitis, liver cirrhosis, as well as HCC. HCV infection affects more than 170 million 
individuals worldwide, of whom approximately 20% are at risk of developing HCV-
induced HCC. In contrast to HAV and HBV, a vaccine that protects against HCV is not 
available at this point, and attempts to develop a vaccine have been challenging due to 
the high mutation rate in the HCV RNA genome, resulting in the presence of many 
different HCV strains. Nevertheless, research is ongoing in this field, and the company 
Inovio is currently testing a plasmid DNA vaccine against HCV in a clinical phase II trial 
(www.inovio.com).  
 Human T-lymphotropic virus-1 (HTLV-1) is the only known human tumor virus 
that belongs to the family of retroviruses (Table 1). Its discovery depended heavily on 
the identification of reverse transcriptase (RT) in 1970 in independent studies by 
Howard Temin, and David Baltimore, who were both able to demonstrate RNA-
dependent DNA polymerase activity in RSV (26, 27). The discovery of RT was awarded 
T
a
bl
e 
1. 
H
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m
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with a Nobel price in 1975, and represents one of many examples in which the study of 
tumor viruses resulted in a major discovery that influenced science across all 
disciplines. In 1979, Bernard Poiesz, a postdoctoral fellow in Robert Gallo’s lab at the 
time, was able to detect RT activity in cell lines derived from adult T-cell 
lymphoma/leukemia patients and electron microscopy confirmed the presence of 
budding HTLV-1 virions (28). Shortly after, Gallo and his team were able to demonstrate 
that HTLV-1 was not only able to infect T-cells, but also transformed them in vitro (29, 
30), and that proviral DNA could be found integrated into the host cell genome (31). In 
addition, they were able to isolate HTLV-1 from additional patient ATL samples and 
detect specific antibodies against the virus in patient sera (32). Subsequent studies from 
research teams worldwide confirmed HTLV-1 association with ATL (33-35). However, 
as is the case with other human tumor viruses, only a small percentage of individuals 
infected with HTLV-1 develop ATL throughout their lifetime. Cellular transformation is 
associated with expression of the viral oncoprotein Tax, which induces T cell 
proliferation and survival (36). 
 Another groundbreaking, and recently deemed Nobel prize-worthy discovery in 
tumor virology is the identification of high-risk papillomaviruses that cause human 
cancers. In 1983-84, a research team led by Harald zur Hausen at the University of 
Heidelberg identified human papillomavirus (HPV) types 16 and 18 by cross-hybridizing 
DNA from other papillomaviruses to DNA from cervical carcinoma biopsies (37, 38). 
Cervical cancer is one of the most common cancers in women worldwide, and the 
identification of its viral etiology has lead to the successful development of a vaccine 
within recent years (39, 40). This vaccine utilizes recombinant HPV capsid proteins L1, 
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and exists in bivalent (protection against HPV 16 and 18) and quadrivalent (protection 
against HPV 16, 18, 6, and 11) forms (41). In addition to cervical carcinoma, various 
types of HPVs are also linked to genital warts, other anogenital cancers as well as close 
to 20% of oropharyngeal cancers in both women and men (42).  
 With regards to cervical carcinoma, 15 high-risk HPV types have been identified 
that are individually necessary, however not sufficient to induce tumorigenesis (43). Of 
these, both HPV types 16 and 18 are most commonly associated with squamous cell 
carcinoma, whereas HPV 18 shows strong association with adenocarcinoma of the 
cervix. High-grade neoplastic lesions and invasive disease are characterized by viral 
integration of high-risk HPV types 16 and 18, with integration events that disrupt the E2 
gene favoring tumorigenesis due to E2’s repressive effect on E6 and E7 oncogene 
expression (43). However, even though the majority of women get infected with HPV, 
only a small percentage will actually suffer from invasive neoplastic disease. This 
indicates that progression to high-grade cervical neoplasia requires additional changes 
within the cervical epithelium, which may include genetic and epigenetic changes that 
have to be taken into consideration when tackling this disease. Non-viral risk factors 
that contribute to HPV-induced malignant disease progression include a high number of 
sexual partners, mutagens, smoking, hormones, immunosuppression, and genetic 
predisposition (39). 
 Most recent efforts to discover new tumor viruses associated with human 
cancers have focused on human malignancies that are more prevalent in 
immunosuppressed individuals including AIDS and transplant patients as well as the 
elderly. Patrick Moore and Yuan Chang have lead the way in scientific endeavors that 
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identified the human tumor viruses Karposi’s sarcoma herpesvirus (KSHV) or Human 
herpesvirus 8 (HHV-8) in 1994 as well as Merkel cell polyomavirus (MCV) in 2008 
(Table 1). Kaposis’s sarcoma (KS) is an angioproliferative malignancy first reported in 
1872 by Moritz Kaposi, who described KS lesions as ‘idiopathic multiple pigmented 
sarcomas of the skin’ (44). Even though KS was initially described as endemic in the 
Mediterranean and in Africa, the HIV epidemic in Europe and the US in the 1980’s 
coincided with increased cases of AIDS-related KS in homosexual men (45). The 
elevated occurrence of KS in immunosuppressed individuals initiated a search for an 
infectious etiology. KSHV was discovered in 1994 using a PCR-based technique called 
representational difference analysis (RDA) (46). Briefly, DNA sequences unique to 
AIDS-KS lesions were isolated following PCR amplification and subtractive hybridization 
(46). Within a year of its discovery, KSHV had also been indicated in multicentric 
Castleman’s disease (MCD), as well as AIDS-related primary effusion lymphoma (PEL) 
(47-49).  
 Merkel cell carcinoma (MCC) is an aggressive skin cancer that arises from 
mechanoreceptor Merkel cells in the basal layer of the epidermis (50, 51). It is more 
prevalent in immunosuppressed (13.4 fold higher incidence in AIDS patients) as well as 
older individuals (52, 53), which prompted the search of an infectious agent that may be 
associated with this cancer. In 2008, Feng et al. performed a direct sequencing-based 
technique called digital transcriptome subtraction (DTS) analysis (54) on cDNA libraries 
derived from four MCC tumors (55). Annotated human sequences were subtracted from 
the MCC cDNA libraries to identify candidate reads of non-human origin. Alignment of 
non-human reads with viral genome databases identified one transcript with high 
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homology to polyomavirus sequences (55). Subsequently, the whole MCV genome was 
sequenced and its association with MCC was confirmed in multiple studies (55-57). 
Detailed descriptions of MCV discovery, its viral features and association with MCC can 
be found in section 1.4 Merkel cell polyomavirus. 
1.2 POLYOMAVIRUS BIOLOGY 
1.2.1 History and phylogeny 
Polyomaviruses are small, non-enveloped viruses that have double-stranded DNA 
genomes of ~5.0-5.4 kb. They have icosahedral capsids of 40-45nm diameter, and have 
been shown to infect various species including humans, monkeys, rodents, rabbits and 
birds. They can be divided into three major subgroups including the mammalian species 
containing groups Wukipolyomaviridae and Orthopolyomaviridae, and the avian group 
Avipolyomaviridae. Polyomaviruses encode for viral proteins called tumor (T) antigens, 
which have been associated with oncogenic transformation in cell culture experiments 
as well as tumor formation in animal models (58). 
The first polyomavirus, murine polyomavirus (MPyV), was discovered as a 
filterable agent from mouse leukemia cells in 1953. Subsequently, MPyV was shown to 
cause cancers in newborn mice, rats, as well as hamsters (59-61), which led the way to 
investigating the oncogenic potential of polyomaviruses discovered ever since. Shortly 
after the identification of MPyV, simian vacuolating virus 40 (SV40) was discovered 
between 1959-1960, and it also was capable of inducing tumors in hamsters during 
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initial experiments (62, 63). SV40’s natural host is the rhesus macaque, and many lots 
of poliovirus vaccine produced in rhesus cells between 1955 and 1963 were found 
contaminated with SV40 (64). It is estimated that 10-30 million individuals received a 
polio vaccine that contained SV40 during that time period, and studies to evaluate the 
potential oncogenic risk of SV40 in humans were initiated afterwards.  
1.2.2 Association with human cancer 
PCR-based studies reported the presence of SV40 DNA in non-Hodgkin lymphomas 
(65), osteosarcomas (66), brain tumors (67) as well as meotheliomas (68). However, 
subsequent studies failed to repeat these results and they were indicated as false 
positives due to PCR template contamination from 293FT cell DNA (HEK293 cells that 
were stably transduced to express SV40 T antigen) or common laboratory plasmids 
containing SV40 sequences (69, 70). Serologic studies to investigate the presence of 
SV40-specific antibodies in the general population as well as in patients with 
supposedly SV40-linked cancers, provide more consistent results due to a high 
specificity of this assay, and less chances for false positive results. The results indicate 
that there is no difference in seroreactivity between the general population and 
individuals with supposedly SV40–linked cancers (71-73). Low levels of seroprevalence 
across all groups tested can be attributed to cross reactivity of antibodies from human 
polyomaviruses BKV and JCV with SV40 peptides (74). In conclusion, there is no 
convincing or repeatable evidence linking SV40 exposure to human cancer to this date 
(58, 70). 
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The human polyomaviruses BKV and JCV (described in more detail in section 
1.2.3) have recently been classified as “possibly carcinogenic to humans” by a WHO 
International Agency for Cancer Research Monograph Working Group (75). Single case 
reports link BKV infection to renal tubular as well as urothelial tumors in the context of 
renal transplantation (76-78). However, other studies failed to detect BKV in these 
malignancies, and a causal relationship is still under debate (79, 80). Some reports 
indicate the presence of BKV DNA in lymphomas, colorectal, pancreatic, prostate and 
brain tumors, but these associations are still controversial (81). In vitro and in vivo 
experiments clearly support an oncogenic potential of both BKV and JCV. Inoculation of 
either BKV or JCV into newborn rodents induces the formation of tumors in various 
tissues, as has been observed in the cases of MPyV and SV40 (82).  
1.2.3 Human polyomaviruses 
The first human polyomaviruses BKV and JCV (BK and JC stand for the initials of the 
patients from which they were isolated) were identified in 1971, and are closely related 
to SV40 by phylogenetic analysis of T antigen sequences. BKV was isolated from the 
urine sample of a renal transplant patient (83), whereas JCV was isolated from human 
brain tissue with progressive multifocal leukoencephalopathy (84). BKV infection is 
wide-spread throughout healthy individuals, with an early and rapid seroconversion of 
over 50% in children 2 years of age, and over 90% in > 10 year old age groups (82). In 
contrast, JCV seroconversion in the general, healthy population can be detected at later 
stages in life. Compared to BKV seroreactivity, it increases much slower but steadily 
over time, reaching 50-70% among older individuals (82).  
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In 2007, the two closely related human polyomaviruses KIV and WUV were 
discovered in children with acute respiratory tract infections (85, 86). Their names 
indicate the institutions at which they were identified: Karolinska intitute (KIV) and 
Washington University (WUV). NCBI genome database analyses of deep sequencing 
derived cDNA lbraries were used to detect non-human sequences and identify these 
two novel viral genomes. Serologic studies have detected both KIV and WUV in a large 
percentage of healthy individuals, with seroprevalence ranging from 55-98% depending 
on age groups evaluated in various geographic locations (87-89). A slightly higher 
prevalence is observed in immunosuppressed individuals, but thus far, experimental 
evidence links neither KIV nor WUV to any disease phenotypes, and infection seems to 
be asymptomatic (82). 
Shortly after the identification of KIV and WUV, MCV was discovered in 
association with MCC in 2008. MCV biology is the focus of this thesis and literature 
reviews on MCC and MCV are described in subsequent sections 1.3 and 1.4. 
Schowalter et al. investigated the presence of MCV on human skin by taking forehead 
skin swabs, and not only revealed that MCV is frequently shed from healthy skin, but 
also identified two novel human polyomaviruses also present on the skin, HPyV6 and 7 
(90). Both of these viruses were less prevalent than MCV in the 35 skin samples tested 
by rolling circle amplification (RCA) in this study (MCV = 14/35; HPyV6 = 5/35; HPyV7 = 
4/35), and serologic evaluation of 95 serum samples revealed a seroprevalence of 69% 
for HPyV6 and 35% for HPyV7 (90). Interestingly, a study testing the presence of 
HPyV6 and 7 in MCV-negative MCCs did not find any association (91). At this point, no 
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disease development has been linked to HPyV6 or 7 infections, and further 
experimental analyses are necessary. 
RCA was also used to identify the 8th human polyomavirus called trichodysplasia 
spinulosa-associated polyomavirus (TSV) in nose spicules collected from a transplant 
patient suffering from trichodysplasia spinulosa (TS) (92), and this viral association was 
subsequently confirmed (93). Seroprevalence of TSV was determined in 528 healthy 
individuals, and ranges from 10% in children to 80% in older adults, with an average 
seroreactivity of 70% (94). TSV viral protein expression is specifically associated with 
affected hair follicles, suggesting a possible role of this virus in TS development (95, 
96). Other disease associations have not been reported, yet, and require further 
investigation.  
In 2011, the 9th human polyomavirus (HPyV9) was identified by generic PCR 
utilizing primers designed against conserved VP1 regions of known polyomaviruses. 
Screening of 597 clinical samples not only detected the above-described human 
polyomaviruses in 84 cases, but also identified HPyV9 in the serum of an 
immunosuppressed kidney transplant patient (97). HPyV9 shares high homology with 
the African green monkey lymphotropic polyomavirus (LPV), which may explain human 
seroreactivity to LPV due to cross reactivity (98). Seroprevalence of HPyV9 lies 
between 21-53% in healthy individuals, and disease associations have not been 
reported at this point (98, 99). 
In 2012, three independent studies identified the 10th human polyomavirus 
referred to as Malawi polyomavirus (MWPyV) (100), human Polyomavirus 10 (HPyV10) 
(101), or MX polyomavirus (MXPyV) (102). Siebrasse et al. identified this new 
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polyomavirus by shotgun pyrosequencing of DNA from virus particles isolated from a 
stool sample from a healthy child from Malawi, and named it MWPyV (100). 
Subsequently, they screened 514 diarrhea samples from children in the United States, 
and found MWPyV present in 12 (2.3%) cases. The MWPyV viral genomes isolated in 
the United States varied from the Malawi viral genome by 5.3% by nucleotide sequence 
comparison (100).  
In the same year, Buck et al. published the identification of HPyV10, which was 
found to share 95-99% nucleotide identities with the MWPyV viral strains, and therefore 
is considered the same virus (82, 101). HPyV10 was discovered by RCA on DNA 
isolated from virions purified from condyloma samples from a patient suffering from a 
genetic disorder known as warts, hypogammaglobulinemia, infections, and 
myelokathexis (WHIM) syndrome (101). It is not clear whether HPyV10 infection 
contributed to the development of warts in this patient, since papillomavirus 6 infection 
was also found, which is known to cause genital warts. 
 Yet another group identified the 10th human polyomavirus in acute diarrheal 
samples from children in the United States, Mexico and Chile in 2012 (102). The virus 
was named MXPyV and its genome was found to contain almost identical nucleotide 
sequence to MWPyV and HPyV10, confirming that these three independent viral 
discoveries describe geographic variants of the same new member of the human 
polyomavirus family (82, 102). MXPyV was found in 23 (3.4%) out of 834 fecal samples, 
but not in blood or urine samples of immunocompromised individuals (102). Whether or 
not the tenth human polyomaviruses is associated with diarrhea or other disease 
phenotypes in humans remains to be elucidated.  
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In 2013, 454 pyrosequencing identified a novel polyomaviral genome in a stool 
sample from a healthy child from Malawi (103), which was named STL polyomavirus 
(STLPyV). It encodes for a 229 amino acid long T antigen splice variant (229T), which 
utilizes distinct splice donor and acceptor sites downstream of the LT splicing sites 
(103). STLPyV is closely related to MWPyV and subsequent PCR analysis indicates the 
presence of this novel polyomavirus in pediatric stool samples from St. Louis as well as 
Gambia. However, neither MWPyV nor STLPyV were detected in 237 fecal samples 
from adult transplant patients. Disease associations with this novel human polyomavirus 
remain to be explored.  
Finally, HPyV12 represents the latest human polyomavirus identified to date (July 
2013). It was identified by PCR using generic polyomavirus primers targeting the VP1 
region (104). 242 specimens from various body sites were tested and a novel 
polyomavirus genome with low homology (51-67%) to known polyomaviruses was 
identified in 4 liver samples (104). Subsequent re-evaluation of the 242 samples by 
PCR using HPyV12 specific primers revealed viral genome presence in 11% of liver 
samples and to a lesser extent in organs of the gastrointestinal tract and feces (104).  
Seroprevalence of HPyV12 lies at 12% in young children (2-5 years) with a rising 
seroreactivity of 15-33% in older adults (104). Interestingly, HPyV12 is the first human 
polyomavirus identified that lacks an LXCXE Rb family targeting domain. Disease 
associations have to be evaluated in future studies.  
 Overall, it is noteworthy to mention that the past 6 years have brought about a 
new era of human polyomavirus research with the discovery of 10 new human 
polyomaviruses in addition to BKV and JCV. Two of the newly identified polyomaviruses 
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(MCV and TSV) have been convincingly linked to human disease. A great contribution 
to these discoveries was the completion of the human genome project in 2003. It 
allowed for the development of new techniques to identify non-human sequences in 
diseased tissue, which ultimately lead to the identification of novel viral agents. Studies 
that center on the epidemiology of polyomavirus infections in humans have revealed 
that humans are frequently infected with multiple polyomaviruses from an early age (74, 
87, 88, 94, 98, 99, 105). Multiple common human polyomaviruses are chronically shed 
from the skin of healthy individuals (90), and have been identified in human serum, 
urine, and cerebrospinal fluid, as well as nasopharyngeal, respiratory, and fecal 
samples thus far (97, 100-102, 106, 107). Most human polyomaviral infections seem to 
be asymptomatic, but further studies are needed to investigate possible disease 
phenotypes. It is apparent that immunosuppression poses a risk factor in the 
development of polyomavirus-induced malignancies such as MCC and TS. Given that 
polyomaviruses seem to be part of normal human flora, it is likely that more human 
polyomaviruses will be discovered in the future. Careful investigations are needed to 
identify human diseases associated with common polyomaviral infections most likely in 
the context of immunosuppression.  
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1.2.4 Genome organization 
Polyomaviral genomes are composed of circular, covalently closed, double-stranded 
DNA, and range from 4.6 kb to 5.4 kb in length. They are divided into three distinct 
regions, which contain genome features common to all polyomaviruses: the non-coding 
regulatory region (NCRR), as well as the early and late transcript regions. Early and late 
designations refer to the timely expression of transcripts during the viral infectious cycle. 
The NCRR, which divides early and late regions, contains the viral origin of replication 
as well as early and late promoter elements. Early transcripts include T antigen 
 
Figure 1. MCV, JCV, BKV , and SV40 T antigen splice isoforms 
The splicing patterns of JCV, BKV , and SV40 early regions are compared to MCV T antigen 
splice variants. Different colors represent individual T antigen isoforms: Orange (LT), Lavender 
(sT), and Green (additional virus unique isoforms). Dottet lines represent intronic regions and 
nucleotide positions are indicated with respect to genome position for each respective virus. 
(Modified from Gjoerup and Chang, 2010) 
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isoforms, which are expressed before the onset of viral replication. Late transcripts are 
expressed afterwards and encode VP gene products involved in viral genome 
packaging and capsid formation. 
The early region encodes between 2 to 5 differentially spliced T antigen isoforms 
that differ between individual polyomaviruses (Figure 1). Open reading frame analysis 
predicts Large (LT) and small T (sT) antigen expression for all known polyomaviruses. 
LT and sT protein expression has been confirmed for a great number of polyomaviruses 
including MPyV, SV40 BKV, JCV and MCV. Additional T antigen isoforms can be found 
in various polyomaviruses and include: middle and tiny T from MPyV (108, 109), 17kT 
from SV40 (110) (Figure 1), truncT from BKV (81) (Figure 1), T’135, T’136 and T’165 
from JCV (111) (Figure 1) as well as 57kT from MCV (56) (Figure 1). While the N-
terminal region is shared among T antigens from a given polyomavirus, alternative 
splicing creates T antigen isoforms with unique C-terminal domains (Figure 1). 
Polyomavirus T antigens are not only essential for viral genome replication (described in 
more detail in section 1.2.5), but also have been shown to interact with many cellular 
proteins to alter signaling pathways in ways that benefit the viral lifecycle (described in 
more detail in section 1.2.7). Due to their small genome size, polyomaviruses are 
depended on multi-functional T antigen proteins that are involved in many different 
aspects of the viral life cycle.  
The late region encodes for the viral capsid proteins VP1, VP2 and VP3, which 
are also generated through alternative splicing. SV40 is the only polyomavirus that is 
known to encode a VP4 isoform, which creates pores in the cell membrane to promote 
viral release (112). Viral capsids are comprised of 72 VP1 pentamers, with VP2 and 
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VP3 buried internally (113, 114). When expressed alone, the major capsid protein VP1 
forms virus-like particles (VLPs) that are successfully used in serological studies to 
determine the prevalence of a given polyomavirus in a population.   
1.2.5 Viral life cycle  
The infectious cycle of polyomaviruses can be divided into 8 distinct phases (Figure 2). 
The first step involves the interaction of the major capsid protein VP1 with the host cell 
membrane. Host cell specificity depends on the receptors utilized by polyomaviruses, 
which include ganglioside receptors with differentially linked sialic acids. SV40 has been 
shown to bind to ganglioside GM1 (115, 116), whereas MPyV specifically interacts with 
GD1a and GT1b (116). BKV utilizes GD1b as well as GT1b gangliosides (117), and 
JCV has been shown to require both the 5HT2A family of serotonin receptors as well as 
gangliosides with alpha 2-6–linked sialic acids to successfully infect cells (118). The 
MCV mode of entry is still controversial. A 2009 report indicated that MCV VP1 binds to 
GT1b, with the unique feature of binding sialic acids on both branches of this 
ganglioside (119). However, subsequent studies refute the requirement of sialylated 
glycans for MCV attachment to cultured cells (120, 121), and identified a linear Neu5Ac-
α2,3-Gal disaccharide as a specific MCV binding motif (120). 
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Figure 2. The polyomavirus lifecycle 
The stages of the polyomavirus life cycle in a permissive host cell are indicated at each step of 
this simplified diagram. (1) Virus attachment, endocytosis and transport to nucleus. (2) T antigen 
(Tag) expression. (3) Tag mediated re-programming of the cellular environment and late gene 
expression. (4) Viral DNA replication. (5) Virion assembly and release. (Modified from Fanning 
et al., 2009 (122)) 
 
 
Following attachment to host cell receptors, polyomaviruses enter the cell via 
specific endocytosis mechanisms. Most polyomaviruses utilize caveolae-mediated 
endocytosis, while JCV requires the formation of clathrin-coated pits (123). Once the 
virus has entered the cell, it depends on the cellular cytoskeletal machinery for transport 
through the cytosol to the nucleus, a process that requires intact microtubules (123). 
Once the nucleus is reached, uncoating of the viral genome begins, followed by 
transcription of the early region. Early gene expression is vital for providing a cellular 
milieu that supports viral genome replication by driving the cell into S-phase through 
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interactions with various cellular proteins (described in detail in section 1.2.7). LT 
assembles into a hexameric helicase unit that initiates bi-directional replication from the 
viral origin in the NCRR (124). After complete viral DNA replication, LT subsequently 
inhibits early gene expression, while promoting late gene transcription. Capsid protein 
expression leads to capsid assembly and viral genome encapsidation. The new viral 
progeny then lyses the cell and exits to infect more cells. A simplified diagram of the 
polyomavirus lifecycle is depicted in Figure 2. 
1.2.6 Permissive vs. non-permissive infection 
The successful completion of the viral life cycle depends on several host cell factors, 
and can therefore only be accomplished in the appropriate cell type of the species that 
is considered the natural host for the virus (permissive cell). Factors that influence 
species tropism include available receptor molecules on the cell surface (as described 
in section 1.2.5) as well as the appropriate DNA replication machinery to facilitate viral 
DNA synthesis. Viral DNA replication requires the cooperation of T antigen with cellular 
replication factors including replication protein A (RPA) and DNA polymerase alpha 
primase (polα) (125). The Pol interaction in particular has been shown to be functional 
in a species-specific manner (126). SV40 genome replication for example cannot 
successfully proceed in rodent cells (non-permissive), due to insufficient primosome 
assembly and primer synthesis on SV40 origin DNA (126). Therefore, only infection of a 
permissive cell leads to virion production followed by cell lysis (Figure 3A). 
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Figure 3. Possible outcomes of SV40 infection in different cell types 
(A) Infection of a permissive cell results in virus particle production and cell lysis. (B) SV40 
infection of some rodent cells fails to support viral DNA replication or virion production and 
eventually leads to loss of the viral genome. (C) Infection of a non-permissive cell rarely leads to 
integration of the viral genome into the host genome generating a stably transformed clone. 
(Modified from Ahuja et al., Oncogene 2005) 
 
There are two possible outcomes upon infection of a non-permissive cell type 
(Figure 3 B-C). SV40 infection of rodent cells for example results in expression of the 
early region T antigens, while the late transcripts and virion production are missing. T 
antigen expression leads to an increase S-phase entry followed by mitosis, which 
promotes cell proliferation even in quiescent mouse fibroblasts. Since the viral genome 
cannot be replicated, the majority of rodent cells infected with SV40 will initially go 
through increased rounds of proliferation, but eventually lose the viral DNA through 
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step-wise dilution or degradation, and revert to their normal state (127) (Figure 3B). 
Various cell types allow for polyomavirus entry upon infection, but fail to support the late 
phase of the infectious cycle resulting in what is called an abortive infection.  
Infection of a non-permissive host cell can also involve the integration of viral 
genomic DNA into the host cell DNA, which provides a mechanism to pass on the viral 
genome to daughter cells even after multiple cell division cycles (Figure 3C). During 
this process, which is considered a “biological accident” because it is a dead end 
scenario for the virus, the viral DNA integrates randomly with regards to the cellular as 
well as the viral genome. Integration events that preserve intact T antigen sequences 
promote T antigen driven cell proliferation, and in the context of a replication defective 
environment can result in the outgrowth of transformed clones (128).  With regards to 
MCV induced tumorigenesis, viral genome integration is a signature feature in MCC, 
indicating that even though humans are considered the natural host for MCV, Merkel 
cells may not be a permissive cell type and therefore are susceptible to transformation. 
Details about MCV genome integration in MCC can be found in section 1.5.4. 
1.2.7 Cell transformation assays 
Polyomaviruses provide excellent tools for studying the molecular basis of neoplastic 
transformation, which is characterized by the extended proliferation potential or 
increased survival of a cell (127). In cell culture systems it is possible to evaluate the 
effects that viral proteins have on the host cell, and determine specific cellular pathways 
that contribute to the transformation phenotype. The SV40 interactions with host cell 
proteins described in section 1.3.1 have been useful in identifying genes that are altered 
 26 
in many human cancers (for example p53), highlighting the relevance of studying 
tumorviruses like SV40.  Cellular pathways perturbed by SV40 (described in section 
1.3.1) have been assessed for their contributions to oncogenic transformation by a 
number of different in vitro and in vivo assays described below.  
1.2.7.1 Loss of contact inhibition 
Focus formation assays demonstrate the loss of contact inhibition that can be observed 
in cancer cells of diverse origins. Upon oncogenic signaling, adherent cells that usually 
would grow in a one cell-thick monolayer start to pile-up and grow on top of each other, 
forming visual foci on the dish. SV40 transformed rodent fibroblast cells readily form foci 
when co-cultured with, or plated on top of a monolayer of non-transformed, growth-
arrested cells (127). In addition to focus formation, saturation density measurements 
can also indicate loss of contact inhibition. Transformed cells exceed the maximum 
number of cells per unit area and fail to undergo growth arrest upon contact with 
adjacent cells. 
1.2.7.2 Immortalization 
Primary cells cannot be passaged in culture indefinitely. After a certain number of 
population doublings, they undergo growth arrest and senesce irreversibly. Rodent 
fibroblasts that are infected with SV40, however, are capable of dividing indefinitely, and 
are considered immortalized (127). Human fibroblasts on the other hand do not behave 
this way upon expression of SV40 T antigens, and require additional expression of 
human telomerase reverse transcriptase (hTERT) to maintain telomere length and 
escape senescence (127).  
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1.2.7.3 Anchorage-independent growth 
Soft agar growth has been established as another in vitro technique that tests the 
oncogenic potential of cells. In this assay cells are plated in a semi-solid agar medium in 
which non-transformed cells cannot grow. Cancer cells however, are able to grow 
anchorage-independently in this soft agar environment, forming sphere-like clumps 
called colonies. Cell transformation studies using rodent fibroblast cells have identified 
several polyomaviruses that are capable of inducing soft agar growth in addition to 
focus formation and immortalization (127, 129-131).  
1.2.7.4 Growth under nutrient deprivation 
In addition to focus formation and soft agar assays, serum starvation through culture 
medium provides insight into another characteristic specific to cancer cells, which is 
growth under nutrient deprivation. Non-cancerous cells usually stop dividing when they 
are placed in an environment with decreased serum growth factors (growth conditions 
are typically changed from 10% to 1 or 0.1% serum). Transformed cells however still 
continue to proliferate, overcoming environmental signals that would normally indicate 
growth arrest.  
1.2.7.5 Tumor formation in animal hosts 
The ultimate experimental evidence that supports the presence of a cellular transformed 
state is growth after xenograft transplantation into an immunocompromised host. In 
mouse experiments, cell lines are often injected subcutaneously and monitored for 
tumor formation at the site of the injection. However, transformed cells do also 
metastasize and form nodules at other body sites indicating an increased 
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aggressiveness of the transformed clone. Non-transformed cells do not grow in a 
xenograft setting due to a competitive environment for nutrients and blood supply with 
the host’s cells that has to be overcome to settle into a niche and support the growth of 
a colony of cells.  Xenograft experiments are especially useful in pre-clinical studies 
(such as described in Appendix A and B), to test drug efficacy and dosing regimens for 
cancers where a transgenic model is not available. Transgenic models that have been 
established for SV40 T antigen expression are described in detail in section 1.3.2. 
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1.3 SV40 EARLY REGION 
1.3.1 SV40 T antigen interactions with cellular proteins 
SV40 is one of the most well studied tumor viruses, and since its discovery in the late 
1950’s a wealth of information has been collected that has uncovered important 
pathways involved in basic cell biology. In its natural host the rhesus macaque, SV40 
infects quiescent epithelial cells in the kidney, which enter the cell cycle upon SV40 T 
antigen expression (127). An important feature of SV40 T antigen expression therefore 
includes its effect on cellular S-phase entry to create an environment that allows for viral 
genome replication. Highlights from studies of SV40 interactions with cellular proteins 
include the discovery of the important cellular tumor suppressor p53 and dissection of 
the retinoblastoma protein (pRB) pathway (132-135). In addition, SV40 LT has been 
shown to interact with a number of other cellular targets including p107, p130, 
p300/CBP, Hsc70, Cul7, Bub1, IRS1, and FBW7 (Figure 5) (136-145). 
1.3.1.1 SV40 LT interaction with Rb family 
It is well established that SV40 as well as all other polyomaviral large T antigens contain 
an LXCXE consensus motif, which targets the Rb family proteins pRB, p107 and p130. 
Other oncoproteins from various tumorviruses (HPV E7, Adenovirus E1A, or KSHV 
LANA2) also share this common motif, emphasizing the importance of the Rb pathway 
in regulating cellular growth (146, 147). Rb family members control the cell cycle by 
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inhibiting the E2F transcription factors including E2F1, E2F2, and E2F3a (activating 
factors) as well as E2F4 and E2F5 (repressive factors). E2F-responsive genes are 
involved in many pathways including cell cycle control, apoptosis, DNA repair and 
replication as well as nucleotide synthesis.  
The repressive E2F factors 4 and 5 preferentially bind p130 within a large 
complex called the DREAM complex that inhibits responsive promoters during G0 and 
in quiescent cells (148). The E2F4/5-p130 complex is also thought to recruit histone 
deacetylase (HDAC) to promoters, which additionally represses transcription through 
chromatin remodeling (149). SV40 LT can disrupt this repressive complex by targeting 
p130 for degradation, which allows for activation of genes involved in cell cycle entry 
(150) (Figure 4A). The ubiquitination and consequent degradation of p130 depends on 
chaperone functions mediated by the DnaJ domain of LT, which recruits cellular Hsc70 
(151, 152). 
In addition to mitigating E2F repressive effects, LT also induces transcription of 
E2F target genes by releasing activating E2Fs. E2F1/2/3a factors are usually bound to 
hypophosphorylated pRb until cyclin/cyclin dependent kinase complexes phosphorylate 
Rb (153). LT binding to pRb releases E2F1/2/3a resulting in E2F-mediated transcription 
of genes involved in S-phase entry, which contributes to LT mediated cell proliferation 
and transformation (Figure 4A). The exact role of p107 in cell cycle progression is less 
well understood. 
1.3.1.2 SV40 LT interaction with p53 
To prevent abnormal S-phase entry and maintain genome integrity, cells have 
established mechanisms to intervene with aberrant up regulation of E2F targets. This 
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process usually involves an increase in p53 protein level, which is generally low in cells 
due to p53 ubiquitination by Mdm2 (154). Activation of p53 by DNA damage, oxidative 
stress, or oncogene signaling leads to p53 stabilization and phosphorylation/acetylation, 
which allows for the transcriptional activation of genes involved in apoptosis and 
senescence (155). SV40 LT binds the p53 DNA binding domain through a bipartite site  
 
Figure 4. Targeting of the Rb-E2F and p53 pathways by SV40 LT 
(A) SV40 LT inhibits Rb-family pocket proteins pRb, p107 and p130 through its LXCXE motif. 
This leads to release of E2F transcription factors, which activate genes that induce S-phase 
entry. (B) Aberrant cell cycle entry leads to p53 activation to facilitate DNA repair or induce 
apotosis. SV40 LT counteracts this by binding to p53 and inhibiting activation of p53 responsive 
genes. (Modified from Sáenz Robles and Pipas, Ann. Rev. Microbiology, 2013) 
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in its C-terminal ATPase domain (residues 351-450 and 533-626), which prevents 
tetramerization of p53, and therefore prohibits its transcriptional activity (156) (Figure 
4B). In contrast to other viral oncoproteins that either target p53 for proteasomal 
degradation (i.e. HPV E6) (157) or repress its transcription (i.e. adenovirus E1B 55k) 
(158), SV40 LT stabilizes p53 levels in the cell, while inactivating its transcriptional 
activity (159). In 1979, p53 was discovered in complex with SV40 LT (135, 160), and it 
was initially mistaken for an oncogene due to its increased protein level in SV40 
transformed cells.  
Even though it is clear that SV40 inactivates p53-mediated apoptosis in response 
to aberrant S-phase entry, the complete extent of the LT-p53 interaction still remains to 
be worked out. p53 has a diverse range of downstream targets, some of which may be 
involved in different aspects of the SV40 cellular reprogramming (161). Studies that 
evaluated the growth promoting effects of SV40 LT in rodent cells discovered that 
transformation efficiency was markedly reduced in the absence of wildtype p53, 
indicating a gain-of-function modality for the SV40 LT interaction with p53 (162). Results 
from a transgenic model of SV40 LT induced beta cell carcinogenesis (Rip1Tag2) 
support this data, with lower tumor volumes observed in mice crossed to p53 deficient 
mice (163). The possible role of a gain-of-function by redirecting wildtype p53 activity 
may also explain why SV40 LT does not degrade p53 protein, but instead stabilizes it. 
One explanation that has been proposed is that LT binds wildtype p53 to recruit the 
CREB binding protein (CBP)/p300 coactivators to allow for posttranscriptional 
modification (acetylation) on LT (164). The significance of this modification or other 
functions achieved by the LT-p53 complex remains to be identified.  
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1.3.1.3 Other SV40 LT cellular targets  
In addition to the pRb family proteins and p53, SV40 LT interacts with a number of other 
cellular proteins, demonstrating its multifunctional nature (Figure 5). Several of these 
interactors have been implicated in LT-mediated transformation. The following 
paragraphs provide a brief overview of the additional SV40 LT cellular targets. 
 
Figure 5. SV40 LT domains and cellular interactors 
SV40 LT is a multifunctional protein that binds to a variety of cellular interactors through 
conserved motifs. Cellular binding partners are indicated in brackets (orange letters) and their 
respective amino acid binding sites on LT are shown (black numbers). (Modified from Gjoerup 
and Chang, 2010) 
 
J Domain 
The N-terminal region of SV40 T antigen, shared by both LT and sT, contains a J-
domain ranging from amino acids 1 to 82 (165), which is functionally conserved in all 
polyomavirus T antigens. The J domain is similar to that of molecular chaperones called 
DnaJ proteins, which interact with cellular heat shock (Hsc) proteins to mediate 
chaperone functions including protein folding and transport. The J domain of SV40 and 
other polyomaviral T antigens consists of a conserved HPDKGG motif and the CR1-like 
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region (141). The CR1 motif is similar to that found in adenovirus E1A and contributes 
to cellular transformation. E1A targets pRb and p300 through its CR1 (166) but this has 
not been confirmed for polyomavirus T antigens, for which the cellular target of this 
region remains to be discovered.  
Both LT and sT bind to the cellular DnaK family member Hsc70 through the 
HPDKGG motif and this interaction is important for both viral replication as well as 
transformation functions of T antigen (141). The ATPase activity of Hsc70 is required for 
LT binding to pRb, p107 or p130 by releasing heterodimeric E2F-DP complexes, which 
are then freed to facilitate cell cycle progression (141, 142, 152). The sT interaction with 
Hsc70 facilitates sT binding to the heterotrimeric protein phosphatase 2A (PP2A) by 
replacing its regulatory B subunit (141). Mutations of the HPDKGG motif reveal the 
importance of this domain for viral replication and transformation. D44N and H24Q are 
two classic mutants that are used in molecular studies to study the significance of this 
motif. The D44N mutant does not bind Hsc70, is defective for viral replication, and 
shows decreased transforming activity (141).  
 
CBP/p300 
Cyclic AMP response element binding (CREB)- protein (CBP) as well as p300 are 
cellular tumor suppressors that possess intrinsic histone acetylase (HAT) activity 
through which they mediate a wide range of cellular processes involved in cell growth 
and transformation (167). SV40 LT binds to the co-activators CBP/p300 (168) and this 
interaction contributes to the transforming activity of LT (137) through an unknown 
mechanism (150). The association of LT with CBP/p300 leads to acetylation of LT on 
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residue K697 through CBP and is dependent on LT binding to p53 (164, 169). The 
significance of K697 acetylation remains to be elucidated. Adenovirus E1A also binds 
CBP/p300 resulting in a changes in histone modification patterns (170) and global re-
localization of RB family members and CBP/p300 on cellular promoters (150). This 
leads to a change in the cellular transcriptional program that results in cell cycle entry 
and progression (150, 171). SV40 LT can rescue non-transforming E1A mutants that 
are incapable of binding to CBP/p300 (143), indicating a similar role for SV40 LT on 
chromatin remodeling and transcriptional reprogramming.  
 
p400 
The chromatin remodeling ATPase p400 is a member of the SWI2/SNF2 family of 
proteins. Adenovirus E1A binds to p400 as well as the scaffolding protein TRRAP, 
which results in stable association of p400 with c-Myc and subsequent stabilization of c-
Myc protein levels (172). This increase of c-Myc protein results in transcriptional 
activation of c-Myc target genes in the presence of E1A (172). SV40 LT has been 
shown to bind to p400 as well (144), but the significance of this interaction with regards 
to T antigen mediated transformation is not well understood. 
 
Cul7 
The molecular scaffold cullin 7 (Cul7) is part of an SCF (Skp1, cullin, F-box) E3 ubiquitin 
ligase complex containing Skp1, ROC1 and Fbw8, which targets specific cellular 
proteins for proteasomal degradation (173). Cul7 was first identified in association with 
SV40 LT (amino acids 69-83) and LT mutants incapable of binding Cul7 are defective in 
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transformation assays even though binding to pRB and p53 remains unchanged (138, 
174). Cellular proteins that are targeted for degradation through Cul7-SCF complexes 
include cyclin D1 (175) as well as insulin receptor substrate 1 (IRS1) (176). Further 
studies are needed to determine whether or not alterations in the degradation of these 
two known Cul7-SCF targets is essential in LT mediated transformation. 
 
Bub1 
The mitotic checkpoint kinase Bub1 ensures appropriate attachment of kinetochores to 
microtubules during the metaphase to anaphase transition (177). A yeast two-hybrid 
screen discovered Bub1 as a cellular binding partner of SV40 LT and genetic mapping 
experiments revealed LT amino acid residues 89-97 as the responsible interaction 
domain (139). Other polyomaviral T antigens that share the Bub1 binding site include 
JCV, BKV, and bovin polyomavirus LTs. Bub1 inactivation by SV40 LT de-regulates the 
cellular DNA damage response (178) and results in cellular senescence in the absence 
of pRb and p53 targeting by LT (179).  
 
IRS1 
Insulin receptor substrate 1 (IRS1) is a docking protein for both insulin and insulin 
growth factor-I receptor (IGF-IR) (180) whose downstream signaling involves PI3K/Akt 
activation (181). SV40 LT binds to IRS1 and this interaction is required for efficient 
transformation by LT (180). While LT is incapable of transforming IRS1 deficient cells, 
its transforming activity can be restored by exogenous expression of wildtype IRS1; 
however, IRS1 that is mutated in its PI3K binding site does not restore transformation. 
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Both SV40 as well as JCV LTs have been shown to interact with and translocate IRS1 
from the cytoplasm to the nucleus (182, 183).  
 
Nbs1 
The Nijmegen breakage syndrome 1 (Nbs1) protein is part of the MRN complex, which 
is composed of Mre11, Rad50 and Nbs1. This complex has been implicated in DNA 
double-strand break repairs (184) and its dysfunction due to Nbs1 mutations in the 
Nijmengen breakage syndrome leads to chromosomal instability, which in turn 
increases cancer incidence. SV40 LT binds to Nbs1 through its origin-binding domain, 
which facilitates unlicensed firing of the viral origin (185). Whether or not the LT-Nbs1 
interaction is important for transformation remains to be uncovered. 
 
Fbw7 
The F-box protein Fbw7 is the substrate recognition component of the SCF-Fbw7 
ubiquitin ligase complex that targets specific proteins for degradation by the 
proteasome. Known targets of this complex include cyclin E (186), c-Myc (187), c-Jun 
(188), and Notch (189). SV40 LT binds to Fbw7 through a conserved Cdc4 phospho-
degron (CPD) site that usually binds cellular target proteins (190). Despite binding to 
this site LT does not get degraded and is thought to compete with cellular targets such 
as cyclin E (190), which are stabilized in the presence of LT due to decreased targeting 
by the SCF-Fbw7 complex. Given that Fbw7 regulates the proteolysis of a number of 
oncoproteins, SV40 LT targeting of the SCF-Fbw7 complex likely plays a role in its 
transformation activity.  
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1.3.1.4 SV40 sT  
SV40 sT shares the N-terminal portion (82 amino acids) with LT, which includes a 
functional J domain (described in section 1.3.1.3). sT is a 147 amino acid long protein 
that can be found in both the nucleus as well as the cytoplasm. The C-terminal region is 
unique to sT and contains two Zinc-binding CXCXXC domains that provide 
conformational stability (191) (Figure 6). 
 
Figure 6. SV40 sT domains and cellular interactors 
Cellular binding partners of SV40 sT are indicated in brackets (orange letters) and their 
respective amino acid binding sites are shown (black numbers). (Modified from Gjoerup and 
Chang, 2010) 
 
SV40 sT cooperates with LT to fully transform cells. Rodent cells that only 
express LT acquire lack of contact inhibition and form foci, but they do not grow 
anchorage independently without the presence of sT (192, 193). Human cells require 
oncogenic signaling events in addition to LT and sT expression to become transformed. 
Hahn et al. demonstrated that BJ fibroblast cells that expressed LT and sT were 
anchorage independent and grew in immuocompromised mice only in the presence of 
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human telomerase reverse transcriptase (hTERT) as well as mitogenic hRas (V12 
mutant) (194). The contribution of sT to transformation depends on sT’s interaction with 
the protein phosphatase 2A (PP2A).  
PP2A is a ubiquitously expressed heterotrimeric serine-threonine protein 
phosphatase that is involved in various proliferation and apoptosis related signaling 
pathways within the cell. It is composed of a scaffold subunit A, a regulatory subunit B, 
and a catalytic subunit C. The PP2A holoenzyme can be composed of different 
variations of splice isoforms of the individual subunits. Subunit A and C each have two 
splice variants α and β, whereas at least 20 different B subunits have been identified 
thusfar (195).  Combinations of the different subunits can assemble into over 100 
different complexes, with the B subunits conferring substrate specificity (195, 196). 
SV40 sT binds to the scaffolding subunit A through sT-unique residues 97-103 
(197). This interaction inhibits binding of the B subunit in a concentration dependent 
manner, and compromises PP2A activity (195, 198). In addition to the direct interaction 
of sT with PP2A through residues 97-103, the J domain of sT, located in the N-terminal 
region of sT, directly contributes to PP2A B subunit displacement and sT binding to the 
A subunit (198). sT preferentially inhibits certain subsets of PP2A complexes but the 
nature of how this selection process occurs is still poorly understood (199). Cellular 
targets that are altered by PP2A inhibition by sT include c-Myc, which is stabilized 
through S62 dephosphorylation (200), as well as Akt, which gets phosphorylated 
leading to mTOR pathway activation and increased cap dependent translation (201, 
202). sT targets a variety of cellular kinases involved in cell proliferation that are 
controlled by PP2A. Examples of these in addition to Akt include MAP kinase signaling 
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(203) and PKCξ activation, which in turn leads to NFκB activation (204). The fact that 
PP2A regulates more than 30 kinases in the cell indicates that sT may have access to 
control a wide range of signaling pathways, which are likely to contribute to sT-mediated 
transformation.  
1.3.2 SV40 transgenic mouse models 
Transgenic mouse models are powerful tools to study the contribution of specific 
genetic elements to tumor formation in an animal host. They provide the opportunity to 
analyze transgene expression in specific tissue types and at different stages during 
development. The SV40 early region has been expressed in a variety of tissues in the 
mouse. Depending on the specific tissue environment, expression of LT, sT, or both can 
lead to the development of hyperplasia, dysplasia, carcinoma, or even malignant 
metastatic disease (127, 205). On the other hand, some tissues show no proliferative 
stimulation at all, underscoring the importance of the specific cell type for tumorigenesis 
(199). A well-characterized SV40 transgenic mouse model targets LT expression to the 
choroid plexus epithelium (CPE) in the brain, which leads to rapid tumor formation 
(206). The aggressiveness of this particular tumor development is emphasized by the 
short life expectancy of only 1-2 months in this mouse model.  
Functional dissection of LT domains responsible for tumor development in this 
model revealed that expression of a N-terminal fragment including amino acids 1 
through 121 (LT1-121) is sufficient for tumor development; however, tumors progress 
much slower compared to full length LT (207, 208). This observation can be attributed 
to the p53 targeting domain, which is present in full length LT but not in LT1-121. p53 
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targeting by full length LT prevents the induction of apoptosis by LT expression, and 
therefore promotes more rapid tumor development (209, 210). Consequently, in a p53 
deficient mouse strain, expression of LT1-121 is able to induce tumor development at 
the same rate as full length LT (210). The LXCXE Rb family-targeting domain is 
essential for tumor development in the context of LT1-121 expression, highlighting the 
importance of pocket protein inhibition for malignant progression in vivo. These results 
point out that while Rb family targeting is required for cell proliferation through 
promoting cell cycle entry and progression, p53 targeting prevents subsequent 
apoptosis induction due to checkpoint activation in response to abnormal cell cycle 
entry. Therefore, full malignant tumor development in the CPE requires both, the Rb as 
well as p53 targeting domains of LT. This was confirmed in the mammary gland, where 
expression of LT1-121 induces tumors to a lesser extend than full length LT due to p53 
mediated apoptosis induction (211). In addition, p53 targeting by full length LT is also 
required for the formation of B and T cell lymphomas in respective transgenic model 
systems (207, 208). 
Interestingly, the requirement of p53 inactivation for tumorigenesis highly 
depends on the specific cell type that is targeted for transgenic LT expression. In 
intestinal enterocytes for example, LT1-121 or LT1-136 expression induces hyperplastic 
development that progresses to dysplasia with age (212) and this is unchanged in a p53 
deficient background (213, 214). Hyperplasia development in enterocytes is however 
dependent on an intact LXCXE Rb family-targeting motif as well as a functional J 
domain, both of which collaborate to bind to pocket proteins and release E2F 
transcription factors, which in turn promote cell cycle entry and progression. Microarray 
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analysis in the context of full length LT and LT1-136 expression in enterocytes revealed 
that the transcriptional profile was almost identical, emphasizing the essential role of the 
Rb-E2F axis for hyperplastic development in the intestine (153). Other cell types in 
which p53 targeting by full length LT is dispensable include astrocytes, the pancreatic 
epithelium as well as hepatocytes. In astrocytes, induction of apoptosis by LT 
expression is mediated through PTEN. Expression of LT1-121 in the context of PTEN 
loss accelerates astrocytomas in this transgenic model (215). Similar results can be 
observed in the pancreas, where tumor evolution is associated with PTEN loss and 
does not depend of p53 inactivation by LT (216). In a liver specific transgenic model, a 
functional J domain and intact Rb family-targeting domain are sufficient to induce 
hepatocellular carcinomas upon expression of LT1-121 (217). 
Overall, it is clear that SV40 LT targeting of the Rb-E2F pathway is necessary for 
tumor formation in all cell types tested thus far. In contrast, p53 inactivation by LT is 
dispensable in some cell types. There are several possibilities that could explain 
heterogeneous requirements for tumor formation in different cell types. It may be 
possible that LT interacts with diverse sets of proteins in different cell types, which in 
turn have differential affects on tumor formation (205). On the other hand, it is also 
possible that LT interacts with the same cellular proteins in all cell types, but that the 
signaling pathways that these proteins are involved in are regulated differently in each 
cell type (205). Either way, SV40 T antigen transgenic mouse models undoubtedly 
recapitulate the heterogeneity of the disease they are modeling, which is cancer.  
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1.4 MERKEL CELL CARCINOMA 
1.4.1 Origin and pathology 
The first description of Merkel cells (MCs) dates back to 1875, when the German 
pathologist Friedrich Sigmund Merkel identified them as “Tastzellen” or “touch cells” 
(51). Merkel’s early observations already predicted the mechanoreceptor function of 
MCs and their role in sensory sensation in the skin, which was established much later 
(218). Located in the basal layer of the epidermis and hair follicle bulges, MCs are 
closely associated with nerve endings, which is essential in their function of transmitting 
mechanical stimuli (219) (Figure 7). 
 For a long time, the exact cellular origin of MCs was a topic heavily debated, but 
recent lineage-tracing studies indicate that MCs arise from epidermal stem cells rather 
than neuronal progenitors (220). MCs give rise to Merkel cell carcinoma (MCC), an 
aggressive, cutaneous neoplasm, which resembles both basal cell carcinoma and small 
cell lung carcinoma (SCLC) in its morphology (221, 222). Interestingly, MCC is positive 
for both epithelial as well as neuroendocrine markers. The most distinguishing 
immunohistochemical markers that are used in the identification of MCC in the clinic 
include perinuclear staining of cytokeratin 20 (CK20) (Figure 8B), and negative staining 
for thyroid transcription factor-1 (TTF-1) as well as leukocyte common antigen (LCA) 
(223).  
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Figure 7. Location of Merkel cells 
Merkel cells (in light blue) are located in the basal layer of the epidermis as well as hair follicle 
bulges, where they make connections with nerve endings. (Modified from Spurgeon and 
Lambert, Virology, 2013) 
1.4.2 Incidence and clinical manifestation 
MCC is more common in immunosuppressed individuals such as AIDS and transplant 
patients as well as the elderly (53). The chance of developing MCC is increased 13-fold 
in AIDS patients compared to the general population (52). Ultraviolet (UV) exposure 
poses an additional risk factor for developing MCC, as is seen in melanoma and other 
skin cancers (224). The majority of MCC patients are Caucasian with a slightly higher 
frequency in males (225). MCC incidence has risen within the past two decades 
reaching approximately 1,500 cases per year in the United States (226). Elevated UV 
exposure in many parts of the world as well as increasing older populations may result 
in even more MCC cases in the future. Potentially due to its association with UV 
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radiation, MCC often arises in the extremities including legs, arms, and the head. 
Figure 8C depicts a MCC lesion on the arm of a patient.  
 
Figure 8. Pathology and clinical manifestation of MCC 
(A) Hematoxylin and Eosin (H&E) and (B) diagnostic cytokeratin (CK) 20 perinuclear stain of 
MCC tumor tissue (C) Red MCC nodule on a patient arm. (Modified from Chang and Moore, 
Annual Review of Pathology, 2012) 
 
 
Clinically, MCC is divided into four stages classifying disease severity and 
prognosis (227). Stages I and II include cases that present as local lesions at the 
primary site on the skin. Stage I encompasses lesions up to 2 cm in diameter, and stage 
II includes lesions that exceed this 2 cm mark (228). MCC cases that involve metastasis 
to local lymph nodes are classified as stage III. Stage IV, the most severe form, consists 
of metastatic MCC beyond the lymph nodes (228). Staging at diagnosis predicts 
disease outcome, and determines the treatment regimen. Survival of MCC patients 
depends on the stage of the tumor at diagnosis. Patients that are diagnosed with stage I 
MCC have a 5-year survival average of 60%, whereas only 18% of stage IV patients 
survive 5 years (229). These statistics highlight the aggressiveness of MCC as well as 
the limited treatment options of progressed disease stages. 
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1.4.3 Treatment 
The standard treatment regimen for local MCC primary tumors includes wide surgical 
excision followed by adjuvant radiotherapy. In addition, sentinel lymph node biopsies 
are necessary to evaluate regional metastases, which are treated by complete lymph 
node resection followed by radiation therapy (227). There is a high recurrence rate of 
30-40%, and primary tumors frequently metastasize to distant sites (230). Distant 
metastatic MCC as well as inoperable primary tumors are often treated with 
chemotherapeutic regimens used for SCLC patients. Chemotherapeutics used for MCC 
include a combination therapy with doxorubicin, cisplatin, and vincristine, or with 
platinum and etoposide (231).  These treatment regimens yield a good response only 
within the first 8 months, resulting in a poor survival prognosis (231). The median 
survival time for patients with advanced disease is only 10 months. For a long time, the 
lack of knowledge about the molecular pathways involved in MCC hindered the design 
of a more targeted chemotherapeutic treatment regimen. However, with the 2008 
discovery of MCV as the causative agent of the majority of MCC (55), new studies have 
already utilized this viral etiology as a target for therapy in pre-clinical studies (232) 
(detailed description in Appendix A and B).  
1.4.4 Molecular features 
Several studies have found karyotypic abnormalities in MCC. These include deletions or 
rearrangements in chromosomes 3p, 4, 5q, 7, 10q, 13q and 17q, as well as 
amplifications of 1q, 3q, 5p, 6 and 8q (233-235). Even though chromosomal aberrations 
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are not consistent across MCC cases, genetic elements that may potentially play a role 
in tumorigenesis include L-Myc as well as pRB1 (235). However, studies linking these 
abnormalities to the development of MCC are missing. 
Gene mutations involved in oncogenic or tumor suppressor signaling have also 
been evaluated as potential links to MCC. The tumor suppressor p53, which is 
frequently mutated in skin cancers due to UV exposure (236), is mutated only in a 
subset of MCC, with a large number of MCC tumors having wildtype p53 sequence 
(237, 238).  Both Ras (Ha-, Ki- and N-Ras) and CDKN2A (INK4a-ARF locus encoding 
p14 and p16) point mutations have been implicated in skin tumorigenesis including 
squamous cell carcinoma (SCC) and melanoma (239-241). In the case of MCC 
however, neither could be detected thus far (237, 242). 
Activating B-raf mutations, which can be observed in melanoma as well as other 
human cancers (243), were not present in a study that tested 49 MCC cases; in 
contrast, classical MAP kinase signaling was reported as silenced in this set of MCC 
(244).  Additionally, the Wnt/βcatenin pathway as well as c-Kit expression have been 
evaluated in MCC for possible mutations; however neither show consistent de-
regulation that could explain tumorigenic development (245, 246). Finally, expression of 
the anti-apoptotic protein Bcl-2 was reported in 15 out of 20 MCC cases (247, 248), 
which may explain evasion from apoptotic cell death, but does not indicate pathways 
involved in cell proliferation in MCC. 
Up until 2007, many studies identified pathways that are not involved in MCC 
tumorigenesis; however, the molecular signaling that does play a role in MCC was still a 
 48 
mystery (226). This all changed with the 2008 discovery of an infectious agent 
associated with MCC. 
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1.5 MERKEL CELL POLYOMAVIRUS 
1.5.1 Discovery of MCV 
In 2008, Feng et al. reported the discovery of a clonally integrated polyomaviral genome 
present in 8 out of 10 MCC samples tested (55). In this study, DTS was used to screen 
MCC cDNA libraries for the presence of non-human sequences, which could indicate 
the presence of a viral agent. Two MCC cDNA libraries were created from a total of 4 
MCC tumor samples and pyro-sequencing generated a total of 216,599 and 179,135 
cDNA sequences of ~150 to 200 bp each (55). A high-fidelity (HiFi) dataset of 382,747 
sequences from both libraries was generated and subjected to DTS analysis (55) 
(Figure 9). In silico subtraction of annotated RefSeq RNA, mitochondrial, assembled 
chromosomes and immunoglobulin sequences from National Center for Biotechnology 
Information (NCBI) databases, yielded a total of 2394 non-human sequences, which 
represented candidates for viral genome sequences (55) (Figure 9).  
Utilizing the Basic Local Alignment Search Tool (BLAST), one candidate cDNA 
sequence DTS1 indicated high homology to T antigen sequences from both African 
green monkey lymphotropic polyomavirus (LPyV) as well as human BK polyomavirus 
(55) (Figure 9). The novel polyomavirus was called Merkel cell polyomavirus (MCV) 
due to its connection with MCC. DTS analysis also identified a second cDNA sequence 
DTS2 aligning with the MCV genome, which showed no homology to any other known  
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Figure 9. Digital transcriptome subtraction 
In silico DTS pipeline applied to MCC cDNA libraries comprised of 4 MCC tumor samples. 
(Modified from Feng et al., AACR meeting presentation) 
 
polyomaviruses (55). Subsequent experiments including Rapid amplification of cDNA 
ends (3’RACE) and genome walking generated the first complete MCV prototype 
genomes MCV350 and MCV339 (Accession numbers EU375803 and EU375804 
respectively) (55). PCR analysis and Southern blotting identified MCV positivity in 80% 
(8 out of 10) of MCC tumor samples as well as one metastasis. In contrast, PCR 
analysis with 13 MCV-specific primer pairs revealed only 8% positivity in 59 control 
tissues from various body sites (from individuals without MCC) and 16% positivity in 
non-MCC skin samples from both immunocompetent and immunosuppressed 
individuals (including KS and AIDS patient samples) (55). 
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1.5.2 MCV genome organization 
MCV is a double-stranded DNA virus with a genome length ranging from 5.2 to 5.4 kb. 
Like other polyomaviral genomes, the MCV genome can be divided into an early and a 
late region divide by a non-coding regulatory region (NCRR) (Figure 10). This NCRR 
contains the MCV origin of replication (described in detail in Chapter 3 of this thesis), as 
well as a bi-directional early and late promoter element. The early region transcribes  
Figure 10. MCV 350 prototype genome organization 
MCV350 has a circular double stranded-DNA (5387 bp) genome including a non-coding 
regulatory region (NCRR), which includes the viral replication origin and a bi-directional early 
and late promoter element. The early region includes T antigen transcripts (LT, sT and 57kT); 
the late region includes viral proteins 1, 2, and 3 (VP1-3). The MCV encoded miRNA miR-M1 is 
indicated with a black arrowhead. (Modified from Chang and Moore, Annual Review of 
Pathology, 2012) 
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alternatively spliced T antigen sequences encoding large T (LT) and small T (sT) 
antigens similar to other polyomaviruses. In addition, MCV encodes a 57 kT splice 
isoform comparable to SV40 17kT (110) (Figure 10 and 11). Initially it was thought that 
neither the middle T (MT) antigen transcript observed in murine polyomavirus (249), nor 
an agnoprotein as seen in other polyomaviruses (250, 251) were encoded  by MCV. A 
recent report however describes a novel MCV MT-like T antigen isoform named ALTO, 
which is translated from an internal start codon in LT exon 2 with an alternative ORF 
(252).  
The MCV late region encodes for the 3 capsid proteins VP1, VP2 and VP3, 
which are capable of self assembly into virus-like particles (VLPs) of icosahedron 
structure (253). Late gene expression has been linked to active replication of viral DNA. 
A tumor-derived point mutation in the origin of the MCV-HF molecular clone abolishes 
viral replication and diminishes late gene expression (254). The viral origin of replication 
is described in detail in chapter 3 of this thesis.   
Members of the polyomavirus family including PyV, SV40, BK and JC have been 
shown to encode viral micro RNAS (miRNAs) that regulate early gene expression (255, 
256). In the case of MCV, the miRNA miR-M1 (Figure 10) has been demonstrated to 
regulate LT expression in vitro as well as in MCV-positive MCC tumors (257, 258).  
Therefore, its function may involve regulation of LT expression to evade immune 
surveillance. Cellular targets of miR-M1 have not been identified at this point.  
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1.5.3 Large T antigen truncations in MCC tumors 
Sequencing of additional LT genomes from MCC tumors revealed a consistent pattern 
of C-terminal truncations due to pre-mature stop codons generated by deletion, 
substitution, frame shift, or missense mutations (56, 259-261). This feature is unique to 
tumor-derived LT genomes, and LT sequences isolated from asymptomatically infected 
tissues (i.e. LT206 derived from appendix) are full length (56). All sT sequences isolated 
from MCC tumors thus far are unaffected by truncation mutations. Figure 11 indicates 
the C-terminal genomic region in LT that harbors tumor specific truncation mutations. 
The LT domain that is eliminated in MCC tumors includes the ATPase/helicase domain, 
which is essential in facilitating viral DNA replication. Thus, tumor-derived truncated LT 
proteins are defective in initiating viral origin replication (56). Recently, the C-terminal 
exon 3 of LT has been shown to have a growth-inhibitory function independent of viral 
replication features (260). Both the viral replication function as well as the growth 
inhibitory effect of the C-terminal portion of LT may explain the selective pressure to 
mutate and eliminate this domain during the process of tumorigenesis. Additionally, 
mutations in the viral origin as well as VP1 region have been observed, both of which 
prevent viral particle formation in tumor cells (254, 262). 
Tumor-derived MCV genomes conserve N-terminal domains that are shared with 
other members of the polyomavirus family as well as other DNA tumor viruses. These 
include the conserved region 1 (CR1), DnaJ domain, PP2A binding site in sT, as well as 
the pocket protein (Rb, p107, p130) binding (LXCXE) motif (Figure 11) (56). In addition, 
the MCV unique region immediately N-terminal to the LXCXE contains an hVam6p 
binding site, which sequesters hVam6p to the nucleus, consequently disrupting 
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lysosome clustering (263). The functional importance of this interaction has not been 
addressed yet. All tumor LT truncating mutations described thus far appear after the 
LXCXE motif (56, 259, 260), which indicates that this interaction domain is important in 
facilitating tumorigenic development and maintenance.  
 
Figure 11. MCV T antigen locus 
Alternatively spliced transcripts from the MCV early region include LT, sT1, sT2 and 57kT. 
mRNA splicing is indicated by the dotted line. Conserved protein interaction domains CR1 
(conserved region 1), DnaJ, Rb (retinoblastoma) binding, hVam6p binding and a nuclear 
localization signal are located in the N-terminal portion of LT. The C-terminal region, which is 
affected by tumor truncations (indicated by arrows for prototypes MCV350 and MCV339) 
contains an origin binding domain (OBD), Zinc finger, leucine zipper and ATPase/helicase 
domain required for viral replication. MCV sT has a PP2A (protein phosphatase 2A) binding 
motif as seen in other polyomaviral sT proteins. The positions of antibody epitopes CM8E6, 
CM2B4, and 5E1.6 are shown within different T antigen isoforms. 
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1.5.4 MCV genome copy number and integration 
When MCV was initially discovered, it was found clonally integrated in MCC tumors 
(55), indicating that MCV infection and genome integration precedes carcinogenesis. 
MCV T antigen copies per cell are usually detected at a level of  >1 by qPCR, with some 
MCCs having more than 10 copies per cell (55, 57, 264). VP region copy number 
determinations repeatedly yield higher copy numbers by qPCR than assays targeting 
the T antigen region (57, 265). At this point the significance of this is unknown, but 
important experimental limitations that have to be taken into account include potential 
differences in primer efficiencies for either VP or T antigen amplification. Viral MCV 
genome copies >1 per cell indicates either multiple cellular integration sites, or viral 
concatenation in a single integration site. Southern blotting analyses have shown that 
viral concatamers are present in some MCV-positive MCC cell lines (56, 265).  
A common cellular integration site in MCC would indicate the interruption or 
activation of a cellular gene by the viral genome as a factor contributing to MCC 
tumorigenesis. Multiple groups have mapped integration sites in MCC, but no consistent 
gene location has been identified (259, 266, 267). This indicates that viral protein 
expression in fact is a key mediator of tumor development. Further details regarding 
viral copy number and genome integration in MCC cell lines are described in Chapter 2 
of this thesis. 
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1.5.5 MCV Serology and transmission 
The fact that low copies of MCV DNA could be detected in healthy tissues of non-MCC 
patients raised the question whether or not MCV infection is ubiquitous in humans, as 
seen with other human tumor viruses. Rolling circle amplification (RCA) as well as 
nested PCR on DNA isolated from skin swabs of healthy individuals revealed that MCV 
is part of the normal human skin flora (90, 268), and serologic studies confirmed 25-
88% seroprevalence in healthy individuals (87, 253, 269, 270). However, when 
comparing healthy individuals to MCV-positive MCC patients, it is clear that MCC 
patients have significantly higher antibody titers against MCV  (Figure 12B) (269).  The 
wide range of MCV seroprevalence in healthy individuals observed between different 
studies could in part be contributed to differences in antigens used. Analyses utilizing 
GST-VP1 fusion proteins detect 25-59% seroprevalence (87, 270), whereas the use of 
VLP-derived VP1 epitopes as antigens detects MCV antibodies with higher sensitivity of 
60-88% in individuals (105, 269, 271). Antibodies against MCV can be detected in 
children as young as 2 years of age, and a study comparing sera from Langerhans cell 
histiocytosis (LCH) patients of different age groups reveals an increase of 
seroprevalence over time, with 80% of people 50 years and older testing positive for 
MCV exposure (269) (Figure 12A). 
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Figure 12. MCV Seroprevalence 
(A) MCV seroprevalence can be detected early in life, and increases with age in Langerhans 
cell histiocytosis (LCH) patients. (Reproduced from Tolstov et al., International journal of cancer, 
2009) (B) Neutralization assays reveal significantly higher anti-MCV antibody levels in 
MCV+MCC patients compared to healthy controls. (Adapted from Pastrana et al., PLOS 
Pathogens, 2009) 
 
No children under the age of 1 showed any MCV seroprevalence, indicating that 
vertical transmission is not likely; yet the fact that young children between the ages of 2-
5 have detectable levels of antibodies against MCV, suggests a casual route of 
transmission (269). MCV, as well as KIV and WUV, may be transmitted by respiratory 
route since DNA from these viruses can be detected in the respiratory tract (272-274). 
In addition, MCV is also found in sewage samples (275), but the possible role of this in 
transmission remains to be elucidated. 
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1.5.6 T antigen expression in MCC 
Immunohistochemical analyses of 51 MCC tumors using either the LT specific antibody 
CM2B4 or an antibody against sT 5E1.6, reveal that 73% of tumors express both T 
antigens (129) (antibody epitopes indicated in Figure 11). In this particular study 75% of 
tumors were positive for LT, whereas 92% were positive for sT expression (129).  MCC 
tumor cells uniquely express T antigens, which cannot be detected in healthy tissue 
adjacent to the tumor (Figure 13 A-B) (129).  MCV-positive MCC cell lines express both 
individually truncated versions of LT as well as sT protein (see chapter 2). MCC tumors 
specifically express MCV T antigens, and immunohistochemical staining with an 
antibody recognizing SV40 LT shows no positivity (Figure 13C). 
 
Figure 13. MCV T antigen expression in MCC 
Immunohistochemical evaluation of a MCC tumor tissue demonstrates (A) MCV sT expression 
using 5E1.6 and (B) MCV LT expression using CM2B4 in tumor cells but not normal adjacent 
tissue. MCC specifically expresses MCV T antigens; (C) SV40 LT expression cannot be 
detected using the antibody Pab419. Original magnification x100; insets x1000. (Modified from 
Shuda et al., Journal of clinical investigation, 2011)  
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To elucidate whether or not MCV-positive MCC cancer cell lines are dependent 
on T antigen protein expression, knockdown studies were performed that evaluated the 
effect of simultaneous knockdown of LT and sT (panT), or sT knockdown alone. panT 
knockdown results in non-apoptotic cell death as well as markedly reduced cell cycle 
entry of MCV-positive MCC cell lines (129, 276). The mechanism of cell death is still 
unknown. On the other hand, sT knockdown alone (targeting the sT unique region in 
intron 1) does not induce cell death, but rather results in growth arrest with moderate 
inhibition of cell cycle entry (129). It is difficult to knockdown LT independently of sT, 
due to an overlap of mRNA sequence of these two transcripts (Figure 11). However, 
one report describes the successful knockdown of LT alone by targeting the splice site 
between exons 1 and 2 (277). LT-specific knockdown results in growth retardation of 
MCV-positive MCC cell lines in vitro, and in a mouse xenograft experiment. Ectopic 
shRNA-insensitive LT expression rescues this phenotype in an LXCXE-dependent 
manner, highlighting the importance of this domain in MCC tumors. 
1.5.7 MCV T antigen interactions with cellular proteins 
Like SV40 and other tumor viruses, the MCV genome contains an LXCXE-pocket 
protein-binding motif in LT, which is essential for interactions with Rb family members 
pRB, p107 and p130 as well as other LXCXE-motif containing proteins. Tumor-derived 
as well as full length MCV LT bind pRB in an LXCXE-dependent manner, and mutation 
of this motif to LXCXK abolishes the interaction (56). As seen with other tumor viruses, 
this interaction is thought to induce cell cycle entry and therefore is probably important 
in MCV induced tumorigenesis. MCV LT has been shown to indirectly target the inhibitor 
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of apoptosis protein (IAP) family member survivin, most likely via E2F transcriptional 
activation of the survivin promoter as this effect is LXCXE motif-dependent (232). MCV-
positive MCC cells are dependent on survivin expression and a survivin inhibitor shows 
promising effects in mouse xenograft studies (232) (details can be found in Appendix B 
and C).  
Interestingly, neither full length, nor tumor-derived LT binds to p53, a common 
cellular target of polyomaviruses and other tumor viruses (260). The C-terminal domain, 
which is responsible for p53 interaction with SV40 LT, is deleted in tumor-derived MCV 
LT indicating that MCV-induced tumorigenesis is either independent of p53 status or 
requires additional cellular mutations in the p53 signaling pathway. 
A study aimed to discover MCV exclusive interactions utilized the MCV unique 
region (nt. 861-1565) in a tandem affinity purification (TAP) assay, and identified human 
Vam6p (hVam6p) bound to MCV LT in close proximity to the LXCXE motif (263). This 
interaction re-localizes hVam6p from the cytoplasm to the nucleus in the presence of 
MCV LT proteins with an intact NLS, including full length LT and the majority of tumor-
derived LTs. One of the observed effects of hVam6p sequestration to the nucleus is the 
disruption of lysosome clustering in the cytoplasm. Whether or not hVam6p exhibits a 
gain-of-function in the nucleus, and whether or not this interaction is significant in MCV-
positive MCC cancers remains to be uncovered.  
As seen with SV40, MCV T antigen interacts with Hsc70 through its HPDK motif 
in the DnaJ domain, and this interaction is important for viral replication (described in 
detail in chapter 3 of this thesis) (278). MCV sT contains a consensus PP2A binding site 
found in other polyomaviral small T antigens that inhibit PP2A activity. Neither the PP2A 
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nor the DnaJ interaction domains of MCV sT contribute to its transforming activity in 
rodent cells (described in section 1.5.8) (129). 
1.5.8 Cellular transformation by MCV T antigens 
The strong dependency of MCV-positive MCC cells on T antigen expression for survival 
posed the question whether or not MCV T antigens are capable of transforming cells. In 
vitro assays revealed that MCV sT is able to transform rodent cell lines and promote 
serum-free human cell proliferation (129). Transforming activities were measured by 
anchorage-independent growth (growth in soft agar) and loss of contact inhibition (focus 
formation). Neither full-length, nor truncated MCV LT however, showed any 
transforming activity in these assays. This was a rather surprising result, given the 
model of SV40-induced cell transformation in which LT is the dominant contributor to 
the transformation phenotype, and sT alone has no transforming activities. These 
results highlight unique molecular interactions of MCV T antigens with cellular proteins 
in comparison to the well-studied SV40 T antigens.  
 Interestingly, MCV sT transformation is independent of its PP2A interaction 
domain, which has been implicated as essential in SV40 sT contribution to 
transformation in the context of SV40 LT. A feature that is necessary for MCV sT-
induced transformation is sT downstream targeting of the mammalian target of 
rapamycin (mTOR) signaling pathway. sT induces mTORC1/mTORC2 independent 
hyper-phosphorylation and subsequent inactivation of the 4E binding protein 1 (4E-
BP1), which results in de-regulation of cap-dependent translation (129). In the presence 
of a constitutively active mutant of 4E-BP1, which cannot be phosphorylated, the 
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transformation phenotype is diminished. This molecular pathway remains to be explored 
with regards to potential clinical applications in MCC management.  
In vitro human fibroblast transformation by MCV T antigens has not been 
reported. However, in the context of SV40 T antigen defined human fibroblast.  
transformation, the additional expression of both hTERT as well as mutated HRas 
(HRasV12) is required. Chapter 4 of this thesis will present data assaying human 
fibroblast transformation in the context of MCV T antigens with the addition of defined 
oncogenic elements. Recently published results by Cheng et al. show that expression of 
tumor-derived MCV LT and sT in human fibroblasts induces growth proliferation, and 
that full-length LT contains a growth inhibitory domain in the C-terminal exon 3 (260). 
Expression of a 100 bp exon 3 fragment inhibited cell growth of MCV-positive MCC cell 
lines and reduced soft agar colony formation of transformed human fibroblasts 
expressing SV40 LT + sT, hTERT, and HRasV12 (260). This data has implications with 
regards to the tumor evolution model for MCV-positive MCC. It indicates that LT 
truncations are not only selected for because of the replication function of LT, which lies 
within the C-terminus, but also because there is an anti-proliferative domain in this 
region. This is further supported by the fact that the MCV tumor genome MCV350, 
which has a point mutation in the viral origin that abolishes origin replication, still 
contains a C-terminal truncation of LT (278, 279). In addition, Cheng et al. 
demonstrated that unlike SV40 LT, MCV LT does not bind to the tumor suppressor p53, 
providing further evidence for differences in molecular targets between MCV and SV40 
(260). Characterization of the functional pathways involved in the growth promoting 
effect of truncated MCV T antigens is described in chapter 4 of this thesis.  
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1.5.9 Evidence for causality 
A vast amount of scientific evidence can be used to argue for a causal relationship 
between MCV infection and the development of MCV-positive MCC. Applying Hill’s 
criteria (12) to this scenario reveals that all of Hill’s criteria are met, with exception of his 
3rd criterion of ‘specificity’.  MCV infection is not specifically associated with MCC 
patients, since healthy individuals are also infected; however, our current knowledge of 
the cancer phenotype as a multi step process explains how MCV can be required, but 
may not be sufficient to induce MCC tumorigenesis. Additional factors including 
immunosuppression, as well as viral genome mutations and integration, possibly 
induced by UV radiation, are needed. Therefore, Hill’s criterion of ‘specificity’ may not 
be useful in establishing causal relationships with regards to cancer development 
associated with tumor viruses.  
Hill’s 1st criterion ‘strength of association’ has been established by the detection 
of MCV DNA in ~80 % of MCC tumors (55). His 2nd criterion of ‘consistency’ is met by 
repeated results that confirm the presence of MCV in MCC from different groups 
worldwide (reviewed by Coursaget et al., 2013 (280)). The 4th criterion of ‘temporality’ is 
supported by the fact that MCV genomes are clonally integrated in MCC (55), indicating 
that MCV infection precedes tumor cell outgrowth. Presence of a ‘biological gradient’, 
Hill’s 5th criterion, can be observed in immunohistochemical evaluations of MCC tumors, 
which show that only MCC tumor cells are positive for viral protein expression, but not 
the adjacent healthy tissue (281). The 6th criterion asks for biological ‘plausibility’, which 
is provided by the fact that other polyomaviruses are capable of transforming cells and 
inducing tumors in respective animal models. MCV, which shares many protein 
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interaction domains that are functionally important for polyomavirus transformation, is 
therefore a plausible agent for tumorigenic development. The 7th criterion of ‘coherence’ 
asks that the causal association under evaluation be in agreement with biological and 
epidemiological aspects already known about the disease. In the case of MCV 
association with MCC, it is coherent for MCC to have a viral etiology, since it is a cancer 
associated with immunosuppression, which suggests an infectious cause. Finally, the 
8th criterion of experimental evidence has been strengthened by various studies that 
show the transforming activity of sT in rodent cells (129), dependency of MCV-positive 
MCC cell lines on T antigen expression (276), as well as growth promoting activities of 
both tumor LT as well as sT in rodent and human fibroblasts (chapter 4) (129, 260).  
Overall, the collective evidence strongly supports a causal link between MCV 
infection and MCC development, but additional factors are needed for clinically 
presented MCC to emerge. MCV-negative MCC arise from an unknown etiology, and 
therefore should be classified as a distinct type of tumor with a differential 
chemotherapeutic treatment regimen. MCV T antigen status in MCC therefore could 
prove useful as a diagnostic marker that can be utilized to distinguish different MCC 
types, and it may even be used to make prognostic evaluations about disease outcome 
(282, 283). 
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2.0  CHARACTERIZATION OF AN EARLY PASSAGE MERKEL CELL 
POLYOMAVIRUS-POSITIVE MERKEL CELL CARCINOMA CELL LINE, MS-1, AND 
ITS GROWTH IN NOD SCID GAMMA MICE 
Work described in this chapter was published in the Journal of Virological Methods 
 
J Virol Methods. 2013 Jan;187(1):6-14. 
with authors Guastafierro A, Feng H, Thant M, Kirkwood JM, Chang Y, Moore PS, 
and Shuda M. 
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This chapter describes the characterization of an early passage MCV-positive MCC cell 
line MS-1, and compares its cellular, immunohistochemical, and virological features to 
previously derived MCV-negative (UISO, MCC13, and MCC26) and MCV-positive cell 
lines (MKL-1 and MKL-2). The MS-1 cellular genome harbors integrated MCV, which 
preserves an identical viral sequence from its parental tumor. Neither VP2 gene 
transcripts nor VP1 protein are detectable in MS-1 or other MCV-positive MCC cell lines 
tested. Mapping of viral and cellular integration sites in MS-1 and MCC tumor samples 
demonstrates no consistent viral or cellular gene integration locus. All MCV-positive cell 
lines show cytokeratin 20 (CK20) positivity and grow in suspension. When injected 
subcutaneously into NOD scid gamma (NSG) mice, MS-1 forms a discrete macroscopic 
tumor. Immunophenotypic analysis of the MS-1 cell line and xenografts in mice show 
identical profiles to the parental tumor biopsy. Hence, MS-1 is an early passage cell line 
that provides a useful in vitro model to characterize MCV-positive MCC. 
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2.1 INTRODUCTION 
Due to the limited availability of patient samples and the lack of an animal model, MCC 
cell lines are critical in investigating MCV-dependent Merkel cell carcinogenesis in vitro 
(264, 276, 279, 284). Historically, MCC cell lines have been divided into classic and 
variant subtypes based on the expression of immunohistochemical markers including 
neuron specific enolase (NSE) and chromogranin A, as well as their neurosecretory 
granule status (285, 286). Further division of MCC into subtypes I-IV has been based on 
SCLC morphology, aggregation, and colony shape in culture (287). Subtypes I and II 
grow in dense, floating, spherical aggregates, with type I showing central necrosis 
(287). Type III cells are aggregated loosely with a 2-dimensional appearance, and type 
IV cells grow in an adherent monolayer (284, 285). Most MCV-positive cell lines studied 
to date are of the classic phenotype and have class III growth morphology in culture, 
while MCV-negative cell lines mostly fall into the variant class IV phenotype (284). 
However, some MCC cell lines diverge from this grouping, and the discovery of MCV in 
2008 has provided a more meaningful classification of MCC cell lines to approach the 
molecular study of MCC. 
Although a number of MCC cell lines have been established from MCC tumors 
(264, 287-289), detailed characterization of features associated with virus positivity, e.g. 
integration sites, viral sequence and truncation patterns, as well as viral protein 
expression in MCV-positive cell lines, has not been performed. In addition, many 
previously derived cell lines are adapted to cell culture conditions as a result of 
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extended passages, which could lead to the accumulation of spontaneous mutations in 
the viral or cellular genomes. Such culture-derived changes can only be detected if the 
sequence of the parental tumor biopsy is known. The establishment of a new cell line 
allows the comparison of viral sequences as well as protein expression data from the 
MS-1 cell line to the patient tumor tissue from which it was derived. This aids in 
determining whether or not this cell line is an appropriate surrogate for its in vivo tumor. 
Comparison of MS-1 phenotypic and genotypic features to previously derived MCV-
positive as well as MCV-negative MCC cell lines in this study supports that MCV-
positive MCC cell lines are distinct from MCV-negative cell lines in their 
immunohistochemical profile as well as cell culture morphology. Additionally, MS-1 is 
tumorigenic in immunocompromised mice, forming xenograft tumors that retain T 
antigen expression as well as phenotypic markers of the cell line in vivo. 
In summary, the MS-1 cell line is a well-characterized early passage MCC cell 
line, which manifests characteristics of the parental MCC tumor tissue, providing a 
valuable tool for studying MCV-induced MCC carcinogenesis in vitro. We describe MCV 
genome copy number, viral and host cell integration sites, as well as the LT antigen 
truncation pattern and viral protein expression in this cell line. The establishment of a 
MS-1 xenograft model that recapitulates features of the original tumor biopsy provides a 
novel tool for in vivo studies of MCV-positive MCC. 
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2.2 MATERIALS AND METHODS 
2.2.1 Preparation of tumor biopsy and cell culture conditions 
The MCC tumor biopsy (R08-05) was minced in RPMI 1640 with (filtered) 10% FBS, 1% 
Pen-Strep, 1% L-Glutamine, and 1% MEM Hepes buffer. Digestion media (0.1% 
Hyaluronidase, 0.02% DNase, 1.0% Collagenase in PBS, Sigma-Aldrich, St. Louis, MO) 
was added, and the specimen was placed at 37°C for 30-40 min. After incubation, the 
suspension was passed through a cell strainer to remove undigested tissue. Cells were 
initially cultured in RPMI medium with 20% human serum, 0.01% Pen Strep, 0.01% 
Fungison, 0.01% Insulin-transferrin-selenous-acid, 50 uM bathocuproine disulfate, and 
1 M L-Cystein.  After 5 passages, serum was switched from 20% human to 20% fetal 
bovine (FBS), and following passage 10, serum concentration was reduced to 10% FBS 
in RPMI for culture.  Experimental analyses in this this study were performed using MS-
1 cells of passage <40. 
2.2.2 Real time quantitative PCR 
Quantitative PCR was performed using primers amplifying the MCV T antigen promoter 
region (pTAg 98-184 nt; forward primer: 5’-CCC AAG GGC GGG AAA CTG-3’, reverse 
primer: 5’-GCA GAA GGA GTT TGC AGA AAC AG-3’) and VP2 locus (4563–4472 nt, 
forward primer: 5’-AGT ACC AGA GGA AGA AGC CAA TC-3’, reverse primer: 5’-GGC 
CTT TTA TCA GGA GAG GCT ATA TTA ATT-3’) with internal TaqMan probes (pTAg: 
5’-CCA CTC CTT AGT GAG GTA GCT CAT TTG C-3’, VP2: 5’-GCA GAG TTC CTC-3’) 
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labeled with FAM and BGH quencher for pTAg (Biosearch Technologies, Carlsbad, 
CA), and MGB quencher for VP2 (Applied Biosystems, Novato, CA). Standard curves 
for copy number calculations were generated for TAg and VP2 primers separately using 
values from serial dilutions of known copy numbers of the full-length MCV-HF genomic 
clone (254). Water was used as control and no evidence of PCR template 
contamination was observed. An RNase P primer probe mixture (Applied Biosystems) 
was used to determine cell genome copy number. qPCR reaction was performed in 
triplicates as described previously (281). Results are expressed as numbers of viral 
copies per cell calculated from Ct values of viral and cellular gene standards.  To 
determine T antigen and VP2 mRNA expression levels, the expression of the human 
RNase P gene was used as a reference, and RNAs from MCV-negative cell lines were 
used as controls.  
2.2.3 MCV genome sequencing 
Genomic DNA from MCV-positive MCC cell lines as well as the MS-1 tumor biopsy 
R08-05 was extracted by the standard phenol chloroform extraction method. 13 PCR 
primer sets (contig 1- contig 13) were used for PCR amplification of the MCV genome 
as described before. All PCR reactions were performed with High Fidelity Platinum Taq 
DNA polymerase (Invitrogen, Carlsbad, CA). Standard Sanger sequencing of PCR 
products was performed using DNA analyzers from Applied Biosystems. 
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2.2.4 Phage library screen of MCV integration site 
Ten micrograms of genomic DNA extracted from MKL-1 and MS1 cells were digested 
with EcoRI (New England Biolabs, Ipswich, MA), and ligated into Lambda Zap II 
predigested EcoRI/CIAP-treated vector using the Gigapack III Gold Packaging Extract 
(Stratagene, Santa Clara, CA) to construct the phage library.  After titer optimization, 7 
µl of a 1:10 dilution of phage library mixed with 600 µl MRF’ cells at an OD600 of 0.500 
were plated on NZY agar, and incubated at 37°C overnight.  Two rounds of screens of 
virus-positive clones were performed with a32P dCTP-labeled MCV DNA probes 
according our previously published protocol (55).  Positive clones were isolated, and 
inserts were sequenced. 
2.2.5 RACE analysis 
Both 5'-RACE and 3'-RACE were used to identify integration sites in MCC cases with 
GeneRacer Kit (Invitrogen) according to the manufacturer's instructions. For 
MCC347/348 tumor cases, primer sequences were described previously (55).  For 
MCC350, 5'-GCT AGA TTT TGC AGA GGT CCT G-3' and 5'-TTT CCT TGG GAA GAA 
TAT GGA A-3' primers were used to identify a viral integration site by 3'-RACE analysis. 
 For MCC345, 5'-AAA CAA CAG AGA AAC TCC TGT TCC-3' and 5'-TGA TCT TTC 
TGA TTA TCT TAG CCA TGC TG-3' primers were used in 3'-RACE analysis.  For 
MCC352, 5'-GGG AGG CTC AGG GGA GGA AA-3' and 5'-TCC AGA GGA TGA GGT 
GGG TTC C-3' primers were used in 5'-RACE analysis. PCR fragments were isolated 
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from 1.2% agarose gel, extracted with QIAEX II Gel Extraction Kit (Qiagen, Valencia, 
CA), and ligated into pCR2.1 vector (Invitrogen) for DNA sequencing. 
2.2.6 Southern blot  
Genomic DNA was extracted by the standard phenol chloroform extraction method.  
Fifteen micrograms of genomic DNA from cell lines were digested with MCV genome 
single cut enzymes EcoRI and BamHI separately or together.  Digested DNA was 
separated on 0.7 % agarose-TBE gel, followed by denaturation for 45 min (1.5M NaCl, 
0.5M NaOH), and neutralization for 1h (3.0M NaCl, 0.5M Tris-HCl pH7.4). RNA was 
extracted using Trizol (Invitrogen). Genomic DNA was transferred onto a Hybond-C 
nitrocellulose membrane (GE Healthcare) with 10X SSC. To generate a32P dCTP-
labeled probes for Southern hybridization, five MCV DNA fragments (contig1, contig3, 
contig6, contig9 and contig12) described previously (55) were used as templates for the 
Amersham Rediprime II Random Prime Labeling kit (GE Healthcare). Hybridization was 
performed as described previously (279). 
2.2.7 Immunoblotting 
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer containing 50mM Tris, 
150 mM NaCl, 0.1% SDS, 0.5% Na Deoxycholate, 1% NP40, and protease inhibitors 
(Complete cocktail, Roche, Indianapolis, IN). Lysates were kept on ice for 15 minutes, 
and then centrifuged 20,000 x g for 10 minutes at 4°C. Supernatants were mixed with 
5X sodium dodecyl sulfate (SDS) loading dye, and denatured at 100°C for 5 minutes. 
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Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE), and 
transferred onto a Hybond-C nitrocellulose membrane (GE Healthcare). Proteins were 
detected using CM2B4, CM8E6, CM5E1 and 9B2 antibodies as described before (129, 
254, 281, 290) 
2.2.8 Xenograft model 
Triple immunodeficient NOD scid gamma (NSG) mice (Jackson laboratories, Bar 
Harbor, MN) were housed in a specific pathogen-free area at the Division of Laboratory 
Animal Research (DLAR) facility at the Hillman Cancer Center, University of Pittsburgh 
according to University of Pittsburgh Institutional Animal Care and Use Committee 
(IACUC) regulations (IACUC protocol #1102226). At 6 weeks of age, mice were injected 
in the flank with 2x10^7 cells in 100 ul PBS subcutaneously. For MS-1 and MKL-1 cell 
lines, 5 mice were injected each. Mice were sacrificed when tumors reached a diameter 
of 2 cm. Tumor volumes were calculated according to the following formula: (width) 2 x 
(length/2).  
2.2.9 Immunohistochemistry 
For immunohistochemical staining of paraffin embedded xenograft tumor tissues, 
epitope retrieval was performed using 1mM EDTA buffer pH 8.0 at 125°C for 3:15 min 
after deparaffinization and hydrogen peroxide treatment. After blocking with Protein 
Block (Dako, Carpinteria, CA), primary antibody was applied for 30 min at room 
temperature with dilutions described below. After washing, samples were incubated with 
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Mouse Envision Polymer (Dako) for 30 min at room temperature for subsequent 
deaminobenzidine (DAB) reaction. Antibodies and dilutions used for 
immunohistochemistry were: CM2B4 (1:1000; Santa Cruz, Santa Cruz, CA), CK20 
(1:50; Dako), CK7 (1:50; Dako), Chromogranin A (1:600; Dako), TTF-1 (1:50; Dako), 
AE1/3 (1:100; Dako), CAM5.2 (1:10; Becton Dickinson, Franklin Lakes, NJ), 
Synaptophysin (1:100; Biogenex, Fremont, CA), NSE (pre-dilute; Ventana, Tucson, AZ), 
and LCA (pre-dilute; Ventana). Each cell line was stained once for every marker, and 
negative human control tissue was stained with the same antibody dilutions for each 
marker to ensure minimal background reactivity.  
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2.3 RESULTS 
2.3.1 MS-1 cell culture morphology and immunohistochemistry 
The MS-1 tumor biopsy was obtained from a MCC metastasis to the right adrenal gland 
of a 59-year-old woman.  In culture, the cells form floating aggregates of 3-dimensional 
cell clusters similar to other MCV-positive MCC cell lines including MKL-1, and MKL-2 
(Figure 14 and Table 2). In contrast, the MCV-negative MCC cell lines UISO, MCC13, 
and MCC26 grow in an adherent monolayer (Figure 14 and Table 2).  
 
Figure 14. Morphological features of MCC cell lines 
MCV-positive cell lines MS-1 (A), MKL-1 (B), and MKL-2 (C) grow in floating aggregates in cell 
culture, whereas MCV-negative cell lines UISO (D), MCC13 (E), and MCC26 (F) are adherent 
cells. 
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As described before (276), immunohistochemical analyses of MCC cell lines 
reveal differences in various markers diagnostic for MCC between MCV-positive and -
negative cell lines (Table 2). In comparison to data published previously (276), this 
immunohistochemical analysis of MCC cell lines is expanded to include MCC 26, as 
well as the negative markers CK-7, TTF-1, and LCA. Cytokeratin 20 (CK 20) is a low 
molecular weight cytokeratin with perinuclear distribution in MCC, which is used to 
distinguish MCC from other small cell carcinomas (291). MCV-positive cell lines MS-1, 
MKL-1 and MKL-2 are positive for CK20 by immunohistochemistry, whereas the MCV-
negative cell lines UISO, MCC13 and MCC26 are not (Table 2). MS-1, MKL-1, MKL-2 
and MCC13 are positive for the pan-keratin markers, AE1/3 (anion exchanger 1/3), and 
CAM5.2 (cytokeratin 8 and 18). Cytokeratin 7 (CK7), which has been reported to stain 
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Table 2. Immunohistochemical features of MCC cell lines 
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negative in MCC (292), is positive only in MCC 13 tumor cells. All MCV-positive and –
negative cell lines except MCC26 express neuron-specific enolase (NSE), and only 
MKL-2 expresses chromogranin A (Table 2). All cell lines are negative for leukocyte 
common antigen (LCA) and thyroid transcription factor 1 (TTF-1) (Table 2), markers 
that have been described as negative in MCC biopsies (292, 293). 
2.3.2 MCV status  
MCV copy number per cell was determined by qPCR in three separate experiments 
(Table 3) for the MCV-positive cell lines MS-1, MKL-1, and MKL-2. MS-1 harbors an 
average of 2.1 copies of T antigen per cell, whereas MKL-1 and MKL-2 harbor 3.5 and 
1.7 copies per cell respectively. No positivity was detected in the three MCV-negative 
MCC cell lines UISO, MCC13, and MCC26 used as controls. VP2 specific primers 
consistently detect higher genomic copy numbers than T antigen specific primers with 
MS-1 containing an average of 3.6 VP2 copies per cell. MKL-1 and MKL-2 contain 8.6 
and 3.0 copies, respectively (Table 3).  
!"#$%&'&
 Table 3. MCV genome copy number, and viral RNA expression 
Relative 
MCV RNA  
expressiona 
MS-1             
MKL-1 
MKL-2 
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                              TAg            VP2              TAg           VP2 
2.1 ± 0.1b 
3.5 ± 0.4b 
1.7 ± 0.5b 
NDc 
NDc 
NDc 
3.6 ± 0.9b 
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3.0 ± 0.6b 
NDc 
NDc 
NDc 
0.069a 
0.073a 
0.014a 
NDc 
NDc 
NDc 
NDc 
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NDc 
NDc 
NDc 
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a normalized to RNase P RNA  expression 
b standard deviation of three independent experiments 
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Table 3. MCV genome copy number and viral RNA expression 
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To determine whether there is any correlation between viral DNA load and viral 
mRNA expression in the MCV-positive cell lines, total RNA was extracted from the MCC 
cell lines and treated with DNase to eliminate genomic DNA amplification. Quantitative 
RT-PCR was performed with the same primers used to determine T antigen and VP2 
copy numbers per cell. All three MCV-positive cell lines express T antigen mRNA 
transcripts at different levels, whereas none of them express VP2 transcripts (Table 3). 
MS-1 mRNA levels are 0.069-fold RNaseP expression, whereas MKL-1 and MKL-2 are 
0.073-, and 0.014-fold respectively (Table 3). There is no apparent evidence for a linear 
correlation between DNA copy number and mRNA levels. 
Southern blot analysis using previously described MCV probes that cover the 
entire viral genome (55), reveals a ~1.6 kb band in the MCV-positive cell lines MS-1, 
MKL-1, and MKL-2, when digested with the restriction enzymes BamHI and EcoRI. Both 
enzymes are single cutters within the MCV genome sequence, and double digestion 
cleaves a ~1.6 kb internal virus sequence (Figure 15A). Consistent with qPCR results 
(Table 3), the intensities of viral internal 1.6 kb bands were similar between MS-1 and 
MKL-2, whereas MKL-1 shows a 1.6 kb band of higher intensity. Single digestions with 
either BamHI or EcoRI generate multiple MCV-related bands in MS-1 (BamHI), MKL-1 
(EcoRI), and MKL-2 (EcoRI) consistent with random clonal integration in different cell 
lines, as has been shown in MKL-1 previously (279). Single digestion with either BamHI 
or EcoRI yields a 5.4 kb band representing the whole MCV genome in MKL-1 and MKL-
2, demonstrating virus concatenation in these cell lines. 
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Figure 15. MS-1 harbors clonally integrated MCV and expresses viral T antigens 
(A) Southern blot analysis of MCV-positive cell lines shows clonally integrated viral genomes. 
(B) The MCV-positive MCC cell lines MS-1, MKL-1 and MKL-2 have C-terminal LT truncations 
as determined by direct sequencing performed on genomic DNA. LT protein sizes correspond to 
428 aa, 330 aa, and 275 aa, respectively. (C) Western blotting using antibodies CM2B4 for LT 
and CM8E6 as well as CM5E1 for sT shows differences in size of LT proteins from different 
MCV-positive MCC cell lines, whereas sT size is the same. The CM2B4 antibody picks up a 
faint non-specific band in MCV-negative MCC cell lines (marked *).  
2.3.3 T antigen truncations and corresponding protein sizes 
Next, we sought to determine the T antigen truncation pattern in MS-1 as well as MKL-
2. The MKL-1 LT truncation (GenBank accession no. FJ173815.1) has been mapped 
previously (279). Genomic DNA was isolated from MS-1, MKL-1 and MKL-2, and 
subjected to direct sequencing using MCV contiguous primer pairs spanning the whole 
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MCV genome (55).  Sequencing of the PCR products revealed premature stop codons 
in all three cell lines (Figure 15B). MS-1 LT terminates at nucleotide position 1910, 
whereas the MKL-1 and MKL-2 LT truncations can be found at positions 1618 and 1495 
respectively (Figure 15B).   
The differential LT truncation patterns of MCV-positive cell lines are reflected by 
varying LT migration speeds by immunoblotting (Figure 15C).  MS-1 expresses the 
largest LT protein among the MCV-positive MCC cell lines in this study, with the 
truncation occurring after the origin-binding domain (OBD) of LT, yielding a 428 amino 
acid (aa) long protein. MKL-1 (330 aa) and MKL-2 (275 aa) LT truncations are N-
terminal to the MS-1 truncation mutation, while all three truncated LT proteins maintain 
the LXCXE Rb binding motif (Figure 15B). This truncation pattern and conservation of 
the N-terminal motifs is consistent with LT sequences derived from MCC tumor tissues 
in various studies (279, 294, 295). In agreement with the truncation patterns in Figure 
15B, MS-1 expresses a 60 kDa truncated LT protein as compared to a 105 kDa full 
length LT expressed exogenously in 293 FT cells (Figure 15C compare lane 3 to lane 
2). MKL-1 and MKL-2 also express shorter forms of LT, which migrate at 50 kDa and 40 
kDa, respectively. Even though sequencing results reveal intact splice donor and 
acceptor sites for the 57 kT isoform, neither MS-1 nor MKL-2 express a 57 kT protein 
that is detectable by immunoblotting (Figure 15C). MKL-1 has already been reported to 
have a deletion in the second splice donor site of 57 kT (279), which explains the 
absence of this isoform. All MCV-positive cell lines consistently express an intact 19 
kDa sT protein (Figure 15C). While sT protein size does not differ between cell lines 
(Figure 15B-C), sequencing results reveal one single nucleotide polymorphism, which 
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results in a difference in amino acid 20 of sT between cell lines. MS-1 and MKL-1 have 
an alanine at this position, whereas MKL-2 has a serine.   
Viral sequence comparison between the MS-1 cell line and its parental tumor 
biopsy (R08-05) reveals the same pre-mature stop codon mutation of LT as well as an 
identical MCV genome sequence with a deletion from nucleotide 1912 to 1951 and a 5 
base pair insertion at position 5218 (Figure 16).  As described previously, the MKL-1 
viral genome has a deletion at nucleotide position 1612-1657 (FJ173815.1). The MKL-2  
Figure 16. MCV genome comparison 
MCV genomes from published clones MCV-HF, MCV 350 and MKL-1 were compared to MCV 
genomes from MKL-2, MS-1 and the R08-05 tumor biopsy based on genomic sequence 
alignments. Genomic deletions (black box) as well as insertions (vertical dotted line) are 
indicated for early (gray) and late (white) regions. 
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genome has two deletions at nucleotide positions 3082-3083 and 4828-5348 (Figure 
16). MCV viral genome sequences have been deposited to GenBank with 
corresponding accession numbers JX045709 (MS-1) and JX045708 (MKL-2). 
2.3.4 Viral genome integration site 
To determine the integration site of the MCV genome within the cellular genome of MS-
1, a lambda phage library was constructed from MS-1 genomic DNA and used for 
library screening. The MCV genome integration in MS-1 maps to a non-coding DNA 
region on human chromosome 5 (5q11.2). In the MCV genome, the integration event 
occurs after base pair 2843, which maps to the ATPase/helicase domain of LT (Table 
4).  Four MCC tumor samples (347/348, 345, 350, and 352), identified previously as 
MCV-positive (55), were tested for MCV integration sites by RACE, and no common 
cellular or viral integration sites were found (Table 4), consistent with previous studies 
(259, 294, 296). 
 
 
 Table 4. Chromosomal integration sites in MCC  
!"#$%&'()*
MCC 
MS-1 
347/348 
345 
350 
352 
Type 
cell line 
tumor tissue 
tumor tissue 
tumor tissue 
tumor tissue 
Methods 
Phage library 
3’RACE 
3’RACE 
3’RACE 
5’RACE 
Chromosome 
5q11.2 
3p14.2 
6p24.3 
3q26.33 
10q23.1 
Locusa  
2,282,589 
61,561,985 
9,842,760 
88,824,524 
36,041,150 
Gene 
Non-coding region 
PTPRG (intron1) 
MRDS1 (intron6) 
Non-coding region   
Unidentified ORF 
MCV breakpoint 
2843 
2140 
1836 
596 
491 
+!,-.*&*
Table 4. Chromos mal integration site  in MCC 
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2.3.5 Tumorigenicity of MS-1 cells in vivo 
The MCV-positive cell line MKL-1 (288) has been shown to induce tumors in 
immunocompromised mice. The established MS-1 cell line was tested in NSG mice for 
in vivo growth. After injecting MS-1 cells subcutaneously in the flank, tumor formation 
was observed at injection sites after 30 days (Figure 17A). This represents a 14-day 
delay in tumor onset as compared to MKL-1, and a slower growth behavior 
subsequently (Figure 17A). The mice did not develop metastasis during the 80-day 
observation period, and were killed when the tumor reached a diameter of 2cm. LT and  
 
Figure 17. MS-1 xenograft model 
(A) Tumor volume graph represents average tumor volumes of 5 animals for each MS-1 and 
MKL-1 cell lines. (B) Immunoblot analysis of MS-1 and MKL-1 xenograft tumors shows LT as 
well as sT protein expression in vivo. Three separate xenograft tumor lysates were prepared for 
each cell line; one representative is shown here. (C) Immunohistochemical analysis of MS-1 
xenograft tumors validates LT protein expression and nuclear localization (CM2B4), as well as 
CK20 positivity in vivo.  
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sT protein sizes were unchanged in vivo as demonstrated by immunoblot (Figure 17B). 
Nuclear localization of LT protein expression was maintained, as shown by 
immunohistochemistry (Figure 17C), as was perinuclear distribution of CK 20 in the 
MS-1 xenograft tissue (Figure 17C). 
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2.4 DISCUSSION 
Tumor-derived MCV-positive MCC cell lines represent a valuable tool for in vitro 
analyses of MCV related MCC carcinogenesis. For example, Houben et al. 
demonstrated that T antigen knockdown in MCV-positive MCC cell lines results in 
growth arrest and cell death (297) underscoring the critical role of viral T antigen 
expression in MCC tumorigenesis. 
 The MS-1 cell line is a newly established MCC cell line that has been maintained 
in culture for few passages (<40 passages). MS-1 is positive for MCV, and displays a 
tumor specific C-terminal LT truncation pattern. Using RNase P as a cellular reference 
gene, T antigen copy number in MS-1 was determined by qPCR, to be 2.1 copies per 
cell, which could be explained by either multiple viral integration events or virus 
concatenation. At this point however, we do not have experimental evidence that would 
suggest multiple integration events nor virus concatenation in MS-1. MCV-positive MCC 
cell lines MKL-1 and MKL-2 also have T antigen copy numbers >1 (Table 3), and 
southern blot data (Figure 15A) supports the presence of concatenated viral genomes 
in these cell lines. In addition, southern blot analysis confirms higher genome copies in 
MKL-1 cells than MS-1 and MKL-2 cells, which is consistent with qPCR results. In 
agreement with our results, Fischer et al. have also described variations in MCV copy 
number per cell in other MCC cell lines (264). However, the use of different reference 
genes for qPCR copy number determination has to be taken into account since cancer 
cells often harbor chromosomal aberrations. In MCC, specific chromosomal aberrations 
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for chromosomes 1, 3-8, 10, 13, and 17 have been reported (234, 235). However, there 
is no reported data that suggests deletion or amplification of the RNase P reference 
gene, located on chromosome 14, in MCC. 
T antigen copy number per cell corresponds to LT protein expression by 
immunoblot, which shows a stronger protein band for MKL-1 LT as compared to MS-1, 
which has a lower copy number of T antigen per cell compared to MKL-1. One 
explanation for the variations in LT expression levels observed between cell lines may 
be due to a difference in protein stability caused by different truncations. However, 
further studies are needed to investigate this. Even though VP2 copy numbers in the 
three MCV-positive MCC cell lines are higher than the T antigen, neither VP1 protein 
immunoblot (data not shown) nor quantitative RT-PCR on VP2 transcripts (Table 3) 
detect expression of late gene products. These results do not support one reported 
observation of viral particle production in MCC by electron microscopy (298). Instead, 
our data suggests that late gene expression or viral particle production of MCV is 
absent in MCC tumors.  
LT proteins expressed in the MCV-positive MCC cell lines migrate at higher 
molecular weights than the predicted sizes from their individual truncations. MS-1 LT is 
truncated after 428 amino acids and has a predicted molecular weight of 48 kDa, but it 
migrates at ~60 kDa on SDS-PAGE (Figure 15B-C). MKL-1 and MKL-2 LT protein have 
predicted molecular weights of 37 kDa and 31 kDa, respectively, but they migrate at ~ 
50 kDa, and ~ 40 kDa. Explanations for this difference in migration may include aberrant 
migration due to charge as well as post-translational modifications of LT such as 
phosphorylation or acetylation, both of which have been reported previously for T 
 87 
antigens of other polyomaviruses including murine polyomavirus middle T antigen and 
SV40 LT (299, 300). Phosphorylation of LT in MKL-1 has been confirmed 
experimentally (data not shown), and results in higher molecular weight of LT on SDS-
PAGE. Other modifications are likely, and require further experimental analyses.  
The MCV integration site within the cellular genome of MS-1 as well as several 
other MCC tumor samples was determined. A common integration site could point 
toward the disruption of a cellular gene as a factor in MCC tumorigenesis. However, the 
MCC tumor samples including MS-1, did not show any common integration sites nor 
any interruptions of tumor suppressor genes (Table 4).  Therefore, it is less likely that 
the interruption of a common host cell gene by viral integration contributes to 
tumorigenesis in most MCV-associated MCC. 
Sequence comparison between the MS-1 cell line and its parental tumor biopsy 
reveals identical viral sequences and LT truncation patterns (Figure 16). This suggests 
that additional mutations of the viral genome acquired during cell culture are not 
necessary to maintain the tumorigenic phenotype of MS-1 neither in culture nor in an in 
vivo xenograft setting. All three MCV-positive cell lines conserve the LXCXE Rb binding 
motif in LT as observed in other MCC tumor-derived LT (279). Experimentally, the 
importance of LT binding to Rb has been demonstrated by Houben et al. in vitro and in 
an in vivo xenograft model using the MCV-positive MCC cell lines WaGa and MKL-1 
(297). However, another report demonstrates that MCV LT cannot transform rodent NIH 
3T3 and Rat-1 cells in contrast to MCV sT, which alone is sufficient to transform rodent 
cells (129). Therefore, LT’s Rb-targeting function may play an essential role in human 
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cell transformation in concert with sT’s oncogenic function, which is expressed intact in 
all three MCC cell lines (Figure 15C).   
Morphological comparison between MCV-positive and -negative cell lines 
demonstrates a significant difference in appearance as has been described before 
(276). Immunohistochemical analysis of the MCV-positive and MCV-negative MCC cell 
lines shows that only the MCV-positive lines conform to diagnostic criteria that 
distinguish MCC tumors from other neuroendocrine cancers (Table 2).  These results 
are in concordance with published data (276) for CK20, pan-CK as well as NSE 
markers in the MCC cell lines studied. In contrast, the immunohistochemical data for 
chromogranin, as well as synaptophysin presented in this study, show differences from 
published results (276) for the cell lines MS-1, MKL-1, and MCC13. These differences 
may be a result of different experimental techiques used, as Houben et al. determined 
their results by qPCR instead of immunohistochemistry. 
Despite a report by Fischer et al. of the adherent MCV-positive MCC cell line 
MCCL12 (264), all MCV-positive MCC cell lines tested in this report demonstrate a 
suspension growth pattern in culture. The MCV-negative cell lines used in this study are 
not only immunophenotypically different from MCC they also grow adherently in vitro. In 
SCLC, adherent cell growth is associated with loss of neuroendocrine marker 
expression and adherent growth (286). Despite the data on UISO, MCC13 and MCC26, 
the MCV-negative cell line MaTi, was found to grow in suspension similar to MCV-
positive cell lines. However, MaTi neither expresses CK20 nor other cytokeratin 
markers similar to the MCV-negative cell lines studied by us. Among the MCV-negative 
MCC cell lines analyzed, one cell line, MCC26, lacks expression of all neuroendocrine 
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markers examined. Those markers could be attenuated by de-differentiation of cells 
associated with tumor progression. However, the difference in growth morphology and 
the lack of CK20 positivity in UISO, MCC13, MCC26, and MaTi raises concern whether 
they were originally derived from correctly diagnosed MCC tumors. Alternatively, 
outgrowth of another cell population during the process of culturing is possible, and 
could explain the difference in morphology as well as phenotypic markers by 
immunohistochemistry. This is an important factor to take into account when using 
MCV-negative putative MCC cell lines as controls for MCV-positive MCC cell lines.  
 In vivo analysis of the MS-1 cell line confirms its tumorigenic growth potential by 
forming tumors in immunocompromised mice as has been shown in other MCC 
xenograft studies before (277, 301, 302). MS-1 cells maintain viral T antigen expression 
and LT nuclear localization, as well as CK20 positivity in vivo, demonstrating the validity 
of this xenograft model with regard to MCC tumorigenesis.  In vivo, MS-1 xenografts are 
less tumorigenic compared to MKL-1, with a 14-day delayed onset of tumor growth as 
well as a slower growth rate after tumor onset. In concurrence, xenograft models 
described in the literature for different cancer cell lines show varying onsets of tumor 
growth as well as differential levels of metastasis (303, 304). It is possible that higher 
protein expression of LT in MKL-1 compared to MS-1 (Figure 15C) is a factor 
contributing to increased tumorigenicity in vivo. Surprisingly, no metastatic growth was 
observed in mice injected with MS-1 despite the aggressive nature of MCC in humans, 
and the fact that MS-1 was derived from a metastasis.  
 The data presented in this study emphasizes that MS-1 and MCV-positive MCC 
cell lines in general, represent important tools to understand MCV biology and potential 
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mechanisms of viral tumorigenesis in MCC. MS-1 in particular is a good cell culture 
model due to its low passage number, and well-characterized viral features. Importantly, 
MS-1 has identical features to the parental MCC tumor from which it was derived. To 
conduct translational research focusing on the viral etiology of MCC, having an accurate 
model system that reproduces the virus-associated features of clinical disease is 
essential. MS-1 is a cell line that provides these benefits and shows great potential in 
pre-clinical applications including drug screening of chemotherapeutic agents.  
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3.0  THE MINIMUM REPLICATION ORIGIN OF MERKEL CELL POLYOMAVIRUS 
HAS A UNIQUE LARGE T-ANTIGEN LOADING ARCHITECTURE AND REQUIRES 
SMALL T-ANTIGEN EXPRESSION FOR OPTIMAL REPLICATION 
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This chapter describes the genomic mapping of the 71 bp minimal MCV replication core 
origin that is sufficient for initiating eukaryotic DNA replication in the presence of wild-
type MCV large T (LT) protein.  The origin includes a poly (T) rich tract and eight 
variably oriented, GAGGC-like pentanucleotide sequences (PS) that serve as LT 
recognition sites.  Mutation analysis shows that only four of the eight PS are required for 
origin replication.  A single point mutation in one origin PS from a naturally occurring, 
tumor-derived virus reduces LT assembly on the origin and eliminates viral DNA 
replication.  Tumor-derived LT having mutations truncating either the origin-binding 
domain or the helicase domain also prevent LT-origin assembly.  Optimal MCV 
replication requires co-expression of MCV small T (sT) protein together with LT.  An 
intact DnaJ domain on the LT is required for replication but is dispensable on the sT. In 
contrast, PP2A targeting by sT is required for enhanced replication.  The MCV origin 
provides a novel model for eukaryotic replication from a defined DNA element and 
illustrates the selective pressure within tumors to abrogate independent MCV 
replication. 
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3.1 INTRODUCTION 
Unlike human cellular DNA replication origins, polyomavirus replication origins are 
discrete and well-defined yet retain many features of eukaryotic cellular origins. For this 
reason, polyomavirus replication origins, particularly the SV40 origin, have been used 
as easily tractable models to define eukaryotic replication requirements (305).   
Polyomaviruses are small, double-stranded DNA viruses with circular genomes 
functionally divided into coding and noncoding regions (306).  The early coding region 
for all polyomaviruses encodes large tumor (LT) and small T (sT) antigens that serve as 
viral oncoproteins and a late coding region that produces viral structural proteins.  Aside 
from LT and ST, other T antigen isoforms, such as middle T antigen (MT) and 
17kT/57kT, may be present and are virus-specific.  LT has pleiotropic functions that 
include initiation and maintenance of viral DNA replication, regulation of early and late 
genes transcription, and virion assembly (307-313).  Expression of LT also leads to the 
transformation of susceptible cell lines mediated in part by functional regions such as 
the DnaJ, pocket protein binding, and p53 binding domains that target growth-
suppressing and cell cycle regulatory proteins (314).  Additionally, sT has been shown 
to play an important role in LT mediated cell transformation in SV40 (315-319) and has 
been reported to increase virus replication efficiency in JCV (320).  
Polyomavirus origins are situated within a noncoding site, located between early 
and late viral coding regions, which also contains promoters for early and late 
transcriptional units and enhancers that mediate cis-activation of early gene 
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transcription (306). Polyomavirus replication origins contain a central region, referred to 
as Site 1/2 in murine polyomavirus (Py) and Site II in SV40, with variable numbers of 
LT-binding pentanucleotide sequences.  Since MCV is more closely related to Py, we 
will use the Py nomenclature in this chapter.  Site 1/2 is flanked by AT-rich regions: the 
homopolymeric T tract on the late side of MCV Site 1/2 is called the AT-rich tract and is 
an initial site for polyomavirus DNA melting during replication (321).  For SV40, the AT-
rich region on the opposite, early side of Site 1/2 is palindromic and referred to as the 
early palindrome (EP).  While this region is also AT-rich in the MCV origin, no 
palindrome is present (55).   
An initial step in polyomavirus DNA replication is seeding of LT at consensus 
DNA 5'-G(A/G)GGC-3' pentanucleotide sequences (PS) in the LT binding site 1/2 region 
followed by oligomerization of double LT hexamers in a head-to-head orientation (306).  
Three structural domains of SV40 LT, the DnaJ domain, the origin-binding domain 
(OBD), and the helicase domain, have all been subjects of structural studies (322, 323).  
Although precise mechanistic details remain unclear, it is known that the helicase 
domain works in concert with the OBD to initially melt dsDNA in the AT-rich tracts.  In 
SV40, the melted DNA is believed to be threaded through the double hexamer of TAg 
such that the two 3' ends leaving Site II (Site 1/2 in Py) pass through the centers of two 
opposing hexameric rings formed by the LT helicase domain.  Once loaded, LT 
functions as an ATPase-driven DNA pump that also recruits cellular machinery 
(replication protein A, topoisomerase, and the polymerase alpha complex) for DNA 
replication (322-329).  Sequence analysis shows that the MCV origin has a comparable 
arrangement of sequence motifs to the replication origins of Py subgroup 
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polyomaviruses (55). In contrast to the SV40 origin, which has a minimum, definable 
boundary, the replication functions of the origin of Py are more diffusely distributed 
(330-333).  Despite similarities between MCV and SV40 origins, neither MCV nor SV40 
T antigen initiate replication of the heterologous origins from the other virus (279).   
In this study, we identify an MCV core origin and define the requirement for 
individual PS in LT-mediated replication that suggests the possibility of a more complex 
orchestration of LT seeding for MCV than the head-to-head double hexameric 
arrangement for SV40.  Further, a single origin point mutation in a tumor-derived MCV 
strain at a critical PS outside of the canonical LT interaction region (Site II for SV40 and 
Site 1/2 for Py) abrogates MCV origin replication.  We show that optimal LT initiation of 
MCV replication requires both viral sT protein expression and intact cellular Hsc70 
binding by LT to fully support efficient viral DNA replication.  
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3.2 MATERIALS AND METHODS 
3.2.1 Plasmids 
Construction of genomic (TAg206.wt, TAg350, TAg339) and cDNA (57kT.wt) TAg 
expression plasmids were described previously (279, 281).  For the LT cDNA constuct, 
cDNA was first amplified by PCR (281) followed by site directed mutagenesis to delete 
the 57kT exon 3 splice acceptor site using PCR primers 5'-CAC TTT TCC CCA AAA 
GCA AAT CTA AGA GAT TCC C-3' and 5'-GGG AAT CTC TTA GAT TTG CTT TTG 
GGG AAA AGT G-3'.  To generate sT-eGFP, the open reading frame of sT was 
amplified from MCC350 (55) using primers (LT.EcoRV.S: CCG ATA TCA TGG ATT 
TAG TCC TAA ATA GG, sT.XhoI.AS: GGG CTC GAG TAG AAA AGG TGC AGA TGC 
AG) and cloned into pcDNA6/V5-HisB (Invitrogen) using EcoRV and XhoI restriction 
sites.  The sT fragment was then transferred into pEGFP-N1 (Clontech) using the NheI 
and SacII sites. 
For DnaJ domain mutants of LT genomic constructs, D44H and D44N were 
generated by a QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) using 
TAg206.wt (279) as a template and the following primer pairs: T.D44H(S) (5'-GCT TAA 
AGC ATC ACC CTC ATA AAG GGG GAA ATC C-3') and T.D44H(AS) (5'-GGA TTT 
CCC CCT TTA TGA GGG TGA TGC TTT AAG C-3'); T.D44N(S) (5'-GCT TAA AGC 
ATC ACC CTA ATA AAG GGG GAA ATC C-5') and T.D44N(AS) (5'-GGA TTT CCC 
CCT TTA TTA GGG TGA TGC TTT AAG C-3'). For LXCXK.D44N, primers T.D44N(S) 
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and T.D44N(AS) was used for PCR reaction using TAg206.wt.LXCXK (279) as a 
template.  
MCV replication origin plasmids were amplified by PCR from MCC339 genomic 
DNA (GenBank # EU375804) with published primer sets (278) and cloned into pCR2.1 
(Invitrogen). 
3.2.2 Generation of Antibodies 
Monoclonal antibodies, CM8E6 and CM2B4 (281), were generated by standard 
methods of immunizing mice with KLH-derivatized MDLVLNRKERREALC or 
CSRSRKPSSNASRGA peptide that correspond to the MCV TAg exon 1 and 2, 
respectively (Epitope Recognition Immunoreagent Core facility, University of Alabama).   
3.2.3 MCV origin replication assay 
Human embryonic kidney (HEK) 293 cells were maintained in DMEM supplemented 
with 10% FBS, 2 mM glutamine and penicillin/streptomycin. 293 Cells were transfected 
with MCV origin constructs and either empty vector or TAg expression vector by 
Lipofectamine 2000 (Invitrogen). Cells were harvested 48 h after transfection, lysed with 
TE/0.6% SDS buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 0.6% SDS) for 10 min 
and then NaCl was added at a final concentration of 1 M. Lysates were centrifuged at 
14,000 rpm for 30 min at 4°C to collect episomal DNA. After phenol-chloroform 
extraction, 5 µg of the collected DNA was double digested overnight with 10 units each 
of DpnI and BamHI. Digested DNA was loaded on 0.8% agarose gel, transferred onto 
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nitrocellulose membrane, and subjected to Southern hybridization (279). Replication 
efficiency was detected by Southern hybridization with 32P-labeled probe produced by 
PCR with primer pairs (Rep-S, 5'-GCC GCC AAG GAT CTG ATG-3'; pCR2.1-AS, 5'-
CTG CGC AAG GAA CGC CCG TCG-3') and analyzed by PhosphorImager (Typhoon 
9400, GE Healthcare) and ImageQuant software (GE Healthcare). All replication assays 
were performed at least twice and a representative experiment is shown.  Expression 
levels for LT and sT-eGFP were confirmed in each transfection by immunoblotting using 
anti-V5 (Invitrogen), CM2B4, or anti-GFP (B-2) (SantaCruz). 
3.2.4 Immunoprecipitation 
293 cells were cotransfected with pCMV-myc/Hsc70 (334) and either pcDNA6/V5-
His/lacZ plasmid (Invitrogen) or TAg plasmid (TAg206.wt, D44H and D44N) using 
Lipofectamine 2000 (Invitrogen). Cells were harvested 48 h after transfection, 
suspended in lysis buffer (50 mM Tris-HCl, 0.15 M NaCl, 1% Triton-X100, pH 7.4) 
supplemented with protease inhibitors. Precleared lysates were immunoprecipitated 
with either mouse monoclonal anti-c-myc (9E10) (SantaCruz) or rabbit anti-V5 (Bethyl) 
overnight at 4°C. Lysates were incubated with Protein A sepharose beads (Amersham) 
for 3 h at 4°C, collected and washed with lysis buffer. Beads were resuspended in 
2SDS loading buffer and proteins were separated by SDS/PAGE. Immunoblotting was 
performed with either anti-c-myc (SantaCruz) or anti-V5 (Invitrogen). 
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3.2.5 shRNA knockdown 
Short hairpin RNA (shRNA) sequences targeting TAg (shT) and sT (shsT) alone were 
designed and inserted into a short hairpin RNA expressing plasmid pLKO.1-TRC 
(Addgene). Sequences for shT (sense strands, 5'-CCG GAA GAG AGG CTC TCT GCA 
AGC TCT CGA GAG CTT GCA GAG AGC CTC TCT TTT TTG-3') and shsT (sense 
strand, 5'-CCG GAA GTT GTC TCG CCA GCA TTG TTC AAG AGA CAA TGC TGG 
CGA GAC AAC TTT TTT TG-3') were cloned using AgeI and EcoRI sites in the shRNA 
cassette of pLKO.1, respectively. A scrambled non-targeting short-hairpin RNA plasmid 
(scr) (Addgene) was used as control shRNA. For origin replication assay, 2 µg of TAg 
expression construct, 1 µg of origin construct were cotransfected with 2 µg of short 
hairpin construct into 293 cells grown in 6 well plate by Lipofectamine 2000 (Invitrogen). 
Cells were harvested and processed as described above. 
3.2.6 Chromatin immunoprecipitation (ChIP) 
TAg expression plasmids (TAg206.wt, TAg339, TAg350) or pcDNA6/V5-His empty 
vector (Invitrogen) were transfected with Ori339(97) or Ori350(97) plasmid into 293 cells 
using Lipofectamine 2000 (Invitrogen). Cells were cross-linked with 1% formaldehyde in 
PBS and DNA was sheared by sonication in lysis buffer (50 mM Tris (pH 8.0), 1% SDS, 
10 mM EDTA (pH 8.0) with protease inhibitors). Cell lysates were diluted 10 times with 
dilution buffer (20 mM Tris (pH 8.0), 1 % Triton X-100, 2 mM EDTA (pH 8.0), 150 mM 
NaCl with protease inhibitors) and one third of diluted lysates was precleared with 
protein A sepharose (GE Healthcare)/ 2 µg of sonicated salmon sperm DNA 
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(Stratagene) for 2 h at 4°C. Cell lysates were incubated overnight at 4°C with anti-V5 
(Bethyl) antibody and then with Protein A sepharose beads/2 µg salmon sperm DNA for 
2 h at 4°C. Beads were washed 4 times with buffer I (20 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 1% Triton X-100, 2 mM EDTA, 0.1% SDS), buffer II (20 mM Tris-HCl (pH 8.0), 
500 mM NaCl, 1% Triton X-100, 2 mM EDTA, 0.1% SDS), buffer III (10 mM Tris-HCl 
(pH 8.0), 500 mM LiCl, 1% NP40, 1% deoxycholate, 1 mM EDTA) and TE (10 mM Tris-
HCl (pH 8.0), 1 mM EDTA). DNA was extracted with buffer (100 mM NaHCO3, 1% SDS) 
and incubated at 65°C overnight to reverse cross-linking. DNA was purified and 
resuspended in distilled water followed by real time quantitative PCR (qPCR) performed 
with primers, Rep-S 5'-GCC GCC AAG GAT CTG ATG-3' and Rep-AS, 5'-GAG AAC 
CTG CGT GCA ATC-3' using Smart Cycler 5RX4Z01 (Cepheid) and SYBR GreenER 
qPCR SuperMix reagents (Invitrogen) according to manufacturer’s instruction. 
3.2.7 Molecular modeling 
The model of the MCV origin-binding domains on DNA was generated in COOT (335).  
A homology model of the MCV TAg OBD on a fragment of double-stranded GAGGC-
containing DNA was generated using the SV40 OBD structure (PDB code 2NCG) as a 
template.  Copies of the MCV OBD model were placed on idealized B-form DNA with 
the MCV origin sequence by superimposing the GAGGC sequence within the homology 
model onto each of the GAGGC-like sites in the model of the origin. The figure shown 
was generated in Pymol (http://www.pymol.org). 
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3.3 RESULTS 
3.3.1 The minimum MCV replication origin is defined by a 71 nucleotide genomic 
region 
MCV is more closely related to the Py subgroup of polyomaviruses than to other human 
polyomaviruses or SV40 (55). We aligned the sequences of the MCV origin with 
presumptive origin sequences of SV40 and Py (Figure 18A). The common features of 
the core origin in the SV40 subgroup are the presence of the AT-rich tracts contributing 
to DNA melting (321, 336), flanked by a Site 1/2 region containing six GAGGC 
pentanucleotide repeats.  An early promoter region containing additional GAGGC 
binding sites is also present.  This region is required for Py virus replication but is 
dispensable for SV40 origin replication (337-339).  The entire origin of MCV contains ten 
potential LT binding sequences (PS1-PS10, Figure 20A), six on one strand and four on 
the opposite strand.  Eight of these pentanucleotides match the most common LT 
binding sequence 5'-GAGGC-3', while two, PS2 and PS3, in Site 1/2 have imperfect 
consensus sequences: 5'-GGGGC-3' and 5'-GAGCC-3', respectively.  
To define the elements required for LT-mediated replication of MCV, deletions 
were generated for a tumor-derived MCV origin construct (Ori339(589), nt 4669 to 269) 
from MCV clone 339 (GenBank # EU375804) (Figure 18A).  This origin fragment is 
perfectly conserved in most tumor and all nontumor-derived MCV strains thus far 
sequenced.  Origin constructs were cloned into pCR2.1 (Invitrogen) and co-transfected 
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together with a full-length wild-type T antigen genomic expression construct 
(TAg206.wt, isolated from intestine tissue of a patient without MCC) into 293 cells.  In 
this study, we refer to the genomic T antigen cassette as TAg, which expresses small T 
(sT) and 57kT proteins from alternatively spliced mRNAs in addition to LT protein (279).  
Origin replication was determined by Southern hybridization in which DpnI-resistant 
(replicated) signal is normalized to DpnI-sensitive (unreplicated) signal.  In contrast to 
Py but similar to SV40, the MCV origin can be reduce to a discrete region such that 
constructs encompassing only an 80 bp origin show efficient replication by MCV TAg 
(Figure 18B).  Replication is completely abolished for a shorter 69 bp origin construct.  
The 80-bp fragment (nt. 5356-nt 48) contains, in addition to the AT-rich tract, eight of 
the identifiable LT binding PS (Figure 18A) indicating that PS9 and PS10 are not 
required for origin replication. 
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Figure 18. Mapping  of the MCV core origin 
(A) Comparison of the origin sequences among 
polyomavirus family. The straight and dotted arrow 
heads indicate complete (GAGGC) or incomplete 
pentanucleotide sequences (GXGGC, GAGXC) serving 
for LT binding sites, respectively. The origin of SV40 
subgroup (GenBank# EF59667.1) consists of highly 
conserved region, including AT-rich tract on the late 
gene side, Site II GAGGC repeats, early palindrome 
(EP), and early enhancer region on the early gene side. 
MCV origin (GenBank# EU375804) is closely related to 
the origin of Py (GenBank# J02288).  MCV origin 
constructs of different lengths (589 bp-69 bp) were 
cloned into pCR2.1 vector (Invitrogen) to identify the 
core origin sequence. (B) Deletion analysis of MCV 
origin. The origin constructs were cotransfected into 
293 cells with either TAg206.wt or empty vector as a 
negative control and the replication from the MCV origin 
was analyzed by Southern blotting. The autoradiogram 
was quantified using ImageQuant software (GE 
Healthcare). The DpnI sensitive DNA band was used 
as an internal standard for the amount of input DNA.  
 
 
To define a minimal core origin, we successively truncated single-base pairs from 
the early and late sides of the 80 bp origin until replication was completely abolished 
(Figure 19). A significant decline in MCV replication efficiency occurs only after deletion 
of four of the ten thymidines in the polyT tract (dN70).  This is in contrast to the SV40 
origin which requires an intact polyT tract for efficient replication (321).  MCV origin 
replication also declines sharply starting at the dC78 deletion that truncates PS8 on the 
early side of the origin.  Thus, unlike Py, a minimal MCV core origin consisting of the 71-
bp region from nucleotides 5364 through 47 can efficiently sustain LT-mediated DNA 
replication.  
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Figure 19. Definition of the minimal MCV core origin 
Single-base pair deletions from both sides of the origin sequence (late-nt 5356, early-nt 48) 
were performed to define a minimal core origin. The expression level of TAg was observed by 
Western blotting (data not shown) and autoradiogram of replication was quantified as in Fig. 1B 
(middle panel). 
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3.3.2 Pentanucleotide requirements for MCV replication.  
Four LT binding sites (Figure 18A) are present in the SV40 core origin, and all four 
pentanucleotides are necessary for origin DNA unwinding and replication events with 
pentanucleotides 1 and 3 needed for double hexamer formation (340, 341). These 
pentanucleotides are arranged on opposite strands allowing the double SV40 LT 
hexamer to form in a head-to-head orientation (342).  
Figure 20. Pentanucleotide requirements 
(A) Mutation of each pentanucleotide in 97-bp origin was generated by PCR-based direct 
mutagenesis (AT to GC) to define the essential pentanucleotides for MCV origin replication. 
Replication efficiency was examined by Southern blotting (B). 
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To determine whether a similar pentanucleotide arrangement is needed for MCV 
replication, mutations were introduced that disrupted all five nucleotides of 
pentanucleotide sequences PS1-8 in the 97-bp origin (Figure 20A).  Mutations in three 
pentanucleotides within the region most analogous to Site II (PS1-4) (Figure 18A) and 
two pentanucleotides (PS7, 8) near the early enhancer region abolish replication.  The 
PS4 mutant significantly diminishes replication. In contrast, PS5 and PS6 are 
dispensable (Figure 20B).  
Since PS2 and PS3 partially overlap, as do PS7 and PS8, complete 
pentanucleotide substitutions affect overlapping elements because of shared 
nucleotides.  We therefore investigated critical nucleotides in these four elements (PS 2, 
3, 7, 8) by introducing single mutations to determine which of the overlapping PS 
sequences are essential (Figure 21A) as well as critical nucleotides in PS1.  Figure 
21B shows that single base pair mutations in three pentanucleotides (PS1, 2 and 7) 
impair efficient replication.  In the non-consensus PS2 element, a single substitution 
mutation that reconstitutes a canonical GAGGC site remains competent for replication 
(Figure 22B).  Single mutations unique to the PS3 site that do not overlap with the 
opposite strand PS2 have no effect on replication suggesting that PS2 is the critical LT 
binding element in this overlapping pair.  A PS3 (S3-2C) mutation that creates the same 
head-to-head LT binding site as in the Py origin (GGGGCCCC) (Figure 18A) has no 
replication capacity (Figure 22B), indicating that the MCV LT replication complex may 
form assemblies on the DNA that are distinct from Py and SV40.   
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Figure 21. Single base pair mutational analysis of pentanucleotides 
(A) Each sequence of Pentanucleotides 1, 2-3 and 7-8 was mutated by AT to GC substitutions 
to disrupt TAg binding site. To avoid reconstitution of T Ag binding site (5'-G(A/G)GGC-3') by 
mutation, AG to T substitutions were introduced in S7-2, S8-2, S2-2 and S3-2. (B) Southern blot 
results demonstrate that single base mutations in pentanucleotides 1, 2 and 7 can abolish 
replication efficiently indicating that these pentanucleotides sites are critical for MCV origin 
replication as a functional unit.  
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Figure 22. Reconstitution of pentanucleotide sequence to GAGGC 
(A) In the non-consensus PS2 element (GGGGC), a single substitution mutation that 
reconstitutes a canonical GAGGC site (S2-2A) by A:T to G:C base pair substitutions remains 
competent for replication. (B) Southern hybridization results. 
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The importance of PS7 to MCV replication is illustrated by naturally arising 
mutations at the viral origin (Ori350(97) lane of Figure 21B).  We sequenced MCV 
origins from one non-tumor tissue, 8 MCC tumors and 2 cell lines (55).  Only the origin 
sequence from one tumor, MCV350 (GeneBank# EU375803), has a C to A substitution 
in position 5 of PS7 that also alters the sequence of the overlapping PS8.  This natural 
mutation completely abrogates origin replication in the presence of TAg (Figure 21B).  
The TAg gene from this virus also possesses a TAg locus truncation mutation (279) that 
eliminates both the LT OBD and helicase domain. 
3.3.3 Effects of Tumor-derived LT mutations on origin binding and replication 
As shown here (Figure 21B), and described previously (279), tumor-derived MCV TAg 
is unable to initiate MCV origin replication due to truncating mutations in the LT protein.  
We compared origin-binding properties for wild-type LT protein (TAg206.wt) on the wild-
type origin (Ori339(97)) and the mutated Ori350 (Ori350(97)), as well as mutant LT 
proteins from tumor derived viral strains (MCV339 and MCV350) (Figure 23).  MCV339 
LT protein retains the OBD but has a truncated helicase domain, whereas the MCV350 
LT mutation eliminates both the OBD and helicase domains (279).  Quantitative 
chromatin immunoprecipitation (ChIP) assays demonstrate that wild-type TAg206 
efficiently binds to the wild-type origin Ori339 but binding to Ori350, possessing the 
PS7/PS8 mutation, is reduced ~50%.  Origin-binding by MCV339 and MCV350 TAg 
proteins is comparable to vector alone controls for both viral origins suggesting that 
structural or enzymatic features of the MCV LT helicase domain are required for 
efficient recognition of the DNA element.  
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Figure 23. Chromatin immunoprecipitation (ChIP) analysis 
(A) The binding efficiency of both non-tumor and tumor-derived TAg to MCV origin in vivo was 
examined using ChIP assay. The 97 bp origin-containing plasmid (Ori339(97) or Ori350(97)) 
and the TAg constructs from non-tumor (TAg206.wt) or tumor (TAg350, TAg339) tissues (279) 
were co-transfected into 293 cells and the binding of LT to the origin was investigated by 
quantitative PCR (qPCR). All experiments were repeated at least three times. Error bars 
indicate the standard deviation. (B) Immunoblot analysis confirming protein expression of 
TAg206, TAg350 and TAg339 using the LT specific antibody CM2B4. 
Other factors influencing MCV replication  
Four major TAg transcripts (T1-T4) have been identified using RACE and Northern 
blotting that correspond to LT, sT, and 57kT (279) (Figure 24A).  The sT of MCV shares 
exon 1 with LT, which contains the conserved CR1 (LXXLL motif) and DnaJ (HPDK 
motif) domains, but lacks the LT OBD required for DNA recognition.  The sT also 
encodes a PP2A binding site (CXCXXC) that is spliced out of LT and 57kT cDNAs.  To 
test the effect of sT and other transcripts on viral origin replication, each cDNA transcript 
was cloned to express a unique TAg isoform.  Each cDNA construct, singly and in 
combination, was then transfected into 293 cells to assess effects on origin replication.  
As seen in Figure 24B, LT cDNA expression alone is not sufficient for fully efficient 
replication, but replication efficiency is restored to that of the wild type genomic TAg by 
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coexpression of LT with sT. Coexpression of LT with 57kT does not increase replication 
over LT alone, and neither MCV sT nor 57kT individually have replication capacity.   
To confirm the importance of sT in replication, we generated two short hairpin 
RNA (shRNA) constructs: shT targets all TAg transcripts and shsT targets only sT  
(Figure 24A) (279). We also generated a monoclonal antibody, CM8E6, directed 
against an exon 1 peptide shared by all TAg isoforms. Western blotting shows that shT 
down-regulates LT, sT, and 57kT protein expression as expected, whereas shsT only 
reduces sT expression (19 kDa) (Figure 24C).  Knockdown of TAg proteins by either 
shT or shsT results in inhibition of origin replication compared to shScr control, 
confirming the functional importance of sT expression to MCV origin replication (24D). 
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Figure 24. Other factors influencing MCV replication 
(A) Alternative spliced products (T1-T4) of the early region give rise to large T (LT), small T (sT), 
and 57kT. Arrows indicate the position of shRNAs, shT and shsT.  shT targets all TAg 
transcripts while shsT targets only sT transcripts. Asterisk and star show epitope sites of 
CM8E6 and CM2B4 antibodies, which detect LT/57kT/sT or LT/57kT proteins, respectively. The 
predicted MCV LT gene sequence retains all major conserved features of other polyomavirus 
LTs, including DnaJ, Rb-targeting, origin-binding, and helicase/ATPase domains. (B) LT, 57kT, 
and sT expression plasmids were cotransfected in combination into 293 cells to test contribution 
of origin replication. The genomic TAg construct (TAg206.wt) was used to express all three 
transcripts (LT, sT, 57kT).  For the sT expression, EGFP fused sT expressing plasmid was 
used. Western blotting was performed to monitor the expression level of each transcript product 
using V5 antibody (Invitrogen) for LT and 57kT, and anti-GFP (SantaCruz) antibody for sT. 
Knockdown of LT, 57kT, and/or sT expression (C) and the effect on replication (D) by shRNA 
was examined.  A scrambled non-targeting short-hairpin RNA plasmid (scr) was used as a 
control.  Three specific bands (120, 57, 19 kDa) are detected by Western blotting using CM8E6 
antibody in 293 cells transfected with genomic TAg expression constructs (TAg206.wt) (C, right 
panel). CM2B4 detected both ~120 kDa and ~57 kDa bands corresponding to the full-length LT 
and 57kT protein products, respectively (281) (C, left panel). (E) Interaction of TAg with Hsc70. 
To examine the interaction between TAg and Hsc70, Myc-tagged Hsc70 construct (pCMV-myc-
Hsc70) was transfected into 293 cells with either V5-tagged wt TAg (TAg206.wt) or mt TAg 
(D44H, D44N). Lysates were immunoprecipitated with anti-myc or anti-V5 antibody and 
immunoblotted with anti-V5 or anti-myc antibody in a reciprocal way, respectively. The LacZ 
gene expressing vector, pcDNA6/V5-His/LacZ (Invitrogen) was used as a negative control for 
binding and 2% of the lysate was used for input control (~115 kDa). (F) Hsc70 binding to TAg 
promotes efficient viral replication. For the replication assay, TAg206.wt or mutants (Rb binding 
mutant, LXCXK; Hsc70 binding mutant, D44N; Rb/Hsc70 binding mutant, LXCXK/D44N) were 
cotransfected with MCV origin plasmid (Ori339(97)) into 293 cells. Replication efficiency was 
measured and quantified using ImageQuant (GE Healthcare). 
 
 113 
Both MCV LT and sT contain DnaJ motifs encoded by exon 1 that are conserved 
among polyomaviruses and recruit interaction with chaperone heat-shock proteins 
(343).  SV40 TAg association with Hsc70 (344) is mediated through the HPDK motif 
within the DnaJ domain (334, 345) which is required for efficient origin replication.  We 
confirmed that this motif in MCV is a site for Hsc70 interaction by coimmunoprecipitation 
of V5-tagged wild-type (TAg206.wt) and DnaJ domain mutant (D44H and D44N) 
proteins with myc-tagged Hsc70 (Figure 24E). 
To test whether Hsc70 interaction with MCV TAg is required for efficient viral 
DNA replication, wild type (TAg 206.wt) and the LT DnaJ mutant D44N were tested for 
origin replication using the Ori339(589) (Figure 24F).  Mutation of the LT DnaJ domain 
markedly decreases origin replication compared to wild-type MCV TAg, whereas 
mutation of the MCV LT retinoblastoma-binding motif (LXCXE) does not, similar to 
results found for SV40 TAg (334).  The MCV D44N LT mutant is less stable than wild-
type MCV LT but enhanced expression to generate comparable levels of both proteins 
does not increase replication with the DnaJ-binding deficient protein (data not shown).  
In contrast, mutation of the DnaJ domain in sT has no effect on the ability of sT to 
enhance wild-type LT replication efficiency.  In addition, mutation in the PP2A domain of 
sT abolishes its ability to enhance LT-mediate origin replication (Figure 25).  
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Figure 25. MCV origin replication assay with TAg mutants in DnaJ domain and PP2A 
binding site 
The HPDK motif in the LT DnaJ domain was mutated (D44N) in constructs, gTAg206.wt, 
cLT206.wt and sT.wt. A PP2A binding site mutant of sT was generated by substituting Cys 109 
to Ser. Origin plasmid (Ori339(97)) was cotransfected with wild type or various mutant TAgs into 
293 cells and Southern blotting was performed. Mutation of the DnaJ domain in sT 
(sT.DnaJ.D44N) has no effect on wild-type LT replication efficiency.  In contrast, the PP2A site 
mutant of sT (sT.PP2A.C109S) abolishes contribution of sT to enhance origin replication 
efficiency. 
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3.4 DISCUSSION 
We find that a minimal MCV 71 bp core origin sequence is sufficient for TAg-directed 
DNA replication.  Like other polyomaviruses, this MCV core origin contains three 
subdomains: an AT-rich tract, a LT-binding domain, and an early enhancer region.  The 
AT-rich tract for SV40 directs DNA bending that may be a structural signal for LT 
binding (321).  Adjacent to the AT-rich tract, pentanucleotides sequences are arranged 
as two pairs of imperfect repeat sequences (PS 1-4) inverted with respect to each other.  
These repeats are similar, but more closely spaced than those in SV40.  Of these four, 
only three (PS1, PS2, and PS4) are required for origin replication.  In addition to these 
three PS elements, the MCV origin has an additional LT binding site at PS7, which is 
required for origin replication and if disrupted, as found in a naturally-occurring tumor-
derived strain, markedly reduces LT binding to the origin element in our quantitative 
ChIP assay and completely ablates origin replication.  Mutational substitution analysis 
shows that even single point mutations on other essential PS also disrupt origin 
replication.   
The origin binding domains of MCV, Py and SV40 are similar in sequence, and 
the residues shown to bind GAGGC pentamers are highly conserved in the three 
viruses. Sequence comparison reveals that the MCV OBD is 49% identical to Py and 
48% identical to SV40 (data not shown). To better understand why MCV requires fewer 
GAGGC binding sites than other viruses for its replication, the crystal structure of the 
SV40 OBD on DNA was used to model the interaction of MCV TAg with the MCV origin.  
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As shown in Figure 26, the closely spaced PS sites also position the OBD of LT closely 
to one another.  Given this proximity, it is likely that OBD-OBD interactions occur while 
apposing LT molecules are bound to the DNA.  Such interactions are not observed in 
SV40, where the GAGGC sequences are farther separated, but they do occur in the 
more distantly related bovine papilloma virus (BPV) system (346, 347).  In BPV, the 
analogous domain is part of the E1 protein and is not capable of recognizing its binding 
site without the help of the virally-encoded E2 protein.  MCV origin recognition may 
share features of both SV40 and BPV.   
 
Figure 26. Model of the MCV OBDs on the MCV origin 
A model of the MCV OBD was placed on each of the putative binding sites.  OBDs positioned at 
the required PS1, PS2, PS4 and PS7 are shown in blue. The remainder are yellow. The 
GAGGC sequences are shown in cyan.  The AT-rich tracts of DNA that flank Site 1/2 are shown 
in purple. 
 
MCV is similar to SV40 in that replication does not require an E2-like protein, but 
like BPV, interactions among the OBDs may help stabilize the complex on the DNA, 
perhaps alleviating the need for well-formed binding sites at all positions.  Based on our 
modeling, two sets of OBD-OBD interactions may occur on the DNA, both of which are 
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head-to-head interactions.  The first is between the OBDs bound to PS2 and PS3, and 
the putative protein-protein interface involves amino acids within the major groove of the 
DNA.  The second potential interaction involves residues well outside of the DNA-
binding cleft and could occur between OBDs on PS1 and PS3 and between OBDs on 
PS2 and PS4.   
We also examined non-origin factors related to viral replication efficiency.  
Previously, several studies using SV40, Py and JCV sT defective viruses or constructs 
have demonstrated that the absence of a functional sT reduces replication efficiency 
(320, 348, 349).  In this report, we generated separate cDNA constructs for each early 
gene transcript product (LT, 57kT, sT) to clarify the role and contribution of sT in viral 
replication.  We find that sT, but not 57kT, has a major role in enhancing LT mediated 
replication in MCV.  The mechanism for sT replication enhancement in MCV remains 
poorly understood but it is likely that sT does not act directly in the LT-origin replication 
complex.  Like other polyomavirus sT, MCV sT binds PP2A (129), a serine/threonine 
phosphatase critical to development, growth control and tumorigenesis (350).  MCV sT 
might stimulate cell cycle entry through PP2A binding thus providing conditions for 
origin replication.  Alternatively, sT expression might selectively affect the 
phosphorylation state of LT to enhance its binding affinity to the origin DNA binding site 
(351, 352).  Intriguingly, both MCV LT and sT possess DnaJ domains that recruit 
Hsp70; while an intact LT DnaJ domain is required for efficient replication, an intact sT 
DnaJ domain is not.  Site-directed mutagenesis of DnaJ domain residues reveals that 
this domain is necessary for LT and MT stability (353).  We also find that MCV TAg 
DnaJ domain mutants are destabilized.  While reduced protein expression may account 
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for some of the reduced activity of LT having DnaJ domain mutations, replication 
remains reduced even when the mutant protein is expressed at comparable levels to 
the wild-type protein. 
The minimal replication origin of MCV provides a novel model for a defined 
genetic replication element.  Our studies suggest that there is strong selective pressure 
within MCV-infected MCC tumors to eliminate independent viral DNA replication.  
Tumor-derived mutant MCV TAgs and origins may prove useful for structural and 
functional studies dissecting steps involved in TAg-dependent DNA replication.  
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4.0  MERKEL CELL CARCINOMA-DERIVED MERKEL CELL POLYOMAVIRUS T 
ANTIGEN INDUCES HUMAN CELL PROLIFERATION THROUGH ITS RB 
TARGETING DOMAIN BUT IS INSUFFICIENT TO TRANSFORM HUMAN 
FIBROBLASTS 
Work described in this chapter is unpublished. Parts of the data presented here are in 
preparation for manuscript submission 
 
with authors Anna Guastafierro, Masahiro Shuda, Huichen Feng, Yuan 
Chang and Patrick S. Moore. 
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microarray data and generated heat map images. All authors contributed to data 
interpretation and manuscript preparation. 
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4.1 INTRODUCTION 
 
The study of tumor viruses has elucidated a large number of protein signaling networks 
that are involved in cancers of diverse cellular origins (354, 355). Despite the fact that 
oncogenic viruses cause only a small percentage of all human cancers, experimental 
models have defined gene elements required for human cell transformation by using 
viral oncogenes as tools to target specific combinations of intracellular pathways in vitro 
(194).  The cancer phenotype is a multi-step process of genetic changes that lead to a 
loss of homeostasis in cellular mechanisms responsible for controlling diverse protein 
signaling networks. During this process normal cells acquire mutations that allow them 
to replicate indefinitely (immortalization), escape apoptosis, and promote cell cycle 
progression (356).  
Hahn et al. described the creation of a human tumor cell by expressing simian 
vacuolating virus 40 (SV40) T antigens, as well as the telomerase catalytic subunit 
hTERT and oncogenic hRas (hRasV12) in BJ primary human fibroblasts (357). 
Immortalization of primary human cells can be achieved by hTERT expression, which 
elongates telomeres and therefore allows for an indefinite replicative lifespan of a cell 
(358, 359). SV40 large T antigen (LT) has been extensively studied and was crucial in 
the discovery of p53 as well as dissection of the Rb family pathways (360, 361). SV40 
LT contains a conserved LXCXE motif, which can be found in a number of oncoproteins 
from other tumor viruses including HPV E7, adenovirus E1A and MCV LT (55, 362). The 
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LXCXE motif facilitates binding of Rb family members pRb, p107 and p130, which 
results in E2F-mediated cell cycle entry and progression (362, 363). In addition, SV40 
LT binds to p53 through a C-terminal bi-partite binding site (364). This interaction has 
been shown to contribute to SV40 LT-mediated transformation of rodent cells not only 
by inactivating p53 transcriptional activity, but also by inducing a gain-of-function as a 
result of this interaction (162). In contrast, neither MCV full length LT nor tumor-derived 
truncated LT bind to p53 directly (260). SV40 small T antigen (sT) binds and perturbs 
the serine/threonine phosphatase PP2A through a conserved motif (197, 365). This 
interaction contributes to human cell transformation in combination with SV40 LT in 
human fibroblasts (194).  
Recent data from our group shows that, in contrast to to SV40, MCV sT is 
capable of transforming rodent fibroblasts independent of its PP2A binding motif, as 
evaluated by soft agar as well as focus formation assays in Rat-1 and NIH3T3 cells 
(129).  Neither MCV full length LT nor MCC-derived, truncated LT are capable of fully 
transforming rodent cells in these assays even though small cell aggregates are 
observed in soft agar. Nevertheless, tumor-derived MCV LT has growth promoting 
effects in both rodent as well as human fibroblasts (260). Most MCC tumors express 
both MCV LT as well as sT proteins, which indicates that both viral proteins are 
essential in MCC tumorigenesis (129).  
In MCC tumors the MCV genome is clonally-integrated, which demonstrates that 
the viral integration event precedes tumor cell outgrowth, and therefore supports a 
causal relationship between the two processes (55). In addition to viral genome 
integration, all MCV genomes isolated from tumors have been shown to have truncating 
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deletions in the C-terminal ATPase/helicase domain of MCV LT, which is necessary for 
viral replication (56).  Recent data from Cheng et al. demonstrates that the terminal 
exon 3 domain of LT, which is always deleted in MCC, has a growth inhibitory effect in 
human fibroblasts as well as MCV-positive MCC cells expressing a truncated LT (260). 
The mechanism that leads to this inhibitory activity of the C-terminus was recently 
associated with a DNA damage response resulting in p53 protein stabilization and 
phosphorylation, as well as downstream p21 activation in U2OS cells (366).  
In this study, we show that tumor-derived MCV LT enhances human fibroblast 
proliferation in an LXCXE-dependent manner, and that MCV sT only minimally 
contributes to proliferation.  In addition, we performed a microarray analysis, which 
indicates that G1/S phase transition regulators are specifically up-regulated by 
truncated LT, resulting in an increased percentage of cells entering S-phase. Additional 
expression of oncogenic hRasV12 and p53 knockdown in BJ-hTERT are required to 
induce soft agar colony formation in the presence of MCV sT; however, we did not 
observe soft agar colony formation in the presence of 339LT. 
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4.2 MATERIALS AND METHODS 
4.2.1 Cell culture 
The Merkel cell lines were grown in RPMI 1640 supplemented with 10% fetal calf 
serum. BJ and BJ-hTERT fibroblasts were grown in DMEM supplemented with 10% 
fetal calf serum, penicillin and streptomycin. All cells were grown at 37 °C in humidified 
air containing 5% CO2. 
4.2.2 Generation of stable cell lines 
BJ-hTERT cells were infected with lentiviruses in the presence of 6ug/mL polybrene. 
Medium was changed after 24 hours, and antibiotic selection was added (puromycin = 
1ug/mL; G418 = 400ug/mL; blasticidin = 5ug/mL) on day 3 after infection. Cells were 
grown under selection medium until all mock infected cells died. 
4.2.3 Lentivirus production 
Lentiviruses for pLKO knockdown as well as pLVX and pSMPUW overexpression 
constructs were produced in HEK293FT cells (Invitrogen) using pPax2 and pMD2.G 
helper constructs that were obtained from Addgene.  At 3 days following transfection, 
virus supernatants were harvested and filtered through 0.45 µm pore size filters. 
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4.2.4 Overexpression and short hairpin RNA (shRNA) constructs 
Overexpression constructs for 339LT, 339LT.LXCXK and sT were described previously. 
An shRNA sequences designed to target human cyclin E (shCyclinE: sense strand, 5’- 
CCT CCA AAG TTG CAC CAG TTT CTC GAG AAA CTG GTG CAA CTT TGG AGG 
TG -3’) was cloned into AgeI and EcoRI sites of the pLKO.1.puro lentiviral vector. An 
shRNA designed to target to human p53 (shp53: sense strand, 5’- CAC CAT CCA CTA 
CAA CTA CAT CTC GAG ATG TAG TTG TAG TGG ATG GTG-3’) was cloned into 
pLKO.1.neo lentiviral vector.  The control pLKO.1 plasmid, having a scrambled non-
targeting short-hairpin RNA sequence, was obtained from Addgene. 
4.2.5 Cell counting and doubling time determination 
To evaluate cell proliferation in different stable cell lines, cells were seeded in triplicates 
in 6 well plates at a density of 2.5 x 10^4 cells per well. Each day cells were counted in 
triplicates. Cells were treated with Trypsin (Millipore), collected, mixed with equal 
volume of Trypan blue (Lonza, 0.4%) and counted using a hemocytometer under the 
microscope. Doubling times were calculated using an exponential regression calculator 
(Roth V. 2006 http://www.doubling-time.com/compute.php) 
4.2.6 Immunoblotting 
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer containing 50mM Tris, 
150 mM NaCl, 0.1% SDS, 0.5% Na Deoxycholate, 1% NP40, and protease inhibitors 
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(Complete cocktail, Roche, Indianapolis, IN). Lysates were kept on ice for 15 minutes, 
and then centrifuged 20,000 x g for 10 minutes at 4°C. Supernatants were mixed with 
5X sodium dodecyl sulfate (SDS) loading dye, and denatured at 100°C for 5 minutes. 
Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE), and 
transferred onto a Hybond-C nitrocellulose membrane (GE Healthcare). Viral proteins 
were detected using CM2B4 (LT), CM8E6 (sT), and CM5E1 (sT) antibodies as 
described before (129, 254, 281, 290). SV40 LT and sT were detected using the mouse 
monoclonal antibody Pab419 (Santa Cruz) at 1:1000. Cyclin E was detected using the 
rabbit polyclonal antibody C19 (Santa Cruz) at 1:1000. CDK2 was detected using the 
mouse monoclonal antibody clone SC-6248 (Santa Cruz) at 1:1000. Cyclin A was 
detected using the rabbit polyclonal antibody SC-596 (Santa Cruz) at 1:1000. Cyclin D1 
was detected using the rabbit polyclonal antibody M20 (Santa Cruz) at 1:1000. p53 was 
detected using the mouse monoclonal antibody clone D-O1 (Santa Cruz) at 1:1000. p21 
was detected using the mouse monoclonal antibody clone OP64 (Calbiochem) at 
1:1000. Ras was detected using the rabbit monoclonal antibody clone 27H5 (Cell 
Signaling) at 1:1000. Alpha tubulin was detected with either the mouse monoclonal 
antibody clone B-5-1-2 (Sigma) at 1:10000, or with the rabbit monoclonal antibody clone 
11H10 (Cell Signaling) at 1:2000.  For secondary antibody detection the Odyssey 
Infrared Imaging system (LI-COR) was used with IRDye 680- or 800-conjugated 
secondary antibodies (1:8000 dilution, Rockland Immunochemicals). SV40 LT and sT 
were detected using the mouse monoclonal antibody Pab419 (Santa Cruz) at 1:1000. 
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4.2.7 Semi quantitative RT-PCR 
RNA was extracted from BJ-hTERT stable cell lines using Trizol reagent (Invitrogen). 
RNA was DNaseI treated and cDNA was synthesized using SuperScript III First Strand 
Synthesis (Invitrogen). Primer sequences were as follows: Cyclin E (forward: 
AGTGCTACTGCCGCAGTATC; reverse: TGCTTCTTACCGCTCTGTGG), CDK2 
(forward: ACAGCTGTGGACATCTGGAGC; reverse: GCTATCAGAGTCGAAGATGG), 
Cyclin D1 (forward: CCGTCCATGCGGAAGATC; reverse: 
GAAGACCTCCTCCTCGCACT), and GAPDH (forward: CTGCCCAGAACATCATCC; 
reverse: AGCCGTATTCATTGTCATACC). PCR reaction was performed using Taq 
polymerase (Invitrogen) for 30 cycles. 
4.2.8 Soft agar assay 
BJ-hTERT stable cell lines were trypsinized to single cells, counted, suspended in 
complete medium containing 0.3% agarose (Sigma-Aldrich), and seeded over a 0.6% 
agar layer in 6 well plates (2.5 × 104 cells/well) in triplicates. After 4 weeks, plates were 
photographed at a magnification of 100X. 
4.2.9 Microarray 
RNA was extracted from biological triplicate stable cell lines BJ-hTERT empty, 339LT, 
339LT.LXCXK, and 339LT+sT using Trizol reagent (Invitrogen). RNA was DNaseI 
treated, and RNA integrity was assessed. For microarray analysis, RNA samples had to 
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have a RNA integrity number (RIN) of 6 or above. We used a Human HT-12 v4 
Expression BeadChip from Illumina, which was processed at the University of 
Pittsburgh Genomics and Proteomics Core facility. Microarray data was normalized to 
total fluorescence intensity using cubic spline normalization. For multiple probes per 
gene, averages of all probes were used for individual gene analyses. All values used for 
analysis represent averages of three biological replicas. Standard deviations were 
calculated for genes that were detected with ≥3 probes. 
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4.3 RESULTS 
4.3.1 The effect of MCV T antigens on BJ-hTERT proliferation  
To test whether the proliferative effect of truncated MCV T antigens in human fibroblast 
cells depends on its LXCXE motif and whether sT contributes to this phenotype, we 
generated BJ-hTERT stable cells that express different combinations of MCV T antigen 
cDNA codon-optimized constructs by lentiviral transduction, and evaluated cell 
proliferation. We expressed a truncated MCV LT (339LT) previously described (56) 
(also see Figures 11 and 34 for truncation pattern), and a LXCXK domain mutant of 
339LT (339LT.LXCXK), which lacks RB-family pocket protein binding. 339LT was 
chosen because it represents one of the longest truncated MCV LT proteins described 
thus far. Protein expression of 339LT, 339LT.LXCXK, and sT was confirmed by 
immunoblot (Figure 27A). Cell counts over a 10-day period revealed that tumor-derived 
339LT expression provides a significant growth advantage over empty vector control 
(Figure 27B). In addition, we observed that mutation of the LXCXE pocket protein-
binding motif reverses this growth advantage, and MCV co-expression of sT slightly 
enhances proliferation of empty vector or 339LT expressing cells (Figure 27B). The 
doubling times and saturation densities of BJ-TERT stable cells reflect this LXCXE-
dependent, growth promoting effect of tumor-derived 339LT (Figure 27C).  
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Figure 27. Tumor-derived MCV LT promotes human fibroblast proliferation through it 
LXCXE RB targeting domain 
(A) Immunoblot analysis of BJ-hTERT stable cell lines was performed to detect truncated MCV 
339 LT, 339 LT.LXCXK (339LT.XK) and sT using CM2B4 for 339LT and CM8E6 for sT 
detection. Tubulin blot serves as a loading control. (B) Proliferation assay of stable cell lines 
was performed twice in 10 % serum. This graph depicts one representative experiment of 
technical triplicates. (C) Doubling times Saturation densities of BJ-hTERT stable cell lines were 
measured on day 12 after seeding. Counts represent two replica in triplicates in a 6 well plate 
format. 
 
4.3.2 Transformation assays 
Given the strong proliferative effect of MCV T antigens, we evaluated whether MCV T 
antigens could be substituted for SV40 T antigens in the context of defined human cell 
transformation studies. Hahn et al. have previously identified elements capable of 
inducing human fibroblast transformation using SV40 LT (Rb and p53 inactivation; 
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possible gain of function due to p53 interaction), SV40 sT (PP2A inactivation), 
hRasV12, and hTERT (316). Since MCV LT does not bind p53 (260), we reasoned that 
p53 knockdown might be necessary in addition to MCV LT and sT as well as hRasV12 
expression to transform BJ-hTERT cells.  
 
 
 
 
Figure 28. Generation of BJ-hTERT stable cell lines for transformation assays 
(A) BJ-hTERT cells were infected with shscr and shp53 lentiviruses and selected to create 
stable cell lines. Immunoblot analysis using a p53 antibody shows knockdown efficiency. (B) BJ-
hTERT shscr and shp53 stable cell lines were infected with empty, 339LT or 339LT.LXCXK 
(339LT.XK) lentiviruses and selected to create stable cell lines. LT expression was confirmed by 
immunoblotting using the CM2B4 antibody. (C) Stable cell lines used for soft agar seeding 
(Figure 30) were analyzed for p53 and Ras protein expression.  
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We created p53 knockdown BJ-TERT cell lines by lentiviral transduction of p53 
shRNA. The p53 knockdown efficiency in our stably selected cell line is shown in Figure 
28A. We infected the shp53 and shscr cell lines with lentivirus expressing MCV 339LT, 
MCV 339LT.LXCXK, or empty vector control (Figure 28B). After the antibiotic selection 
period, we infected each stable cell line with either empty vector or MCV sT expression 
lentivirus, followed by antibiotic selection and transient infection with lentivirus 
expressing either empty vector or hRasV12. We performed immunoblot analyses to 
confirm p53 knockdown and Ras protein expression in the resulting 24 different 
combinations of stable cell lines (Figure 28C). Endogenous Ras expression as well as 
ectopic hRasV12 expression varied between cell lines and p53 levels were slightly 
increased by 339LT expression in a LXCXE-dependent manner. To determine whether 
any of the oncogene combinations resulted in cell transformation, we performed a soft 
agar colony formation assay (Figure 30). As a positive control we seeded BJ-hTERT 
cells expressing SV40ER and hRasV12 in soft agar and observed large colony 
formation at 4 weeks (Figure 29). In the case of MCV T antigens, the results indicate 
that only BJ-hTERT fibroblast expressing hRasV12 and MCV sT in the presence of p53 
knockdown form small soft agar colonies. Additional expression of 339LT did not result 
in colony formation (Figure 30).  
 
Figure 29. BJ-hTERT SV40ER and hRas stable cell line soft 
agar positive control 
A BJ-hTERT stable cell line expressing the SV40 early region 
(ER) and hRasV12 was seeded in soft agar and photographed 4 
weeks later at a magnification of 100X. 
 
SV40ER + hRasV12 
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Figure 30. BJ-hTERT stable cells soft agar colony formation result 
BJ-hTERT stable cell lines were seeded into soft agar at a density of 2.5x10^4 per 6 well plate 
well in triplicates. Pictures were taken 4 weeks after seeding at a magnification of 100X. 
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4.3.3 Microarray gene expression profile in BJ-TERT cells expressing MCV T 
antigens 
To obtain mechanistic insights into the growth promoting effect of tumor-derived LT, we 
characterized the transcriptional gene profiles of the BJ-hTERT stable cells used in the 
cell proliferation studies (Figure 27). We performed a whole human microarray analysis 
using an Illumina-based Human BeadChip on three biological replicates of BJ-hTERT 
stable cell lines empty, 339LT, 339LT.LXCXK and 339LT+sT. To validate the integrity of 
our microarray, we analyzed a subset of E2F activated genes. As shown in Figure 31, 
 
Figure 31. Microarray gene expression profile of E2F targets 
Cubic spline normalized microarray expression data from biological triplicate averages for E2F 
target genes is represented as fold expression over empty control BJ-hTERT cells. Fold 
changes for E2F2 represent values from a single probe detection. Fold changes for all other 
genes shown here represent averages of 2 probes each. 
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this subset of E2F responsive genes is induced by 339LT expression in an LXCXE-
dependent manner. This confirms that our microarray gene expression profile behaves 
accurately for gene changes already known to occur through LXCXE targeting. 
We then plotted average gene expression values for each 339LT or 
339LT.LXCXK against empty control and determined the number of up- and down-
regulated genes in each case. This analysis reveals that 339LT expression has a 
significant affect on the cellular transcriptome in BJ-hTERT cells, with 549 probes up-
regulated and 278 probes down-regulated over empty control (Figure 32). In contrast, 
mutation of the LXCXE motif results in a drastic reversal of this transcriptional 
modulation. 339LT.LXCXK cells have a transcriptional profile most closely resembling 
empty control cells, with only 23 probes up-regulated and 11 probes down-regulated 
(Figure 32). This highlights the notion that LT exhibits most of its transcriptional 
regulation through pocket protein binding and presumably E2F mediated transcription. 
Figure 32. Transcriptome modulation by 339LT 
Microarray data points from the 339LT or 339LT.LXCXK (339LT.XK) expressing BJ-hTERT cells 
were plotted against empty control. All data points represent averages of biological triplicates. 
Probes are considered up- or down-regulated if the fold change compared to empty is equal or 
greater to 2. 
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Figure 33. Heatmap of cell proliferation related genes 
The heatmap was generated for cell proliferation related genes retrieved from Gene ontology 
(GO, http://www.geneontology.org/) and Kyoto Encyclopedia of Genes and Genomes database 
(KEGG, http://www.genome.jp/kegg) using R. Average intensities were calculated from 
biological triplicates after background subtraction and cubic spline normalization. The mock 
group was used as control to calculate ratios of transduction groups 339LT, 339LT.LXCXK, and 
339LT+sT. Fold changes greater than 2 were considered as "2" for visualization comparison. 
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Next, we focused on pathways involved in cell proliferation. Figure 33 shows a 
heat map of genes involved in controlling cellular proliferation and cell cycle regulation. 
The heatmap reveals a cluster of genes that is strongly regulated by tumor-derived LT, 
whereas 339LT.LXCXK only has a minimal effect on the transcription of these genes. 
Additional expression of sT did not greatly affect transcription of the majority of genes 
analyzed here. Zoomed-in regions highlight gene clusters that are up or down regulated 
by 339LT. Genes highlighted by the heatmap analysis (Figure 33) that are affected by 
339LT expression include genes involved in a variety of biological functions related to 
cell cycle progression, DNA synthesis, mitosis, DNA repair, DNA damage response, 
embryonic development, differentiation and immune signaling (Figure 33 and Table 5). 
In addition to genes required for cell proliferation and DNA replication, 339LT also 
induces or represses genes to regulate apoptosis or other forms of cell death (Figure 
33). Tumor necrosis factor alpha induced protein 3 (TNFAIP3) for example, which is 
known to be an inhibitor of programmed cell death, is increased 4.3 fold by 339LT 
according to our microarray data. In addition, the tumor protein D52-like 1 (TPD52L1), 
which positively regulates MAP3K5-induced apoptosis, is down-regulated 2.9 fold by 
339LT expression. This data highlights the wide variety of genes that are modulated by 
339LT to change the cellular milieu allowing for increased DNA replication without 
triggering an unfavorable response such as cell death. 
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Table 5. Biological functions affected by 339LT expression in BJ-hTERT 
Biological Function Genes regulated by 339LT*
Cyclin E (CCNE1 and CCNE2)
Ubiquitin-like with PHD and ring finger domain 1 (UHRF1)
Cyclin-dependent kinase 2 (CDK2)
Cell division cycle 7 (Cdc7)
Cell division cycle 25A (Cdc25A)
Deleted in bladder cancer 1 (DBC1)
Growth arrest-specific 1 (GAS1)
Cyclin-dependent kinase inhibitor 2C (CDKN2C/p18)
Primase I (PRIMI)
Minichromosome maitenance proteins (MCM2-7)
Proliferating cell nuclear antigen (PCNA)
Replication factor complex (RFC2,4)
Thymidylate synthetase (TYMS)
Ligase 1 (LIG1)
Polymerase epsilon 2 (POLE2)
Ribonucleotide reductase M2 (RRM2)
Flap structure-specific endonuclease 1 (FEN1)
Chromatin licensing and DNA replication factor 1 (CDT1)
GINS complex subunit 2 (GINS2)
Polymerase delta 1, catalytic subunit (POLD1)
Topoisomerase (DNA) II alpha (TOP2A)
Polymerase 2A (POL2A)
Polymerase epsilon, catalytic subunit (POLE)
Polymerase alpha 1, catalytic subunit (POLA1)
Replication protein 3 (RPA3)
Kinetochore associated 1 (KNTC1)
Centromere protein K (CENPK)
Centromere protein M (CENPM)
MLF1 interacting protein 1 (MLF1IP)
Extra spindle pole bodies homolog 1 (ESPL1)
Cell division cycle associated 2 (CDCA2)
MIND kinetochore complex component homolog (DSN1)
ZW10 interactor, kinetochore protein (ZWINT)
Centromere protein P (CENPP)
Nucleolar and spindle associated protein 1 (NUSAP1)
non-SMC condensin II complex, subunit G2 (NCAPG2)
Pyridoxal phosphatase (PDXP)
SAC3 domain containing 1 (SAC3D1)
RAD54-like (RAD54L)
Retinoblastoma binding protein 8 (RBBP8)
Fanconi anemia, complementation group I (FANCI)
Fanconi anemia, complementation group G (FANCG)
MutS homolog 6 (MSH6)
Checkpoint kinase 1 (CHEK1)
BRCA1 associated RING domain 1 (BARD1)
RAD54-like (RAD54L)
Hematopoietically expressed homeobox (HHEX)
Lymphoid enhancer binding factor 1 (LEF1)
Secreted frizzled-related protein 1 (SFRP1)
SRY box 15 (SOX15)
Dapper, antagonist of beta catenin, homolog 1 (DACT1)
Forkhead box O4 (FOXO4)
SRY box 4 (SOX4
Interleukin 8 (IL8)
Interleukin 1 beta (IL1B)
Interleukin 1 alpha (IL1A)
Interleukin 12A (IL12A)
Immune signaling
* Genes are considered regulated by 339LT if the average fold change from 3 biological 
replicates is greater or equal to 2 when compared to empty control
Table 5. Biological functions affected by 339LT expression in 
BJ-hTERT
DNA replication 
machinery
Mitosis and cytokinesis
DNA damage and DNA 
repair
Embryonic development 
and differentiation
G1/S transition
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It is well known that E2F transcription factors induce genes involved in cell cycle 
entry. We therefore analyzed our data set for genes related to cell cycle regulation. 
Table 6 lists fold changes of cell cycle regulatory genes that are changed greater than 2 
fold in 339LT expressing BJ-hTERT cells in comparison with empty control cells. Cyclin 
E is the highest up-regulated gene of this group with a 9.9 fold induction (CCNE2) over 
empty BJ-hTERT. Cyclin-dependent kinase 2 (CDK2), which complexes with cyclin E to 
induce G1/S transition is up-regulated 3.8 fold over empty control (Table 6). Cell 
division cycle 25 A homolog (Cdc25A), which is also required for G1/S transition is up-
regulated 2.9 fold in 339LT expressing cells (Table 6). Curiously, cyclin D2, which also 
acts to promote G1/S transition, is the highest down-regulated gene of this group (Table 
6). Cyclin-dependent kinase inhibitor 2C (p18), which counteracts G1/S transition, is 
down-regulated 2.2 fold by 339LT. All gene changes listed in Table 6 are 
LXCXEdependent, indicating the importance of LT pocket protein binding in modulating 
the cellular environment to promote S-phase entry. 
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Table 6. Cell cycle regulatory genes differentially regulated by 339LT 
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4.3.4 Confirmation of LXCXE-motif dependent up-regulation of cyclin E and 
CDK2 transcript levels  
To validate the microarray result, which demonstrates up regulation of cyclin E and 
CDK2 transcripts (Tables 5, 6), we performed semi-quantitative RT-PCR on a panel of 
BJ-hTERT stable cell lines expressing different MCC-derived LTs (350, 339 and MKL-1 
truncations, Figure 34A) and saw increased cyclin E and CDK2 transcript levels with all 
three truncated LT proteins (Figure 34C). Expression of an experimentally cloned LT 
construct that deletes LT sequence C-terminally from the start of the LXCXE motif 
(∆LXCXE) or expression of 339LT.LXCXK show no change of cyclin E transcript levels 
compared to empty control (Figure 34C).  Cyclin D1 transcripts, which showed no 
increase in our microarray analysis (data not shown), shows no consistent change 
across cell lines. GAPDH transcript levels serve as controls and are not significantly 
increased in the different stable cell lines (Figure 34C). 
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Figure 34. Semi quantitative RT-PCR analysis confirms up-regulation of cyclin E and 
CDK2 transcripts by tumor-derived LTs 
(A) Diagram indicating different LT truncation constructs (∆LXCXE, 339LT, 350LT and MKL-1 
LT) as well as full length LT (FL-LT). (B) BJ-hTERT stable cell lines expressing different tumor-
derived MCV LTs or the ∆LXCXE truncation mutant were immunoblotted for LT expression 
using the CM2B4 antibody as well as αTubulin as a loading control. (C) RT-PCR analysis of BJ-
hTERT stable cell lines using cyclin E, CDK2 and cyclin D1 primer pairs. GAPDH was amplified 
as a housekeeping gene control. 
 
4.3.5 Validation of increased Cyclin E and CDK2 protein expression in BJ-hTERT 
To confirm that up-regulated Cyclin E and CDK2 transcripts in tumor LT 
expressing cells correlates with increased protein expression, we immunoblotted lysates 
from BJ-hTERT stable cell lines used for proliferation assays (Figure 27) and 
microarray analyses (Figures 31-33), and checked for cell cycle regulatory proteins. As 
published previously by our group (367), Cyclin E protein level is increased in an 
LXCXE-dependent manner by 339LT (Figure 35A). This increase is slightly enhanced 
by sT co-expression, and coincides with CDK2 protein induction (Figure 35A). Cyclin 
D1 and cyclin A protein levels are not significantly altered by 339LT expression (Figure 
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35A), which indicates that 339LT may act to specifically induce cyclinE/CDK2 
complexes involved in the G1/S transition of the cell cycle. 
 
 
Figure 35. Cyclin E and CDK2 protein levels are preferentially up-regulated by tumor-
derived MCV LT 
(A) BJ-hTERT stable cell lines (lysates from Figure 27A) were analyzed for cell cycle regulatory 
proteins by immunoblot. (B) BJ-hTERT stable cells expressing truncated and full length LT 
(lysates from Figure 29B) as well as BJ-hTERT cells transiently transduced with SV40 ER were 
immunoblotted for cyclin E expression as well as αTubulin as a loading control. (C) BJ-hTERT 
stable cell lines grown in either 10% FBS or 0.1% FBS for 3 days were immunoblotted for 
expression of cell cycle regulators. 
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We then confirmed induction of cyclin E protein levels in the BJ-hTERT stable 
cell lines that express either full length LT (FL-LT) or different truncated LT proteins 
(350LT, MKL-1LT and 339LT) (Figure 35A-B). Stable expression of FL-LT did not 
increase cyclin E protein levels to the same extend as tumor-derived LTs (Figure 35B). 
Expression of the ∆LXCXE construct or 339LT.LXCXK shows no change in cyclin E 
protein compared to empty control (Figure 35A-B) consistent with microarray results. 
The SV40 early region (SV40 ER) was transiently transduced into BJ-hTERT by 
lentiviral infection and SV40 LT and sT protein levels were checked by immunoblot 
(data not shown). Interestingly, expression of SV40 ER, which also contains an LXCXE 
motif, did not alter cyclin E expression (Figure 35B). We also wanted to determine 
whether or not the effect of 339LT is seen in serum starvation conditions. After serum 
starving BJ-hTERT cells in 0.1% FBS, we confirmed up regulation of cyclin E and CDK2 
even under nutrient deprivation (Figure 35C). Notably, the levels of cyclin A were also 
increased in 339LT expressing cells compared to empty and 339LT.LXCXK during 
serum starvation, which is not apparent during normal growth conditions (Figure 35C). 
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4.3.6 Cell cycle analysis of BJ-hTERT stable cells 
To confirm functional consequences of up-regulated cyclin E and CDK2 levels 
we analyzed cell cycle profiles in BJ-hTERT 339LT as well as 339LT.LXCXK cells by 
BrDU incorporation as well as propidium iodide (PI) stain and compared them to empty 
control cells. Unsynchronized BJ-hTERT 339LT stable cells showed an increase in cells 
entering the cell cycle compared to empty and 339LT.LXCXK cells (Figure 36). This 
data supports the hypothesis that tumor-derived MCV LT induces S-phase entry in an 
LXCXE-dependent manner, presumably through increased cyclinE/CDK2 complexes.  
Figure 36. BJ-hTERT 339LT expressing cells show a greater percentage of cells entering 
the cell cycle 
BJ-hTERT stable cell lines empty, 339LT and 339LT.LXCXK were analyzed for BrDU 
incorporation and PI staining by FACS. S-phase populations are indicated by red boxes in the 
top panel. 
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4.4 DISCUSSION 
In this report, we further investigate the proliferative effect that tumor-derived MCV LT 
has on human fibroblast growth. Growth stimulation is dependent on LXCXE-mediated 
signaling, and increased by sT expression to a minimal extend. The growth promoting 
effect of tumor-derived MCV T antigen in human BJ-hTERT cells as well as mouse 
embryonic fibroblasts (MEFs) was reported previously (260), however, the contribution 
of the small T antigen isoform, as well as LXCXE dependence was not addressed. In 
addition, a recent report by Li et al. indicates that truncated LT does not have a growth 
promoting effect in U2OS cells (366), which may be due to the fact that U2OS is a 
transformed cancer cell line with oncogenic signaling already in place. Additional MCV 
LT expression therefore may not further increase the growth rate of this highly 
proliferative cell line. Li et al. did not observe a growth promoting effect of truncated 
MCV LT in MEFs (366), as was reported by Cheng et al. (260), however Li et al. did not 
express sT in addition to truncated LT, and this discrepancy in results may be due in 
part to sT expression. Therefore, sT may be critical in enhancing growth in rodent 
fibroblasts. This is supported by data demonstrating transforming activity of sT in Rat-1 
cells (129). Our results indicating LXCXE-dependence for tumor-derived LT 
enhancement of growth proliferation are in line with a previous report indicating loss of 
MCV-positive MCC xenograft growth upon LXCXE mutation (297) 
The fact that we do not observe soft agar colony formation in BJ-hTERT 
fibroblasts expressing 339LT, sT and hRasV12 in the context of p53 knockdown is most 
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likely due to insufficient hRasV12 transduction efficiency in this cell line (Figure 36C). 
Despite the fact that endogenous Ras levels are decreased in the presence of 339LT, 
the ectopically over-expressed hRasV12 is expressed strongly in most cell lines even in 
the presence of 339LT. Further investigations are needed to distinguish the effect that 
339LT has on endogenous Ras or overexpressed hRasV12, and whether this has any 
effect on transformation. 
When studying cumulative oncogenic events that lead to a transformed 
phenotype, it is important to keep in mind that the specific combination of oncogenic 
pathways that are deregulated in a cell and the specific cell type influence the ultimate 
fate of that cell. In contrast to SV40 T antigen mediated transformation, tumor-derived 
MCV LT may require a different combination of oncogenic hits to induce human 
fibroblast transformation. My findings emphasize further differences between SV40 LT 
and MCV LT and their modulation of the cellular milieu. In addition to MCV LT’s possible 
inhibitory effect on Ras, SV40 induced human fibroblast transformation may also differ 
in that SV40 LT interaction with p53 has been indicated to contribute to transformation 
not only by inactivating p53, but also through a gain of function activity in rodent cells 
(162). Targeting of cellular proteins through the LCXCE motif also seems to differ in part 
between SV40 LT and MCV LT. While MCV tumor-derived LT induces cyclin E 
transcript and protein levels in an LXCXE-dependent manner, SV40 LT expression in 
BJ-hTERT cells does not result in cyclin E protein induction despite the presence of the 
LXCXE motif. 
Microarray analysis reveals strong up-regulation of cell cycle regulators, with 
cyclin E and CDK2 among the top up-regulated genes in this group (Table 6). This 
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indicates that 339LT mainly modulates the cell cycle to promote G1/S transition. This is 
also supported by the fact that Cdc25A, which functions to regulate G1/S transition by 
dephosphorylating CDK2 (368), is also up-regulated in 339LT expressing cells (Table 
6). In addition, the G1/S transition inhibitor p18 is down-regulated in BJ-hTERT 339LT 
cells (Table 6). D-type cyclins are known to partner with CDK4 or CDK 6 to 
phosphorylate RB family proteins resulting in E2F release to promote S-phase entry 
(369). Cyclin D2 is the highest down-regulated cell cycle regulator in 339LT expressing 
cells (Table 6), which could be explained by a negative feedback loop through p16 
(CDKN2A), which is up-regulated by 339LT expression (Table 6). In addition, Cyclin D2 
function may be compensated by Cyclins D1 and D3, which are unchanged in 339LT 
expressing cells compared to empty control cells (data not shown). However, D-type 
cyclin function in general may be dispensable in 339LT expressing cells, due to RB 
family proteins being bound to LT, freeing E2F transcription factors in the absence of 
RB phosphorylation through Cyclin D CDK4/6 complexes.  
In addition to cell cycle regulators, our microarray analysis also identified other 
growth-promoting genes that are affected by by 339LT expression in BJ-hTERT cells, 
with especially high up-regulation of CXC family chemokines (data not shown). CXCL1, 
a CXC family chemokine that has been indicated in proliferation as well as migration 
(370), is highly up-regulated by 339LT (68 fold induction with single probe detection, 
data not shown). The highest up-regulated gene in the presence of 339LT in BJ-hTERT 
cells is IL-8, which is up-regulated 116 fold (average of 2 individual probes, data not 
shown) in an LXCXE-dependent manner. IL-8 is also a family member of the CXC 
chemokines that is known to stimulate cell proliferation and migration in various cell 
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types (371, 372). The proliferation and migration promoting effects of IL-8 is associated 
with EGFR transactivation as well as increased expression and activity of 
metalloproteinases (MMPs) (373), several of which are up-regulated in 339LT 
expressing cells as well (MMP1 = 18.4 fold induction from single probe detection, MMP3 
= 4.3 fold induction from single probe detection; MMP7 = 2.5 fold induction from 2 probe 
detection). Like IL-8 up-regulation, induction of MMPs is LXCXE-dependent. 
Interestingly, a study reports that HPV 16 E6 induces IL-8 production and subsequent 
up-regulation of MMPs (374), indicating that this pathway may be commonly targeted by 
tumorviruses. However, we have not confirmed CXCL1, IL-8 or MMP transcriptional up-
regulation by additional experimental techniques, and we do not know whether 339LT 
expressing BJ-hTERT cells secrete CXCL1 or IL-8. Future experimental analyses are 
needed to elucidate whether or not our microarray results can be validated and proven 
significant in MCV biology. 
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5.0  CONCLUSIONS AND PERSPECTIVES 
5.1 MS-1 CELL LINE 
In the pursuit to uncover novel features of MCV cell biology in vitro, we have developed 
the new MCV-positive MCC cell line MS-1, which provides a valuable tool for future 
studies related to this virus (described in chapter 2). MS-1 has clonally integrated MCV 
genome identical to the tumor biopsy from which it was derived with a tumor signature T 
antigen truncation. It exhibits markers characteristic for MCC in the clinic, and is 
tumorigenic in immunocompromised mice, which makes it a good candidate for 
preclinical chemotherapeutic studies (as described in Appendix B and C of this thesis). 
5.2 MCV ORIGIN REPLICATION 
As part of our quest to study MCV biology, we focused on several functions of the viral 
T antigen proteins that are either absent or conserved during MCC tumorigenesis. In 
chapter 3, we focused on aspects related to MCV genome replication, which is deleted 
in MCC-derived MCV genomes due to T antigen helicase domain truncations as well as 
origin point mutations. We identified domains required for efficient viral origin replication 
and defined a minimal core origin sequence of 71 nucleotides that is needed. We show 
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that the minimal origin region contains 4 essential GAGGC pentanucleotide sequences 
that are known to serve as LT binding sites in other polyomaviruses. The essential MCV 
pentanucleotide sequences however show a different orientation and spacing than is 
known for the well-studied SV40 and PyV origin sequences, which may provide the 
opportunity to study a unique origin replication mechanism in MCV. Further studies are 
needed to determine how LT forms a complex on the MCV origin, and whether or not it 
forms a double hexamer as other polyomaviral LTs do.  
In addition to origin features required for MCV replication, we also evaluated non-
origin viral functions. We find that sT expression is required for efficient origin replication 
by LT; however, additional experiments were needed to determine the precise 
mechanism by which sT expression contributes to replication. Subsequent studies by 
Kwun et al. (Cell Host & Microbe, in press) show that sT’s PP2A targeting function is not 
necessary to enhance replication, but rather a sT domain responsible for stabilizing LT 
protein (LSD) is required. These results stand in conflict with data presented here, 
which indicate that a PP2A binding mutant of sT (C109S) is insufficient to promote 
origin replication. Further evaluation of the C109S sT mutant however demonstrated 
compromised protein stability as compared to wild-type sT protein, which may explain 
its lack of an enhancing effect on replication. Other PP2A mutants used in the follow-up 
study by Kwun et al. include R7A and L142A, which have comparable expression levels 
to wild-type sT and do not compromise sT’s effect on replication. In addition, treatment 
with the PP2A inhibitor Okadaic acid also does not have any effect on sT-mediated 
enhancement of origin replication (data not shown).  Kwun et al. show that sT stabilizes 
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LT protein by targeting the cellular ubiquitin ligase complex SCFFbw7, which targets LT 
for proteasomal degradation otherwise (Cell Host & Microbe, in press). 
We also found that Hsc70 binding by LT through its J-domain is essential for its 
replication function. In SV40, the J domain is required for various functions including 
viral replication, as well as transformation, transcriptional activation, and virion assembly 
(136).  It was discovered that instead of having a direct effect in which the J domain 
would recruit a Hsc70 homologue and facilitate viral DNA replication through physically 
rearranging the DNA replication machinery, the J domain acts indirectly through RB-
family members and E2Fs (136). Published results support an indirect model of DnaJ 
domain functionality in replication, in which the DnaJ domain facilitates T antigen’s 
interaction with RB family members in an ATP-dependent manner to promote E2F-
mediated transcription to induce S-phase entry (152). Whether or not MCV LT mediated 
replication functions through a direct or an indirect mechanism remains to be 
uncovered. Future experiments are needed to investigate ATP dependence as well as 
the requirement to interact with RB family members to elucidate the role of the DnaJ 
domain in MCV replication. 
5.3 PROLIFERATION AND TRANSFORMATION STUDIES 
To further uncover mechanisms that lead to transformation, we investigate the role of 
tumor-derived MCV T antigens in the cellular environment. Chapter 4 focuses on one 
truncated LT, 339LT, which represents one of the longest tumor-derived MCV LT 
proteins identified in MCC tumors thus far. We show that 339LT expression promotes 
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human fibroblast (BJ-hTERT) proliferation in an LXCXE-dependent manner, and that sT 
only minimally contributes to this effect. Transformation studies presented here, which 
aimed to re-capitulate defined human transformation experiments performed by Hahn et 
al. (316, 357) in the context of SV40 T antigens, reveal that MCV T antigens do not 
transform BJ-hTERT cells. Additional knockdown of the tumor suppressor p53, as well 
as mitogenic hRasV12 expression resulted in small soft agar colony growth of cells 
expressing sT and hRasV12 in p53 knockdown conditions. In cells expressing p53 
(shscr control cell line) that are transduced with sT and hRasV12, small soft agar colony 
formation was observed at 4 weeks (Figure 30); however, subsequent evaluation of soft 
agar plates at 8 weeks revealed degradation of the colonies (data not shown), indicating 
that p53 knockdown is required for soft agar colony maintenance.  
Surprisingly, additional expression of 339LT did not result in soft agar colony 
growth in the presence of sT and hRasV12 (Figure 30). Protein expression analysis by 
immunoblotting however reveals that this result may be due to an insufficient 
transduction efficiency of hRasV12 in this particular cell line (condition shp53, 339LT, 
sT, hRasV12, Figure 28).  In addition, endogenous Ras expression was consistently 
decreased in cells expressing 339LT (Figure 28, and Appendix A). Future studies are 
necessary to elucidate the effect that 339LT may have on endogenous Ras signaling. 
Since we utilized a pan-Ras antibody here, which detects N-, K-, and H-Ras, it would be 
important to perform additional analyses to distinguish endogenous expression between 
the different isoforms in the presence of 339LT to uncover mechanistic insight. Our 
microarray result indicates no difference in N-, K-, or H-Ras transcriptional expression in 
339LT stable cells compared to empty controls (data not shown). Therefore, future 
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experiments may also include cyclohexamide treatment in order to determine whether 
or not 339LT has any effect on Ras protein turnover. It would also be beneficial to 
transduce a HA-tagged version of the hRasV12 to distinguish endogenous and 
ectopically expressed Ras by different antibodies, and determine the effect of 339LT on 
either.  If 339LT shows no effect on hRasV12 overexpression in follow up experiments, 
it is necessary to repeat the experiment to ensure proper transduction efficiency of 
hRasV12 to be able to re-evaluate transformation under this condition (BJ-hTERT 
shp53, 339LT, sT, hRasV12). 
Additional efforts aimed at defining genetic elements capable of transforming 
human fibroblasts in the context of MCV T antigen expression should also focus on 
different oncogenes that could replace hRasV12 expression in this set-up. Possible 
candidates include constitutively active forms of c-Myc or Akt, both of which are 
downstream targets of Ras-mediated signaling that promote oncogenesis (375-377).  
Transduction of c-Myc in the presence of MCV T antigens represents a promising 
avenue for transformation studies, since sT has been shown to stabilize c-Myc protein 
levels by inihibiting its proteasomal degradation through SCFFbw7 (Kwun et al., Cell host 
& Microbe, in press). In addition, Rat-1 transformation by sT is in part dependent on c-
myc stabilization (unpublished data, Dr. Shuda). BJ-hTERT express rather low levels of 
c-myc, which are only slightly elevated by sT expression (unpublished data, Dr. Shuda); 
therefore higher, exogenous expression of c-myc may contribute to sT transforming 
activities in BJ-hTERT.  
Expression of constitutively active Akt, may provide another genetic element to 
achieve human fibroblast transformation in the presence of MCV T antigens. MCV sT 
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has been shown to induce 4EBP-1 hyperphosphorylation, by an unknown mechanism, 
leading to Rat-1 transformation (129). It is clear that mTOR activity, which is a 
downstream target of Akt (378), is necessary for sT to induce transformation in this 
setting (129).  If 339LT in fact does inhibit endogenous Ras signaling, this may affect 
downstream Akt activation, which in turn would lead to a loss of mTOR activity. 
Therefore, expression of activated Akt, may result in BJ-hTERT transformation in the 
presence of MCV T antigens. 
Our microarray analysis revealed many additional pathways that are regulated by 
339LT expression in BJ-hTERT cells. Several of these represent promising starting 
points in further investigating MCV biology in human fibroblasts. The highly up-regulated 
chemokine IL-8 has been implicated in proliferation and migration in several cell types. 
Further experiments that are needed to validate microarray results include RT-qPCR to 
confirm transcript up-regulation in the presence of 339LT, as well as ELISA analysis to 
confirm secretion of IL-8 by BJ-hTERT stable cell lines. If BJ-hTERT 339LT cells do 
secrete IL-8, it would be interesting to supply empty and BJ-hTERT 339.LXCXK cells 
with IL-8 in their medium to determine whether or not proliferation is induced. In 
addition, it would be possible to assay for an increased migratory potential of 339LT 
expressing cells, since IL-8 is known to promote metastasis through up-regulation of 
MMPs (379), some of which are also induced by 339LT. Therefore, performing matrigel 
invasion assays or gap closure assays would provide mechanistic insights into the 
migratory potential of 339LT expressing cells.  
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APPENDIX A 
A.1 MOLECULAR FUN FACTS ABOUT BJ-HTERT STABLE CELL LINES 
This section describes additional, unpublished data that was accumulated during 
experimental analyses of BJ-hTERT stable cell lines. Even though this data still leaves 
many questions unanswered, it presents interesting pieces of information on MCV LT 
effects on the cellular environment. Experimental methods are included in section 4.2 of 
this thesis. A. Guastafierro performed all experiments described in Appendix A. A. 
Guastafierro, M. Shuda, Y. Chang, and P.S. Moore interpreted the data. 
A.1.1 Endogenous Ras protein levels are decreased in 339LT expressing BJ-
hTERT human fibroblasts 
Given the result that endogenous Ras and hRasV12 expression varied among the 
different BJ-hTERT stable cell lines with endogenous Ras always reduced in the 
presence of 339LT (Figure 28C), we checked Ras protein levels in our stable cell lines 
used for proliferation and microarray analyses (lysates used in Figure 27). We again 
observed decreased levels of endogenous Ras by MCV 339LT but not 339LT.XK 
(Figure 37). Interestingly, our microarray data did not reveal any transcriptional effect of 
339LT expression on N-, K, or H-Ras (data not shown). 
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A previous report that analyzed the Ras/Raf/MEK/ERK signaling axis before 
MCV was discovered found that only two out of 44 MCC tumor samples showed 
downstream activation of this pathway by phospho-ERK IHC evaluation (244). In line 
with this data, our results indicate that MCV LT may inhibit endogenous Ras protein 
levels, which may result in downstream silencing of this pathway, but further studies are 
needed to demonstrate this. Nevertheless, the discovery of MCV in association with 
MCC, may provide an explanation for why this pathway, which is frequently activated in 
other skin cancers including melanoma (243), may not play a role in MCV-positive MCC 
tumors.  
Figure 37. Endogenous Ras protein levels are decreased in the presence of 339LT 
BJ-hTERT stable cells (lysates from Figure 27) were immunoblotted for endogenous Ras 
expression using an antibody that detects N-,K-, and H-Ras. 
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A.1.2 Tumor-derived MCV LT expression increases p53 protein levels resulting in 
p21 protein up-regulation in BJ as well as BJ-hTERT human fibroblasts 
Unlicensed DNA replication due to increased cell cycle entry induced by oncogenes, 
such as cyclin E, have been shown to induce a DNA damage type response leading to 
enhanced p53 protein levels. This prompted us to evaluate p53 protein levels in the BJ-
hTERT stable cell lines. We observed an increase in p53 protein levels in BJ-hTERT 
stable cells expressing 339LT but not the 339LT.LXCXK (Figure 38A). Addition of MCV 
sT expression did not alter p53 protein levels in the presence of 339LT. Knockdown of 
cyclin E resulted in a reversion of p53 protein to basal levels in BJ-hTERT cells. 
Knockdown of cyclin E was not complete in cells expressing 339LT, and showed higher 
residual levels in cells expressing both 339LT as well as sT (Figure 38A). We also 
checked p53 and p21 protein levels in BJ primary human fibroblasts, which have a 
lower basal expression level of p53 protein than BJ-hTERT fibroblasts (Figure 38B). 
We introduced 339LT as well as FL-LT, each with either an intact or mutated LXCXE 
motif, by transient lentiviral transduction. We observed increased levels of both p53 as 
well as the p53 downstream target p21 in the presence of 339LT as well as FL-LT (to a 
lesser extend) in an LXCXE-dependent manner (Figure 38B). We show that p21 
induction is mediated through increased p53 protein since knocking down p53 reverses 
p21 protein up regulation (Figure 38B). We noticed that knockdown of p53 was less 
efficient in cells expressing 339LT, which results in residual p21 protein expression 
even under p53 knockdown conditions (Figure 38B).  Transcriptional up-regulation of 
p21 in the presence of 339LT was confirmed by microarray results (Table 6). p53 
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transcripts are unchanged in 339LT expressing cells compared to empty control (data 
not shown). 
We were struck by the result that tumor-derived 339LT increases p53 protein 
levels with subsequent p21 activation in human fibroblasts, while still enhancing cell 
cycle entry and promoting cell proliferation. In contrast, SV40 LT binds and stabilizes 
p53 protein levels without full p21 induction, circumventing cell cycle arrest (380). 
Another example of a viral protein that induces p53 mediated p21 protein level is HPV 
E7, which can initiate S-phase entry through cyclin E/CDK2 despite p21 up-regulation 
(381). Nevertheless, p53 regulates a wide range of genes other than p21 including 
transcriptional activation of genes involved in apoptosis.  
 
Figure 38. MCV LT stabilizes p53 protein levels resulting in p21 induction 
(A) BJ-hTERT stable cell lines used for microarray analysis were transiently transduced with 
shscr or shCyclinE and immunoblotted for cyclin E, p53 and αTubulin as a loading control. (B) 
BJ fibroblast stable cells expressing full length (FL-) LT or tumor-derived 339 LT with either an 
intact or mutated LXCXE-motif were transiently transduced with shscr or shp53 lentivirus. 
Lysates were immunoblotted for LT (data not shown), p53, p21 and aTubulin as a loading 
control.  
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We therefore sought to analyze our microarray data for downstream p53 
signaling pathways to determine whether p53 protein stabilization by 339LT results in 
up-regulation of p53 transcriptional targets other than p21. We analyzed 129 confirmed 
p53 target genes (382) from our microarray set, and only 14 genes (including p21) were 
transcriptionally affected greater than 2 fold by 339LT expression in BJ-hTERT 
fibroblasts. Out of these 14 genes we identified 3 genes that are typically repressed by 
p53 including cell division cycle 25 homolog C (Cdc25C), DNA (cytosine-5-
)methyltransferase 1 (DNMT1), and immediate early response 3 (IER3); however, they 
were conversely activated in 339LT expressing cells (Table 7, top column). Discoidin 
domain receptor family member 1 (DKK1), Insulin-like growth factor binding protein 3 
(IGFBP3), and matrix metallopeptidase 2 (MMP2) are genes usually activated by p53, 
but showed transcriptional repression by 339LT (Table 7, top column), indicating that 
out of the 14 p53 target genes de-regulated by 339 LT expression, only 7 genes were 
regulated in a way usually thought of by p53 (Table 7, bottom column). This indicates 
that even though p53 protein is induced in human fibroblasts, only selective target 
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Table 7. Microarray analysis of p53 transcriptional targets 
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genes are transcriptionally regulated in response. The mechanism by which p53 
mediated transcription is inhibited remains to be explored. The microarray dataset 
revealed that the gene encoding pituitary tumor-transforming 1 (PTTG1) is up-regulated 
3.3 fold by 339LT expression. PTTG1 is known to stabilize p53 protein levels, while 
negatively regulate the transcriptional activity of p53 (383, 384), this may be a possible 
explanation of why p53 protein is enhanced in the presence of 339LT yet not fully 
transcriptionally active. In addition, we did not observe p53 Serine 15 phosphorylation in 
the presence of 339LT (data not shown), indicating limited p53 activation despite 
increased p53 protein levels in BJ-hTERT fibroblasts. 
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APPENDIX B 
SURVIVIN IS A THERAPEUTIC TARGET IN MERKEL CELL CARCINOMA 
Work described in Appendix B was published in Science Translational Medicine 
Sci Transl Med. 2012 May 9;4(133):133ra56. 
 
with authors Reety Arora, Masahiro Shuda, Anna Guastafierro, Huichen Feng, 
Tuna Toptan, Yanis Tolstov, Daniel Normolle, Laura L. Vollmer, Andreas Vogt, 
Alexander Dömling, Jeffrey L. Brodsky, Yuan Chang, and Patrick S. Moore 
 
  
R. Arora and M. Shuda performed T antigen and survivin knock down experiments, 
immunoblots and cell cycle analysis. H. Feng performed DTS analysis. T. Toptan and 
R. Arora created stable cell lines and tested and confirmed protein expression by 
immunoblotting. R. Arora, Y. Tolstov, and L. Vollmer performed the drug screen. R. 
Arora tested individual drugs and performed cell titer glo studies. A. Guastafierro and R. 
Arora performed mouse xenograft experiments and qRT-PCR studies. D. Normolle 
performed xenograft tumor volume analysis. A. Vogt, J. Brodsky, and A. Dömling 
provided compounds and supervision on drug screen. R. Arora, Masahiro Shuda, A. 
Guastafierro, Y. Chang, and P.S. Moore interpreted the data and wrote the manuscript. 
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B.1 INTRODUCTION 
By comparing digital transcriptome subtraction (DTS) deep-sequencing profiles, we 
found cellular survivin oncoprotein (BIRC5a) transcripts up-regulated seven-fold in 
virus-positive compared to virus-negative MCC tumors. MCV T antigen knock-down in 
MCV positive MCC cell lines decreased survivin mRNA and protein expression. 
Exogenously-expressed MCV large T antigen (LT) increased survivin protein expression 
in non-MCC primary cells. This required an intact retinoblastoma protein-targeting 
domain that activated survivin gene transcription as well as expression of other G1/S-
phase proteins including E2F1 and Cyclin E. Survivin expression is critical to MCV-
positive MCC cell survival and a small molecule survivin inhibitor, YM155, is a highly 
potent and selective agent for initiating irreversible, non-apoptotic, programmed MCV-
positive MCC cell death. Of 1360 other chemotherapeutic and pharmacologically-active 
compounds screened in vitro, only bortezomib (Velcade) was found to be similarly 
potent, but not selective, for killing MCC cells. YM155 was nontoxic and halted MCV-
positive MCC xenograft tumor growth in mice while bortezomib had significant toxicity 
and was not active in vivo. Xenograft tumors resumed growth once YM155 treatment 
was stopped suggesting that YM155 may be cytostatic rather than cytotoxic in vivo. 
Identifying the cellular circuits, such as survivin, that are targeted by tumor viruses can 
lead to rapid and rational identification of drug candidates for viral cancers that are 
otherwise difficult to treat. 
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B.2 MATERIALS AND METHODS 
B.2.1 Cell culture 
Seven Merkel cell carcinoma cell lines: MKL-1, MKL-2, MS-1, UISO, MCC13, MCC26 
and WaGa (gift of Jurgen Becker); NCI-H69 small cell lung cancer cell line (ATCC); 293 
human embryonic kidney cells (ATCC); U2OS osteosarcoma cell line (gift of Ole 
Gjoerup); BJhTERT immortalized foreskin fibroblast cell line (gift of Ole Gjoerup); and 
BJ primary foreskin fibroblasts (ATCC) were used to screen and evaluate the small 
molecules examined in this study. The Merkel cell lines and NCI-H69 were grown in 
RPMI 1640 supplemented with 10% fetal calf serum, penicillin and streptomycin at 37 
°C in humidified air containing 5% CO2. The remaining cell lines were grown in DMEM 
supplemented with 10% fetal calf serum. 
B.2.2 Compounds 
A total of 1,360 compounds were used in the screening survey (232): 1,280 compounds 
from LOPAC1280 library (Sigma Aldrich, accessed through University of Pittsburgh 
Drug Discovery Institute), 89 compounds from NCI’s Approved Oncology Drug Set II 
(from The NCI/DTP Open Chemical Repository, http://dtp.cancer.gov), 6 LT ATPase 
inhibitors (MAL2-11B, MAL3-101, MAL2-51, DMT3084, bithionol and hexachlorophene 
(385)) and 4 compounds that target and inhibit p53 and MDM2 binding (Nutlin-3, 
YH264A, Y2H265A and KK_NW_16A (386, 387). 19 compounds that were in common 
between the LOPAC 1280 and the NCI Approved Oncology Drug Set II library were 
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screened twice with comparable results. NCI Approved Oncology Drug Set II, SV40 LT 
ATPase inhibitors and MDM2 inhibitors were reconstituted as recommended by 
supplier. YM155 (4,9-Dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-
pyrazinylmethyl)-1H-naphth[2,3-d]imidazolium bromide) was purchased from Active 
Biochemicals Co. Ltd. (Hong Kong, China). Reconstituted compounds were diluted in 
cell culture media to obtain a 100x stock concentration prior to addition to cells. 
Doxorubicin (positive control) was obtained from Sigma-Aldrich and DMSO (negative 
control) was obtained from Fisher Bioreagents. 
 For EC50 measurements, dose-response curves were established for 17 
drugs obtained individually in bulk stocks. Iodoacetamide (I1149), sanguarine chloride 
(S5890), NSC95397 (N1786), chelerythrine chloride (C2932), calmidazolium chloride 
(C3930), tetraethylthiuram disulfide (T1132), bay 11-7085 (B5681), quinacrine 
dihydrochloride (Q3251), ellipticine (E3380), amsacrine hydrochloride (A9809) and 
nutlin-3 (N6287) were purchased from Sigma Aldrich, USA. Mitoxantrone (NSC279836), 
daunorubicin HCl (NSC82151), valrubicin (NSC246131), topotecan HCl (NSC609699), 
teniposide (NSC122819) and bortezomib (NSC681239) were kindly provided by the 
NCI/DTP Open Chemical Repository, http://dtp.cancer.gov.  
B.2.3 MKL-1 cytotoxicity screen 
MKL-1 cells were seeded at a density of 6000 cells in 50 ml of medium per well (120 
cells/ml) in opaque polypropylene 384-well microplates (#781080, Greiner Bio-One, 
Germany). Cells were incubated at 37°C in humidified air containing 5% CO2 for 24 
hours. Thereafter, 25 ml of medium containing 3X drug per well was added to the 
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plates, which were incubated for an additional 48 hours. Cell viability was measured 
using Cell Titer Glo (Promega) following manufacturer’s instructions. The validity of Cell 
Titer Glo results in measuring cell viability was confirmed by trypan blue exclusion 
staining and WST-1 assays (Roche) in pilot studies. 
 The LOPAC1280 library was screened at a final concentration of 10 mM for 
each compound and the NCI library was screened at a final concentration of 1 mM for 
each compound. MAP-C (Titertek Instruments Inc) and Janus MDT (PerkinElmer Inc) 
were used for automated resuspension and the addition of LOPAC library drugs to 
assay plates. NCI library compounds were added to wells by manual pipetting.  
 Cell Titer Glo assays were performed in duplicate using 384 well plates, each 
containing 24 wells with 1% DMSO (negative control) and 32 wells with 200 mM 
doxorubicin (positive control). Screening results were evaluated on the basis of 
percentage cell survival normalized to the DMSO control (100%). Positive candidates 
were identified using a cut-off value of <10% cell survival. The average Z factor was 
0.61 (range 0.34-0.74) for the LOPAC library screen and 0.82 for the NCI library screen 
(range 0.75-0.91). 
B.2.4 Dose-response studies 
Compounds that met the selection criteria < 10% cell survival were purchased or 
obtained in bulk from NCI/NIH Developmental Therapeutics Program. Serial drug 
dilutions from 10-4 M to 10-9 M were used on MCC and non-MCC cell lines. Cells were 
seeded into 384-well plates at 6000 cells in 50 ml of medium per well. After 24 hours, 25 
ml of 3X drugs were added at increasing concentration to each well. Cell viability was 
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then measured using Cell Titer Glo (Promega) kit following manufacturer’s instructions 
as described previously. Each drug concentration was tested in triplicate for each cell 
line and experiments were repeated twice. EC50 doses for the drugs were calculated 
using a four parameter logistic equation (GraphPad Prism). 
B.2.5 Trypan blue dye exclusion assay 
Cells were equally seeded and treated with YM155 for 48 hours. To quantitate cell 
death, cells were treated with Accutase (Millipore), collected, resuspended in PBS, 
mixed with equal volume of Trypan blue (Lonza, 0.4%) and counted using a 
hemocytometer under the microscope. Counting was performed three times, in 
triplicate. 
B.2.6 Expression and shRNA lentivirus construction 
To express codon optimized full-length MCV large T antigen, the gene was synthesized 
(DNA2.0) from the MCV-HF strain large T antigen sequence template (254) (GenBank 
ID: JF813003) and cloned into the lentiviral pLVX EF puro vector (129). Truncated 
tumor LT339 (representing the MCV339 strain, amino acid 1-455) and LT339.LXCXK 
were cloned by site-directed mutagenesis from the codon-optimized full-length LT into 
pSMPUW-hygro vector (Cell Biolabs Inc.) (129). MCV small T codon optimized was also 
cloned into the lentivirus vector. Cells were infected with lentiviruses in the presence of 
1-4 mg/ml polybrene for 24 hours, followed by media change. Stable selection with 
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either puromycin (1 mg/ml) or hygromycin (200 mg/ml) was initiated 48 hours after 
infection.   
shRNA for MCV T antigen knock-down was generated and used as previously 
described (388), we renamed shT1 in Houben et al. to panT1 in this study. To knock-
down survivin gene expression, shRNA sequence (shsur1-5’ 
ccggCCGCATCTCTACATTCAAGAACTCGAGTTCTTGAATGTAGAGATGCGGtttttg-3’ 
and shsur2- 5’ 
ccggCCTTTCTGTCAAGAAGCAGTTCTCGAGAACTGCTTCTTGACAGAAAGGtttttg-3’ 
(Lower cased nucleotides indicate linker sequences used for cloning)) was cloned into a 
pLKO.1puro lentiviral vector. shCntrl is a nontargeting shRNA negative control(388).  
Cells were infected with lentiviruses, washed after 24 hours and then harvested for 
immunoblotting six days after infection. 
B.2.7 Immunoblotting 
Cells were lysed in buffer (RIPA or 10mM Tris-HCl pH 8.0, 0.6% SDS) containing 
protease inhibitor cocktail (Roche). Lysates were electrophoresed in 10% SDS-PAGE, 
transferred to nitrocellulose membrane (Amersham) and reacted with specific antibodies 
CM2B4 (1:5000 dilution)(281), CM8E6 (1:500 dilution), cleaved PARP, cleaved 
caspase3, survivin, XIAP, p53, Bcl-2, Bax (1:1000 dilution, Cell Signalling 
Technologies), E2F1, cyclin E (1:1000 dilution, Santa Cruz Biotechnology), LC3 (1:1000 
dilution, Novus Biologicals) or α-tubulin (1:5000 dilution, Sigma)) overnight at 4°C, 
followed by anti-mouse (1:5000 dilution, Amersham) or anti-rabbit IgG-HRP conjugates 
(1:3000 dilution, Cell signaling) for 1 hour at room temperature. Peroxidase activity was 
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detected using Western Lightning plus-ECL reagent (Perkin Elmer). For quantitative 
immunoblotting, Odyssey Infrared Imaging system (LI-COR) was used with IRDye 800-
conjugated secondary antibodies (1:5000 dilution, Rockland Immunochemicals). 
B.2.8 qRT-PCR 
RNA was extracted from cell lysates using Trizol reagent (Invitrogen) and cDNA was 
synthesized using SuperScript III First Strand Synthesis (Invitrogen). Quantitative real-
time PCR for survivin was performed on cDNA using the SYBR green method (based 
on manufacturer’s protocol, Applied Biosystems). Primers used were 5’-
CTGCCTGGCAGCCCTTT-3’ (Forward) and 5’-CCTCCAAGAAGGGCCAGTTC-3’ 
(reverse) for survivin (389) and 5’-CACTGGCTCGTGTGACAAGG-3’ and 5’-
CAGACCTACTGTGCGCCTACTTAA-3’ for b-actin. The relative change in expression 
was calculated using the Pffal method (390) Experiments for MCC cell lines were 
repeated six times (2 biological repeats done in triplicate). Experiments for BJ cell lines 
were repeated six times (3 biological repeats done in duplicate). Mean and standard 
error of mean was calculated and plotted as column graphs for comparison. 
B.2.9 Cell cycle analysis 
MKL-1 cells were treated with Accutase (Millipore) to break clumps and then 
resuspended in fresh medium containing drug and treated for 12 hours. 
Bromodeoxyuridine (10 mM concentration) was added three hours before harvesting.  
Cells were then harvested and fixed in chilled 70% ethanol overnight. The cells were 
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then washed, resuspended in 200 ml of 2M HCl/Triton X (1%) and incubated for 30 
mins at room temperature. Cells were centrifuged at 2000 rpm for 10 mins and 
neutralized in 200ml of 0.1M sodium tetraborate (pH 8.5). Cells were then washed, 
suspended in 20ml of PBS containing 0.5% tween20, 1% donkey serum and 2ml of anti-
BrdU antibody (1:10 diution, BD Biosciences) and incubated overnight at 4°C. Cells 
were washed and incubated with secondary anti-mouse IgG Alexa488 (1:1000) for 1 
hour at room temperature. Cells were washed, suspended in PBS containing 100mg/ml 
of RNase A, 50mg/ml of PI (propidium iodide) and 0,05% Triton X and incubated for 30 
mins at 37°C in the dark and then analyzed using an Accuri C6 flow cytometer. 
B.2.10 Cell death evaluation by CFDA and PI staining 
After harvesting, cells were resuspended in 2 ml of PBS containing 4mg/ml PI 
(propidium iodide, Sigma) and 10 mM CFDA (Carboxy fluorescin diacetate, Invitrogen) 
at room temperature for 10 mins. Cells were then rinsed in 1X PBS and examined under 
the microscope. Quantitation was performed using ImageJ software. 
B.2.11 Mouse xenograft studies 
Compounds 
For in vivo experiments, clinical-grade bortezomib (Velcade) was purchased from the 
University of Pittsburgh Cancer Institute Pharmacy and YM155 was purchased from 
Active Biochemicals Ltd. (Hong Kong, China).  Compounds were dissolved in sterile 
0.9% saline solution for administration to animals. 
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Animals 
Six-week-old female triple immune-deficient NSG (NOD scid gamma) mice (Jackson 
Laboratory) were maintained in a specific pathogen-free environment at the Hillman 
Cancer Center Mouse Facility, University of Pittsburgh. All animal studies were 
conducted according to protocols approved by the Animal Ethics Committee of the 
University of Pittsburgh (IACUC Protocol # 1102226). 
Xenograft Drug Treatments 
MCC cells were checked for viability >90% by trypan blue staining resuspended in PBS 
(2 × 107 cells in 100 µl) and inoculated subcutaneously into the right flank of mice. Once 
tumors were palpable (2-4 weeks after injection), mice were assigned sequentially into 
receiving either bortezomib, YM-155 or saline treatment arms.  
All treatments were delivered for three consecutive weeks. Bortezomib 
treatment was delivered subcutaneously twice weekly at 1 mg/kg per mouse. To avoid 
previously observed side effects, mice were given hydrogel (ClearH2O) and kept at 
30°C (using a heating blanket to heat up half of the cage) during bortezomib treatment. 
YM-155 (2 mg/kg) was given intraperitoneally on five consecutive days, followed by a 
two-day treatment-free interval. The control group received saline alone (21 mice on 
the same dosing schedule as bortezomib and 20 mice on the same dosing schedule as 
YM155. Day 19 was the last day of drug delivery for both schedules and hence the end 
of treatment. Caliper measurements of the longest perpendicular tumor diameters were 
performed every other day and tumor volumes were calculated using the formula: 
(width) 2 × (length/2). Animals were sacrificed when tumors reached 2 cm in any 
dimension, >20% weight loss or when they became moribund. Survival was defined as 
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time from the first day of treatment until death/sacrifice.   
Statistical analysis 
Two-tailed paired Student’s t test was used to analyze statistical differences in qRT-
PCR results. Mouse survival curves were estimated using the Kaplan–Meier product-
limit method and were compared using the log-rank test (GraphPad Software, La Jolla, 
CA). A piecewise linear hierarchical Bayesian model (391) was used to characterize 
differences in tumor volumes and growth between treatments. 
Immunohistochemistry 
Immunohistochemical staining of mouse tumor tissues was performed as previously 
described (281). 
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B.3 RESULTS 
B.3.1 Survivin Expression in MCV-positive MCC 
To identify pathways perturbed by MCV infection in MCC, we analyzed DTS datasets to 
identify cellular genes differentially regulated between MCV-positive and MCV-negative 
MCC (55). We compared 400,000 cellular transcripts from MCV-positive and MCV-
negative MCC tumors and found 1096 of 11,531 (9.5%) genes elevated >3 fold for the 
MCV-positive compared to the MCV-negative library.  
We next identified sixty-four genes using Gene Ontology (GO) gene definitions 
directly involved in programmed cell death or cell cycle regulation (Figure 39A). 
BIRC5a (Baculoviral inhibitor of apoptosis repeat-containing 5) mRNA encoding the 
survivin oncoprotein were increased 7 fold (p=2.90xe-10) for virus-positive compared to 
virus-negative MCC tumors (Figure 39A). Other genes regulating programmed cell 
death, including TP53, cIAP2, XIAP, BAX, BCL2 and Caspase 3/6 transcripts, were not 
differentially expressed (Figure 39A). Notably, some genes including TRAF2 and PI3K 
were significantly reduced in virus-positive compared to virus-negative MCC tumor 
libraries. 
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Figure 39. Survivin oncoprotein mRNA expression is increased in MCV-positive MCC 
(A) DTS comparison of 64 genes involved in programmed cell death and cell cycle regulation, 
showing that survivin (BIRC5) mRNA transcripts (highlighted in bold) were seven-fold higher in 
a MCV-positive than an MCV-negative MCC DTS cDNA library. The relative expression of 
genes was normalized to total sequence reads for each MCC library (also see Table S1 for 
more details). (B) MCV T antigen is required for survivin expression. Lentiviral MCV T antigen 
exon1 knock-down (panT1) decreased survivin protein expression among four MCV-positive 
MCC cell lines (left panel). shCntrl is a scrambled shRNA control lentivirus. No consistent 
changes in XIAP, BCL-2, Bax or p53 protein levels are seen after MCV T antigen knock-down 
among MCC cell lines (right panel). MKL-1, MKL-2, MS-1 and WaGa are MCV positive and 
UISO is MCV negative. (C) MCV T antigen is required for survivin transcription.  Survivin mRNA 
levels were reduced in MKL-1 but not UISO cells after T antigen knock-down indicating that T 
antigen acts survivin transcription. Survivin mRNA was measured by qRT-PCR and normalized 
to β-actin mRNA. The experiments were performed in triplicate and repeated two times 
(mean+SEM). (D) Survivin expression is required for MCV-positive MCC cell survival. Survivin 
was targeted for knock down with two shRNA lentiviral vectors, shsur1 and shsur2 in MKL-1 
cells and UISO cells. MKL-1 cells initiate apoptosis after survivin knock-down, with increased 
expression of cleaved polyADP ribose polymerase (cPARP) and caspase 3 (cCasp3), whereas 
UISO cells are resistant to survivin knock down-induced apoptosis. a-Tubulin is used as a 
loading control. 
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B.3.2 MCV Large T Induces Survivin Through Retinoblastoma Protein Targeting  
To determine if MCV T antigen increases survivin expression in MCC, we used a short-
hairpin (shRNA) lentivirus (panT1) to perform RNAi targeting of the MCV T antigen 
exon1 sequence that selectively knocks down all MCV T antigen isoforms in MCC cells 
(388). MCV-positive MCC cells infected with this lentivirus undergo non-apoptotic cell 
death (necroptosis) when MCV oncoprotein expression is inhibited (388). MCV T 
antigen reduction correlated with survivin reduction in all MCV-positive MCC cell lines, 
but not in any of the MCV-negative cell lines (Figure 39B). The degree of survivin 
decrease with T antigen knock-down ranged from modest in MS-1 to near complete in 
WaGa cell lines (Figure 39B). This effect is at the level of transcription rather than 
translation since BIRC5a mRNA is significantly reduced by T antigen knock-down 
(Figure 39C).  
Figure 40. MCV sT knockdown in MCC cell lines does not affect survivin expression 
UISO and MKL-1 cells infected with either sT1, which knocks down sT alone (Shuda et al., JCI 
2011), or panT1 shRNA lentiviruses were immunoblotted for survivin and α-tubulin.  
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Use of an shRNA lentivirus that selectively targets only the small T antigen 
isoform (129), however, did not affect survivin expression (Figure 40), indicating that 
increased survivin transcription was dependent on MCV LT but not small T antigen 
(knock-down of LT alone is difficult due to the overlapping structure of the T antigen 
cistron). In contrast to survivin, no consistent changes in protein expression for p53, 
XIAP, Bcl-xL, Mcl-1, Bad, Bik, Bmf, Bim, Puma, Bcl-2 or Bax proteins (Figure 39B and 
ref. (388)) or for cleaved polyADP ribose polyomerase (PARP), cleaved caspase 3 or 
cleaved caspase 9 proteins was seen after panT1 knock down in MCV-positive cells. 
These results are consistent with our DTS findings suggesting that MCV T antigen 
selectively activates BIRC5a transcription. We next sought to determine the importance 
of survivin expression to survival of MCV-positive and MCV-negative MCC cells. 
Although only partial suppression of survivin expression was achieved by shRNA 
BIRC5a targeting, MCV-positive MKL-1 cells, but not MCV-negative UISO cells, 
underwent apoptosis (Figure 39D).  
To confirm that LT is the MCV T antigen isoform responsible for survivin 
activation, we cloned and transduced a tumor-derived LT (LT339) cDNA into 
nontransformed, primary human BJ fibroblasts. Survivin protein levels increased three-
fold when LT was expressed compared to the empty vector control (as measured by 
quantitative LICOR immunoblotting, Figures 41A-B). Also consistent with our knock-
down experiments (Figure 39C), LT directly activates BIRC5a promoter transcription in 
BJ cells (Figure 41C). The LXCXE domain in LT responsible for sequestration of RB1 
mediates survivin activation. Both cyclin E and E2F1, required for cell cycle S phase 
entry (392) are repressed by active RB1 and were used as markers for RB-regulated 
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gene expression. MCV LT339 activates expression of both cyclin E and E2F1 proteins 
in BJ cells whereas LT339 having a point mutation that prevents RB1 binding (changing 
LFCDE to LFCDK) (279) abolishes induction of cyclin E, E2F1 and survivin (Figure 
41A). MCV small T expressed alone in BJ cells did not increase survivin oncoprotein 
expression (data not shown) In contrast to primary BJ fibroblasts, we did not find that 
MCV LT markedly increased survivin expression in cell lines that had been already 
transformed, including 293HEK and U2OS cells (data not shown).  
Figure 41. MCV LT induces survivin oncoprotein expression in primary BJ cells through 
its RB targeting domain 
(A) BJ cells were transduced with either empty vector, a tumor-derived LT cDNA (LT.339) or an 
LT cDNA with an inactive RB binding domain (LT.339LFCDK).  Immunoblotting reveals that 
MCV LT.339 induces survivin expression but LT.339LFCDK does not.  A similar pattern is seen 
for other S phase cell cycle proteins such E2F1 and cyclin E that are also transcriptionally 
repressed by RB. (B) LICOR quantitative immunoblotting for survivin in (A), normalized to a-
tubulin (arbitrary units). (C) Survivin mRNA levels increased in BJ cells expressing LT.339 
protein but not in cells expressing the RB1 binding mutant LT.339LFCDK. BJ cells expressing 
either empty, LT.339 or LT.339LFCDK were serum starved for 48 hours and then harvested for 
RNA. Survivin mRNA was measured by qRT-PCR and normalized to β-actin mRNA. The 
experiments performed three times in duplicate (mean+SEM). 
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B.3.3 Survivin as a target for MCC chemotherapy 
Given the apparent importance of MCV-induced survivin expression to MCC cell 
survival, we examined YM155, an imidazolium small molecule inhibitor of the survivin 
promoter that is currently undergoing Phase II trials for prostate cancer (389, 393). 
YM155 is both highly active and selective for inhibiting MCV-positive MCC cell growth in 
vitro as measured by Cell-Titer Glo assays (EC50 1.34 nM to 12.2 nM) (Figure 42A).  
Figure 42. The survivin promoter inhibitor YM155 inhibits MCV-positive MCC cell growth 
(A) Dose-dependent growth curves at 48 h for YM155-treated cell lines. MCV-negative MCC13, 
BJ and BJhTERT cells showed relative resistance to YM155 treatment, whereas all MCV-
positive cell lines (MKL-1, MKL-2, MS-1 and WaGa) were sensitive to YM155.  MCV-negative 
UISO and MCC26 had intermediate sensitivity to the YM155. (B) Trypan blue vital dye exclusion 
assay showed dose-dependent cell killing at 48 h for MKL-1 cells (blue bars) whereas UISO 
cells (red bars) are relatively less sensitive and BJ cells (green bars) are resistant to YM155. (C) 
A 
Survivin 
!-Tubulin 
YM155 (nM) 
0 1 10 100 1000 
B 
Figure 3 
C 
 177 
Dose-dependent decrease in MKL-1 cell survivin protein expression after 12 h YM155 
treatment.  
MCV-negative MCC cell line growth is also inhibited by YM155 but this occurs at 
concentrations 1-2 orders of magnitude higher than for MCV-positive MCC cells. YM155 
treatment for 48 hours at 10-100 nM preferentially killed MCV-positive MKL-1 compared 
to MCV-negative UISO cells as measured by trypan blue staining (Figure 42B). 
Survivin protein was reduced in MKL-1 cells after YM155 treatment, consistent with 
YM155’s proposed mechanism of action in inhibiting the BIRC5a promoter (Figure 
42C).  
We next examined mechanisms of cell killing by YM155 in MCV-positive MCC 
cells (Figure 43). Survivin plays a role in mitotic progression and loss of survivin can 
lead to cell death through mitotic catastrophe in some tumor cells (394). MCV-positive 
MCC, however, are slowly cycling cells (doubling time of 3 days (388)) and do not 
undergo G1 arrest or G2/M pileup as would occur with mitotic checkpoint activation in 
rapidly cycling cells (Figure 43A, top panels). Instead, bromo-deoxyuridine (BrdU) 
incorporation into DNA reveals a profound inhibition of DNA synthesis by YM155. 
Figure 43A (boxes, bottom left panel) shows the normal inverted-U pattern for BrdU 
incorporation during S phase DNA synthesis in MKL-1 cells. When the topoisomerase I 
inhibitor camptothecin is added (Figure 43A, bottom right panel), accumulation of BrdU-
positive cells in G1 and G2/M/G1-tetraploid becomes evident, and S phase 
incorporation is lost, consistent with repair polymerase activation during DNA damage 
response signaling. YM155 treatment, however, ablates BrdU incorporation (Figure 
31A, center panel), most consistent with disruption of DNA replication forks and 
inhibition of new S phase and repair DNA synthesis, but not mitotic catastrophe.   
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Figure 43. Cell death phenotype of MCV-positive MCC cells treated with YM155 
(A) Cell cycle analysis reveals YM155 treated cells do not undergo mitotic catastrophe. MKL-1 
cells were treated with DMSO, YM155 (100nM) and camptothecin (CPT, 1mM) for 12 h and 
then subjected to PI (upper panel) and BrdU staining (lower panel). Boxes show S phase BrdU 
incorporation without treatment, accumulation at G1 and G2/M/G1 tetraploid during CPT 
treatment, and near-complete loss of BrdU incorporation during YM155 treatment. Box a 
represents G1 phase, box b represents S phase and box c represents G2/M phase (B) YM155 
induces nonapoptotic cell death associated with autophagy in MKL-1 cells. MKL-1 cells were 
treated with DMSO, YM155 (100nM) or bortezomib (100nM) and immunoblotted for (c) cleaved 
PARP, cCaspase 3, LC3 and a-tubulin. In contrast to YM155, the bortezomib proteasome 
inhibitor activates MKL-1 cell apoptosis (also see Fig S2). (C) YM155 treatment initiates 
programmed cell death within 12-24 hours after treatment. MKL-1 cells were co-stained with 
CFDA (green, live) and PI (red, dead). Column graphs (right panel) represent mean and range 
of % CFDA-positive (green) and % PI-positive cells (red). 
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YM155 treatment results in early commitment to nonapoptotic programmed cell 
death. No evidence of apoptosis was present, measured by caspase 3 and PARP 
cleavage (Figure 43B), when MKL-1 cells were treated with 100 nM YM155 for 48 
hours, but YM155 did initiate LC3-II accumulation, a marker for cell autophagy (395). 
This is not due to loss of apoptosis pathway signaling since treatment with the 
proteasome inhibitor bortezomib (Velcade) activated PARP and caspase cleavage 
(Figure 43B). Commitment to YM155-dependent cell death occurs relatively quickly and 
irreversibly: when MKL-1 cells were treated with 100 nM YM155 for 3, 6 or 12 hours, 
followed by wash out with complete cell culture medium, only 51%, 3% and 1.8% of 
cells respectively, remained viable at 48 hours, as measured by trypan blue dye 
exclusion. This was confirmed by a cell viability assay using propidium iodide (PI, dead) 
and carboxyfluorescein diacetate (CFDA, alive) co-staining (Figure 43C). Twelve to 24 
hours of 100 nM YM155 treatment causes MKL-1 cells to lose membrane integrity, 
becoming positive for PI and negative for CFDA staining. 
To search for other MCC chemotherapeutics, we performed a two-stage 
cytotoxicity library screen on 1,360 pharmacologically-active drug compounds including 
1,280 drugs from the Library of Pharmacologically Active Compounds (LOPAC) (Sigma 
Aldrich), 89 drugs from the National Cancer Institute’s Approved oncology drug set II 
(19 compounds in common with LOPAC1280), 6 compounds targeting SV40 LT 
ATPase activity, and 4 compounds targeting MDM2 to activate p53. These compounds 
were screened at 10-5 M for >90% inhibition of MKL-1 cell growth in a Cell-Titer Glo 
assay (Promega). Notably, mTOR inhibitors (everolimus, rapamycin etc), antiviral 
compounds (ribavirin, acyclovir) and MDM-2 inhibitors active in other viral cancers (e.g., 
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nutlin-3 (396, 397)) were not active in our screen (data not shown). This is consistent 
with previous findings that MCV loses replication activity (279) and activates cap-
dependent translation downstream of mTOR in MCC tumor cells (129).   
Eighteen (1.3%) of these 1360 drugs met our initial screening criterion for anti-
MCC activity and were selected for secondary dose-dependent screening on MCV-
positive and MCV-negative cell lines (Table 8). Only the proteasome-inhibitor 
bortezomib (398) was active in vitro at low doses with an EC50 of 1.3-13.2 nM; however, 
this activity was not selective for MCV-positive cells. Other agents, particularly 
topoisomerase I and II inhibitors, also inhibited MCC cell growth but were generally far 
less potent or had variable activity among different MCC cell lines (Table 8). 
 Table 5 
 
EC50 (μM) concentrations for MCC cell lines 
 
Drugs MKL-1 MKL-2 MS-1 WaGa UISO 
PROTEASOME INHIBITOR      
Bortezomib 0.013  0.005  0.002  0.001 0.003 
TOPOISOMERASE INHIBITORS      
Ellipticine 3.2 6.5 6.9 3.0 1.1 
Amsacrine hydrochloride 0.11 3.0 7.5 0.25 2.6 
Teniposide 0.010 2.8 3.0 0.026 7.3 
Valrubicin 0.23 2.8 9.9 0.32 4.0 
Mitoxantrone 0.006 1.3 1.6 0.014 0.97 
Daunorubicin 0.015 0.086 0.15 0.018 1.4 
Doxorubicin 0.21 0.022 0.37 0.022 0.25 
Topotecan 0.028 0.43 0.62 0.015 0.17 
OTHERS      
Iodoacetamide 0.29 0.30 0.64 0.37 2.5 
Sanguinarine chloride 5.3 8.4 4.9 2.5 6.5 
NSC 95397 1.2 1.5 1.8 0.73 2.8 
Chelerythrine chloride 0.60 0.65 0.52 0.70 3.7 
Calmidazolium chloride 2.2 1.7 2.1 2.1 2.0 
Tetraethylthiuram disulfide 0.49 0.19 6.3 1.1 13 
Bay 11-7085 1.4 1.7 2.7 1.2 4.5 
Quinacrine dihydrochloride 5.1 4.6 4.9 5.2 7.1 !
Table 8. EC50 (µM) concentrations for MCC cell lines 
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B.3.4 Effect of YM155 on Human MCC Xenografts in Mice 
We developed an MKL-1 xenograft model to test the in vivo efficacy of YM155 and 
bortezomib on human MCC in NOD scid gamma (NSG) mice. Subcutaneous injection of 
MKL-1 cells generates tumors that are positive for MCV LT and the MCC diagnostic 
marker CK20 (Figure 44A), and progress to endpoint (2 cm tumor diameter) within 2-4 
weeks after tumors are first detected. We treated these mice with bortezomib, YM155 or 
saline for three weeks once tumors became palpable. Bortezomib was administered at 
levels effective on multiple myeloma xenografts (399) (1 mg/kg, twice-weekly 
subcutaneous injections). This did not significantly affect MCC tumor progression or 
volume compared to treatment with saline alone (p=0.53, log-rank test). Bortezomib 
administration at this level was associated with mouse lethargy and weight loss, 
requiring temporary use of heat blankets and Hydrogel (ClearH2O) to prevent animal 
loss during initial treatment.  
In contrast to bortezomib, YM155 (2 mg/kg, subcutaneous 5 times weekly) 
markedly delayed MKL-1 xenograft growth and significantly prolonged survival 
compared to either saline or bortezomib (p<0.0001, log-rank test, Figures 44B-C). This 
YM155 treatment regimen is the standard dosing for mouse xenograft experiments 
based on pharmacokinetic and treatment response studies of Nakahara et al. on six 
different human cancer xenografts (prostate, bladder, melanoma, breast and lung 
cancer) in mice and >100 human tumor cell lines (229, 389, 400). While 66.7-74.2% of 
bortezomib or saline-treated mice reached the euthanasia endpoint during the three-
week treatment period, none of the YM155-treated mice reached this endpoint during 
treatment. Partial tumor regression occurred among some YM155-treated mice but all 
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tumors resumed growth once YM155 was stopped, indicating that a single 3-week 
treatment course was insufficient for tumor eradication (Figure 44B). For the majority of 
the mice, MKL-1 tumor volumes were unchanged or showed delayed growth during 
YM155 treatment, suggesting this drug may be cytostatic rather than cytocidal for MKL-
1 xenografts (Figure 44C). YM155 was well-tolerated and no adverse effects or acute 
toxicities were noted. In smaller cohorts of mice bearing MS-1 (MCV-positive) and UISO 
(MCV-negative) cell xenografts, final tumor volumes for YM155-treated mice were 43-
55% (median) of saline-treated control mice at the end of the three-week treatment 
period (Figure 44D).   
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Figure 44. YM155 inhibits growth of MKL-1 xenografts in NSG mice 
(A) MKL-1 xenograft tumors stained with hematoxylin and eosin, MCV LT (CM2B4 antibody) 
and CK20 (magnification 40X). (B) MKL-1 xenograft survival curves after drug treatment. Mice 
were subcutaneously injected with 20 million MKL-1 cells and assigned to a three-week drug 
treatment after tumors became palpable (see text). No significant difference was found between 
saline and bortezomib treatment. Tumor progression was significantly delayed by YM155, with 
none of the YM155-treated mice dying during treatment (up to day 19) compared to 23 of 31 
(74%) saline and 14 of 21 (67%) bortezomib-treated mice. Tumor progression recurred for all 
YM155-treated mice once treatment was stopped. (C) Piecewise linear hierarchical Bayesian 
model for tumor volumes in treated mice (391) (see supplemental appendix for details). Colored 
lines show estimated central population tumor volumes with shaded regions representing 95% 
credible intervals. Actual tumor volumes (grey lines) for each mouse are shown for comparison. 
YM155 treatment retards tumor growth compared to saline or bortezomib treatment. (D) Table 
showing day of termination and tumor volumes for MS-1 and UISO xenograft mice treated with 
YM155 or saline. 
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B.4 DISCUSSION 
We show here that discovery of a viral cause for most MCC in February 2008, followed 
by the description of the virus’ oncogenes one year later, has now been used to 
rationally identify a survivin inhibitor that may have activity against this cancer. Our 
library screen of 1360 drugs, including the entire NCI Approved Oncology Drug Set II, 
confirmed that MCC is very chemoresistant and identified only one drug (bortezomib) 
that was highly active in vitro. Bortezomib however was not active in vivo against MCC 
xenografts. DTS, a quantitative cDNA deep sequencing method, not only identified MCV 
as a new human polyomavirus in MCC but also helped to uncover cell signaling 
pathways that are potential targets for MCV-positive MCC treatment.   
Survivin, an inhibitor of apoptosis protein (IAP) family member (401), contributes 
to chemoresistance of melanoma (402) and is overexpressed in many cancers including 
MCC (403). It increases during non-neoplastic JC polyomavirus infection (404), and by 
SV40 LT through an E2F-regulated mechanism (405, 406). Our MCV T antigen knock-
down and expression experiments confirm survivin to be activated by MCV LT’s 
sequestration of RB-family transcription repressors. Survivin has pleiotropic activities in 
both preventing apoptosis and activating cell cycle entry (407). Our findings are 
consistent with retinoblastoma protein or other pocket proteins repressing survivin 
expression in primary cells (405), which can be relieved when MCV LT is expressed. 
MCV LT did not further increase survivin levels for transformed cells having the 
retinoblastoma protein pathway signaling blocked by mutation or E1A. MCV activation 
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of survivin through retinoblastoma protein targeting may typically serve to promote virus 
replication but is aberrantly activated during MCV-tumorigenesis (10).  
YM155 is highly cytotoxic in vitro to MCV-positive MCC cells, causing these cells 
to initiate a necroptotic cell death routine. Loss of survivin is commonly linked to mitotic 
catastrophe in cancer cells (408); however, we did not find this to significantly contribute 
to MCC cell death. There was no distinct G1 or G2-M phase accumulation of cells 
during YM155 treatment and irreversible commitment to cell death occurs too quickly for 
most MCC cells to have an opportunity to transit the cell cycle. YM155 does increase 
LC3-II, implicating autophagy in YM155-induced cell death, but may reflect a 
consequence rather than a cause for cell death (409). Intriguingly, a very similar cell 
death phenotype occurs when T antigens are knocked down in MCV-positive MCC cells 
(388), whereas we found that knock-down of survivin alone causes apoptosis rather 
than necroptosis. As with YM155 treatment, this effect was predominant in an MCV-
positive but not MCV-negative MCC cell line. Since knock-down of survivin causes 
apoptosis rather than necroptosis, we cannot exclude the possibility that YM155 targets 
other molecules in addition to survivin, or that different levels of survivin inhibition by 
YM155 and survivin knock-down result in different programmed cell death responses.  
There are several important caveats to our current study. While YM155 was 
highly active in vitro, it was only cytostatic—not cytotoxic—in most mouse xenografts. 
Once YM155 treatment was stopped, tumors re-emerged in all of the treated mice. 
Either prolonged YM155 treatment or combined use with other drugs (e.g., bortezomib, 
topoisomerase inhibitors) may more effectively control MCC. YM155 was relatively 
nontoxic in our study, making it potentially more suitable for prolonged or combined 
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therapy. Practical limitations prevented us from extensively measuring YM155 activity 
on a variety of MCC cell line xenografts and we cannot exclude the possibility of 
resistance among other MCC. But it is encouraging that YM155 reduced tumor masses 
in two additional MCC xenografts, including one from a MCV-negative tumor. Finally, 
MCV sT (also expressed in MCC cells) increases cap-dependent protein translation 
(129), and could contribute to YM155 resistance through a transcription-independent 
mechanism of survivin induction (410). 
DTS (54) is a useful method to discover (55) or exclude (54) viruses being 
present in human cancers. In this study, we show that DTS is also useful in measuring 
cellular gene expression by demonstrating that BIRC5 transcription is activated in MCV-
positive MCC. If carefully performed and rigorously analyzed, DTS data yields useful 
information even when no cancer viruses are discovered (54). Prior to discovery of 
MCV, few clues were available about the molecular causes for MCC (411). Now that 
MCV has been shown to be central to most MCC, rational targeting of survivin and other 
cellular pathways perturbed by MCV may lead to discovery of additional treatments that 
may be more effective and less toxic than current therapies. 
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APPENDIX C 
RESPONSE OF MERKEL CELL POLYOMAVIRUS-POSITIVE MERKEL CELL 
CARCINOMA XENOGRAFTS TO YM155 
The work described in Appendix C has been submitted to Cancer Research in July 
2013  
with authors Lindsay R. Dresang, Anna Guastafierro, Reety Arora, Daniel 
Normolle, Yuan Chang, and Patrick S. Moore 
 
L.R. Dresang performed immunohistochemistry.  L.R. Dresang and R. Arora performed 
CellTiter-Glo studies.  L.R. Dresang, A. Guastafierro, and R. Arora performed mouse 
xenograft experiments.  D. Normolle performed the statistical analyses of survival and 
tumor volume data.  All authors interpreted the data and wrote the manuscript. 
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C.1 INTRODUCTION 
We confirm here that YM155, a survivin suppressor, is cytotoxic to MCV-positive MCC 
cells in vitro at nanomolar levels.  Mouse survival was significantly improved for NOD-
Scid-Gamma mice treated with YM155 in a dose and duration dependent manner for 3 
of 4 MCV-positive MCC xenografts.  One MCV-positive MCC xenograft (MS-1) failed to 
significantly respond to YM155, which corresponds with in vitro dose-response activity.  
Combination treatment of YM155 with other chemotherapeutics resulted in additive but 
not synergistic cell killing of MCC cell lines in vitro.  These results suggest that survivin 
targeting is a promising therapeutic approach for most but not all MCV-positive MCCs.   
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C.2  MATERIALS AND METHODS 
C.2.1 Cell Lines and Tissue Culture 
The MCC cell lines MKL-1 (412), MS-1 (265), MKL-2 (234), and WaGa (gift of J. 
Becker) (297) were cultured in RPMI 1640 with 10% fetal calf serum, and primary 
human fibroblasts, BJ (American Type Culture Collection), were cultured in Dulbecco’s 
modified Eagle’s medium with 10% fetal calf serum, as described previously (232, 265).  
All cells were maintained at 37°C in humidified air containing 5% CO2.   
C.2.2 NOD-Scid-Gamma Mice 
The animals used for these studies are as described previously (232).  NSG female 
mice (413), strain #005557 (Jackson Laboratory), were received at 6-weeks of age and 
maintained in a specific, pathogen-free environment at the Hillman Cancer Center 
Mouse Facility, University of Pittsburgh, for at least one week prior to cell line injection.  
All animal studies were performed with approval from the Animal Ethics Committee of 
the University of Pittsburgh (Institutional Animal Care and Use Committee Protocol 
#12020149).   
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C.2.3 Xenografts and Treatment 
MCC xenografts were generated as previously described (Appendix B (232)). MCC cell 
lines were optimally grown at >90% cell viability as determined by trypan blue dye 
exclusion.  MCC cells were washed with phosphate-buffered saline (PBS) and 
resuspended at 2x107cells per 100uL in PBS and injected into the right flanks of NSG 
mice.  Treatment regimens began as individual animals developed palpable tumors 
(~2mm x 2mm), as outlined in Figure 45.  All treatments followed a five day on, two day 
off regimen of daily intraperitoneal (I.P.) injections.  Three-week treatments ended on 
day 19 of I.P. injection.  Continuous treatments were carried out until the animals 
reached the experimental endpoint.  The experimental endpoint was evaluated by tumor 
burden, with at least one measurable diameter of 20mm, or by the presence of multiple 
signs of distress (respiratory rate elevation, wheezing, hypothermia, behavioral 
changes, inactivity, >20% weight loss, vertebral protrusion, or ruffled fur).  Saline-
treated mice were injected with a fixed volume of 100uL 0.9% Sodium Chloride USP 
Normal Saline (Nurse Assist) per injection.  YM155 was administered at either 2mg/kg, 
4mg/kg, or 6mg/kg, resuspended in 0.9% Sodium Chloride USP Normal Saline and filter 
sterilized.  Tumor volumes were measured three times weekly and at the time of 
euthanization according to the following formula: width2 x (length ÷ 2).  Mouse weights 
were monitored at least once per week throughout the experiment.  Observations, 
including weight measurements, were recorded daily on an individual mouse basis if 
signs of distress were observed. 
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C.2.4 Statistical Analysis of Survival and Tumor Volume Data 
Mixed-effects ANOVA was used for batch-adjusted times to 50% survival per cell line 
and treatment group, with 95% confidence intervals.  Pairwise comparisons between 
treatments or between cell lines were estimated (with 95% confidence intervals) by 
linear contrasts on the estimated ANOVA parameters .  Between-batch variation was 
taken into account for all analyses.  Tumor volumes were assessed for differential 
growth across treatment groups using an extension to the piecewise linear hierarchical 
Bayesian model that accounts for batch effects (391).  All analyses were performed 
using SAS (SAS Institute), R (R Development Core Team) and JAGS software. Average 
tumor growth kinetics with 95% confidence intervals were estimated as described 
previously (232). Briefly, a delay in tumor growth (or re-growth) is estimated by a hinge 
point, called nadir, where the volume at nadir (α) is expressed as a log2(volume) and the 
time at nadir (ρ) is expressed in days.  An initial decrease in growth is estimated as β1, 
where log2(volume) = α+β1*(ρ-day).  Final increase in tumor growth is estimated as β2, 
where log2(volume) = α+β2*(day-ρ).  These four parameters are estimated for each 
animal and for each treatment and cell line. 
C.2.5 Immunohistochemistry 
Immunohistochemistry was performed as described previously (57). Tumor and/or 
normal mouse tissue was cut to size for optimal formalin infusion (10% neutral-buffered 
solution; Sigma) for at least 24hrs prior to paraffin embedding.  Paraffin embedding, 
preparation of unstained slides, and H&E processing was performed by Research 
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Histology Services at the Thomas E. Starzl Transplantation Institute core facilities at the 
University of Pittsburgh.  Unstained slides were baked at 60°C for 1hr under vacuum.  
Deparaffinization continued with xylene treatment (2-3 incubations, 10min).  Slides were 
gradually rehydrated moving from 100% ethanol (2 incubations, 10min), to 95% ethanol 
(2 incubations, 10min), to 80% ethanol with agitation, to 70% ethanol with agitation, and 
finally moving to deionized water.  Slides were treated with 3% hydrogen peroxide to 
quench endogenous peroxidases, rinsed several times with deionized water, and then 
placed in 1mM EDTA pH8.0 for heat-induced epitope retrieval (125°C for 3min and 15s, 
followed by 90°C for 15s).  After 45-60min of gradual cooling, slides were briefly rinsed 
several times with deionized water, rinsed with TBS (68mM NaCl, 10mM Tris pH7.5), 
treated with Protein Block (DAKO) for 5min, and then incubated with CM2B4 (57) 
primary antibody (diluted 0.5-1.5ug/mL) for 30min (PBS pH7.4, 1% BSA, 0.1% gelatin, 
0.5% Triton-X-100, 0.05% sodium azide).  Slides were washed 3 times with agitation in 
TBS.  Secondary mouse-HRP antibody (Mouse Envision Polymer; DAKO) was 
incubated on the slides for 30min.  Slides were again washed 3 times with agitation in 
TBS.  Colorimetric detection with 3,3-diaminobenzidine and chromagen was quenched 
with deionized water.  Slides were counter-stained with Mayer’s hemotoxylin, Lillie’s 
modification (DAKO), rinsed several times in tap water, blued in 1% lithium carbonate, 
rinsed several times in tap water, and then dehydrated through 95% ethanol (twice with 
agitation) to 100% ethanol (twice with agitation).  Slides were incubated twice in xylene 
for 5min and coverslips were adhered using Permount (Fisher Scientific).   
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C.2.6 Chemotherapeutic Compounds 
YM155 was purchased from Active Biochemicals Ltd.  Docetaxel, carboplatin, 
etoposide, topotecan HCl, and bortezomib were provided by the NCI/DTP Open 
Chemical Repository (http://dtp.cancer.gov).   
C.2.7 Dose-Response Studies 
Dose-response studies were performed as previously described (232).  Briefly, 6000 
cells were seeded per well in 384 well plates at a volume of 50uL and allowed to 
incubate overnight at 37°C in a 5% CO2 humidified chamber.  A log range of drug 
concentrations from 10-4 to 10-10 was resuspended in culture medium (with or without a 
fixed amount of YM155) at 3X concentration and then added at a volume of 25uL.  After 
48 hours further incubation in a humidified chamber, cells were treated with 25uL 
CellTiter-Glo Luminescent reagent (Promega) and cell viability was measured as per 
manufacturer’s instructions.  No-drug control wells served as normalization controls per 
cell line.  Each concentration per cell line was plated in triplicate.  Three or more 
biological replicates per cell line were tested with YM155 alone, two or more biological 
replicates were tested with all other single drugs, and combination studies were tested 
independently with either 1nM YM155 or 3nM YM155, with representative analysis at 
3nM YM155 combination shown.  Empty wells were used to separate different cell lines 
and treatment groups to reduce error from luminescent bleed-over.  EC50 values were 
calculated from a four-parameter logistic equation fit to the surviving proportions of cells 
per dose.  
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C.3 RESULTS 
C.3.1 MCV-positive MCC cell line xenograft model experimental outline  
NSG mice were injected with MCV-positive MCC cell lines (Figure 45A) and were 
monitored for tumor growth, weight, and overall health. Once palpable tumors were 
detected (Figure 45B), NSG mice were intraperitoneally (I.P.) injected (once per day for 
five days, followed by two days of rest) with either saline treatment, 2mg/kg YM155 
treatment for three weeks, or were continuously treated with YM155 (2mg/kg or 4mg/kg) 
until the tumor attained a diameter of 20mm or the mouse exhibited multiple signs of 
distress (Figure 45C).   
 
Figure 45. MCC mouse xenograft 
treatment groups and experimental 
outline 
(A) NSG mice were subcutaneously 
injected in the right flank with 2x107 
MCV-positive, MCC cells (MKL-1, MS-
1, WaGa, or MKL-2).  (B) NSG mice 
were monitored for palpable tumors 
(~2mm x 2mm) to determine start of 
treatment.  (C) Mice with palpable 
tumors were randomly assigned to 
either saline treatment, YM155 
treatment for 3-weeks at 2mg/kg, 
YM155 continuous treatment at 
2mg/kg, or YM155 continuous 
treatment at 4mg/kg.  Each week of 
treatment consisted of a single 
intraperitoneal injection per day for 5 
days, followed by 2 days of rest. 
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YM155 at 6mg/kg was tested in two mice, but both mice had >20% weight loss 
and additional signs of distress (ruffled fur, inactivity, and behavioral changes) within the 
first week of treatment and were euthanized (as per Institutional Animal Care and Use 
Committee protocol #12020149).  Mice receiving saline treatment or YM155 treatment 
at 2mg/kg do not lose weight (Figure 46A and 46B, respectively) or show signs of 
distress, whereas mice receiving YM155 at 4mg/kg lose weight (Figure 46C) and 
display minimal signs of distress (only ruffled fur, normal behavior).  This toxicity 
dissipates after the first 1-2 weeks of treatment (Figure 46C).  Thus, 4mg/kg YM155 is 
the maximum tolerated dose in NSG mice when administered by single daily I.P. 
injection.   
 
Figure 46. Mouse weights on saline and YM155 treatment groups 
Average mouse weights with standard deviations are reported according to treatment regimen, 
where weights were normalized to day zero of treatment (100%):  (A) mouse weights on saline, 
continuous-treatment (green line); (B) mouse weights on YM155, continuous-treatment (purple 
line); and (C) mouse weights on YM155 double-dose, continuous-treatment (orange line).  
Mouse weights were adjusted to remove the weight of tumors prior to normalization.  Weights 
from mice with significant liver metastases were not included as metastatic-tumor weights could 
not be determined during the course of treatment. 
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C.3.2 Survival of mice with MCC xenografts is prolonged by increasing YM155 
duration of treatment, as well as by increasing the dosage of YM155, in a cell line 
dependent manner 
Estimated mean survival times with 95% confidence intervals are presented in Figure 
47A according to treatment group and cell line.  Batch variations from independent 
replicates per treatment group and cell line were taken into account for the reported 
statistical analyses.  Figure 47B shows a Kaplan-Meier survival curve for MKL-1 
xenografts treated for a single 3-week course (2mg/kg YM155) or continuously until 
sacrifice (data from this figure include mice treated in preliminary studies, Appendix B 
(232)). Extending the duration of YM155 treatment prolongs survival (relative to saline 
or 3-week treatment, P<0.0001; Figure 47B), which is prolonged further by doubling the 
YM155 dose to 4mg/kg (relative to all treatment arms, P<0.0001; Figure 47B).  The 
EC50 values for YM155 in vitro range from 1.3nM to 12nM for different MCV-positive 
MCC cell lines (232); MKL-1 and MS-1 are at opposite ends of this range, respectively.   
MS-1 was tested in mice to assess the degree of response to YM155 in vivo.  Mice 
were treated with either saline, 2mg/kg YM155 continuously, or 4mg/kg YM155 
continuously. In contrast to MKL-1, Figure 47C shows that MS-1 does not significantly 
respond to YM155 treatment in vivo, despite extended duration of treatment or 
increased dosage.  This is in contrast to two other MCV-positive MCC cell lines, WaGa 
and MKL-2 (Figures 47D-E).  Both WaGa and MKL-2 xenografts responded to YM155 
(4mg/kg) relative to saline treatment (P=0.0034 and P<0.0001, respectively; Figure 
47D-E).  
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Figure 47. Survival of various MCC xenograft models on different treatments 
(A) Estimated survival means and 95% confidence intervals are reported along compressed 
survival summaries per cell line and treatment arm, where open circles correspond survival of 
individual mice.  (B) Mice with MKL-1 xenografts exhibit significantly prolonged survival (****P < 
0.0001) on any of the three YM155 treatment groups (3-weeks at 2mg/kg = red; continuous 
treatment at 2mg/kg = purple; continuous treatment at 4mg/kg = orange) relative to saline 
treatment (green).  Increasing the duration of YM155 treatment from 3-weeks to continuous 
treatment at the 2mg/kg dose significantly prolongs survival (****P < 0.0001).  Increasing the 
dose of YM155 from 2mg/kg to 4mg/kg on continuous treatment significantly prolongs survival 
(****P < 0.0001).  (C) Mice with MS-1 xenografts do not exhibit prolonged survival with YM155 
continuous treatment (either at 2mg/kg or 4mg/kg) relative to saline treatment (NS = not 
significant).  One mouse on saline treatment spontaneously regressed for over 5-weeks and 
was euthanized early (as indicated by x).  (D) Mice with WaGa xenografts exhibit significantly 
prolonged survival (**P = 0.0034) with continuous YM155 treatment at 4mg/kg relative to saline 
treatment.  (E) Mice with MKL-2 xenografts exhibit significantly prolonged survival (****P < 
0.0001) with continuous YM155 treatment at 4mg/kg relative to saline treatment.  Two mice did 
not reach the final 20mm tumor dimension by day 105 and were euthanized early (as indicated 
by ##). 
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C.3.3  Tumor shrinkage and delay of re-growth (regression), and/or slower 
growth rate is observed upon YM155 treatment (relative to saline) in three of four 
MCC xenografts 
Tumor volume data analysis reveals that the delay of tumor re-growth was significant in 
all YM155 treatment arms of mice with MKL-1 xenografts (Figure 48A), relative to 
saline: 2mg/kg YM155 treatment for three weeks (8.6±2.5 days); 2mg/kg continuous 
YM155 treatment (15.8.6±3.2 days); and 4mg/kg continuous YM155 treatment 
(29.9±4.0 days) (Table 9).  The delay in re-growth was significantly greater in the 
4mg/kg arm than the 2mg/kg arm (P<0.05).  After the initial delay, final tumor growth 
rate of MKL-1 xenografts in mice treated continuously with YM155 (2mg/kg or 4mg/kg) 
was slower than mice treated with YM155 for 3-weeks or mice treated with saline (both 
P-values <0.05).  Final tumor growth rates in mice treated continuously at either 2mg/kg 
or 4mg/kg doses were comparable (Table 9).   
Cell 
Line Treatment
Alpha 
(!)
Std. 
Err. (!)
95% C.I. 
(!)
Beta-1 
("1)
Std. Err. 
("1)
95% C.I. 
("1)
Beta-2 
("2)
Std. Err. 
("2)
95% C.I. 
("2)
Rho 
(#)
Std. 
Err. (#)
95% C.I. 
(#)
>20% 
Reg. (*)
MKL-1 Saline 4.633 0.496
(3.530 , 
5.735 ) 0.962 0.060
(0.832 , 
1.092 ) 0.455 0.041
(0.363 , 
0.546 ) -1.294 2.413
(-6.489, 
3.900 ) N/A
MKL-1
YM155 3-
Weeks 2.552 0.498
(1.454 , 
3.650 ) 0.602 0.061
(0.472 , 
0.732 ) 0.426 0.042
(0.334 , 
0.517 ) 8.628 2.501
(3.379 , 
13.878) (8, 35)
MKL-1
YM155 
Continuous 1.847 0.593
(0.599 , 
3.094 ) 0.370 0.078
(0.209 , 
0.530 ) 0.207 0.053
(0.095 , 
0.318 ) 15.751 3.229
(9.092 , 
22.409) (5, 37)
MKL-1
YM155 
4mg/kg -0.474 0.735
(-1.989, 
1.041 ) 0.168 0.098
(-0.036, 
0.372 ) 0.208 0.067
(0.066 , 
0.349 ) 29.889 3.977
(21.415, 
38.362) (3, 50)
MKL-2 Saline 1.929 0.957
(-0.166, 
4.024 ) 0.781 0.119
(0.529 , 
1.033 ) 0.176 0.081
(-0.001, 
0.353 ) 5.940 4.815
(-4.249, 
16.130) N/A
MKL-2
YM155 
4mg/kg -0.443 0.957
(-2.538, 
1.652 ) 0.562 0.119
(0.310 , 
0.814 ) 0.158 0.081
(-0.019, 
0.335 ) 12.449 4.815
(2.260 , 
22.639) (2, 51)
MS-1 Saline 1.972 0.860
(-0.006, 
3.950 ) 0.845 0.100
(0.623 , 
1.066 ) 0.282 0.069
(0.123 , 
0.440 ) 2.355 3.975
(-6.333, 
11.042) N/A
MS-1
YM155 
Continuous 1.822 0.957
(-0.273, 
3.917 ) 0.695 0.119
(0.442 , 
0.947 ) 0.308 0.081
(0.131 , 
0.485 ) 1.965 4.815
(-8.225, 
12.154) N/A
MS-1
YM155 
4mg/kg 1.544 0.957
(-0.551, 
3.638 ) 0.861 0.119
(0.609 , 
1.113 ) 0.278 0.081
(0.101 , 
0.455 ) 1.040 4.815
(-9.150, 
11.229) N/A
WaGa Saline 4.321 1.176
(1.554 , 
7.088 ) 0.941 0.133
(0.637 , 
1.245 ) 0.495 0.092
(0.275 , 
0.714 ) 0.000 5.190
(-11.73, 
11.731) N/A
WaGa
YM155 
4mg/kg 4.619 1.168
(1.856 , 
7.382 ) 0.933 0.131
(0.630 , 
1.235 ) 0.275 0.091
(0.056 , 
0.495 ) 0.000 5.090
(-11.64, 
11.645) N/A
! = Log2 Tumor Volume at Nadir; "1 = Pre-Nadir Slope (Decreasing); "2 = Post-Nadir Slope (Increasing); # = Time at Nadir;
Reg. = Regression; Std. Err. = Standard Error; C.I. = Confidence Interval; N/A = Not Applicable
 Table 9: Average Tumor Growth KineticsTable 9. Average tumor growth kinetics 
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Figure 48. Tumor volume response to YM155 is dose, duration, and cell line dependent 
Tumor volumes (mm3) are reported on a Log2 scale according to treatment group.  Non-
palpable (NP) tumors are indicated at baseline corresponding to tumor regression.  (A) Tumor 
volumes of MKL-1 xenografts undergo an initial regression period with YM155 treatment where 
>20% of mice lack palpable tumors (as indicated by *), which is extended with increased dose 
and duration of YM155 treatment.  Overall tumor growth rate is reduced with increased YM155 
duration and dosage.  A total of 9 mice were euthanized before a diameter of 20mm was 
measured on the primary tumor due to distress associated with liver metastasis (as indicated by 
o).  (B) Tumor volumes of MS-1 xenografts are unaffected by YM155 treatment.  A spontaneous 
regression was observed on saline treatment (as indicated by x).  (C) Tumor volumes of WaGa 
xenografts do not undergo an initial regression, but have a reduced growth rate.  (D) Tumor 
volumes of MKL-2 xenografts undergo an initial regression period with YM155 treatment where 
>20% of mice lack palpable tumors (as indicated by *).  Overall tumor growth rate is reduced on 
YM155 treatment relative to saline treatment.  Two mice did not reach the final 20mm tumor 
dimension by day 105 (as indicated by #).   
 
 
There was no shrinkage in tumor volume, delay of tumor re-growth, or reduction 
in growth rate observed in mice with MS-1 xenografts comparing saline treatment to 
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YM155 treatment at either 2mg/kg or 4mg/kg (Figure 48B and Table 8).  WaGa 
xenografts in mice treated continuously with 4mg/kg YM155 grew slower than mice 
treated with saline (P<0.05), but there was no evidence of initial tumor shrinkage or 
delay of re-growth in these mice (Figure 48C and Table 8).  There was evidence of 
initial tumor shrinkage in YM155-treated mice with MKL-1 (Figure 48A) and MKL-2 
(Figure 48D) xenografts (all P-values <0.05), but the absolute amount of shrinkage was 
small (Table 8).  The delay of tumor re-growth was significantly longer in mice with 
MKL-1 xenografts than in mice with MKL-2 xenografts (P<0.05); tumor shrinkage and 
delayed tumor re-growth correlate with a regression period in which >20% of mice no 
longer had palpable tumors (Table 6, Figure 48A and D, mared by asterisks).  
However, all mice were eventually euthanized due to progressive disease.  Thus, while 
YM155 continuous treatment at 4mg/kg prolongs survival in NSG mice with three of the 
four MCC xenografts, this treatment regimen does not eradicate tumor cells.   
 
C.3.4 MCV-positive MCC xenograft mouse models develop metastases at 
different locations in a cell line dependent manner 
MKL-1, MS-1, and WaGa cell lines are each derived from metastatic lesions (265, 276, 
412); the site of MKL-2 derivation is unknown.  Common sites of metastasis include 
skin, lymph nodes, liver, lung, bone, and brain (reviewed by Eng et al. (414)).  Autopsy 
was performed on each mouse reaching experimental endpoint to assess the metastatic 
capability of each cell line in our mouse xenograft models.  Mice with MKL-1, MS-1, or 
MKL-2 xenografts developed at least one or more metastases.  LT-staining of primary 
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xenograft tumors was confirmed for at least one mouse per treatment group, per cell 
line (data not shown).  Metastatic lesions also stained positive for LT, confirming a MCC 
origin (Figures 49 and 50). 
MCC metastases occurred in the liver of 18/117 mice with MKL-1 xenografts; this 
subset corresponds to 27% of MKL-1-injected mice that survive past day 25.  Diameters 
of metastatic lesions were highly variable.  In 9/117 instances, liver metastasis resulted 
in distress requiring euthanization of mice before primary tumor diameters of 20mm 
were measured (Figure 48A, marked by open circles).  Both MKL-1 xenograft primary 
tumors (Figure 49A-B) and liver metastases (Figure 49C-D) contain nuclear staining 
for MCV-LT.  Dual MKL-2 metastases occurred along the urogenital tract in 1/20 mice 
with separate lesion diameters of 12mm and 13mm.  LT-staining in urogenital 
metastases was similar to staining of MKL-2 xenograft primary tumors (50A-D).  MKL-2-
derived MCV-LT is truncated prior to the nuclear localization signal (265), thus staining 
for LT is not restricted to the nucleus as with MKL-1 or MS-1.  In one instance, a MS-1 
primary tumor regressed spontaneously under saline treatment for more than 5 weeks 
(Figure 48B, marked by x), but autopsy revealed a 3mm-diameter subcutaneous 
metastasis on the abdomen.  This metastasis was confirmed to stain for MCV-LT, 
similar to MS-1 xenograft primary tumors (Figure 50E-H).  Local invasion to 
surrounding tissues within the abdominal cavity, resulting in tumors of ~30mm diameter, 
was also observed in three MS-1 xenografts.  WaGa xenograft primary tumors stain 
positive for LT (Figure 50I-J).  WaGa-derived MCV-LT is truncated within the NLS thus 
staining of LT is not restricted to the nucleus.  WaGa-injected mice did not develop any 
metastases.  
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Figure 49. Immunohistochemistry of MCV LT in a MKL-1 xenograft tumor and liver 
metastasis 
Shown are paired hemotoxylin & eosin (H&E) stained slides and adjacent sections stained with 
CM2B4, the MCV-LT antibody (LT-IHC), in mice with MKL-1 xenografts: (A) MKL-1 xenograft 
primary tumor, H&E; (B) MKL-1 xenograft primary tumor, LT-IHC; (C) MKL-1 xenograft liver 
metastasis, H&E; and (D) MKL-1 xenograft liver metastasis, LT-IHC.  MKL-1 cells contains 
nuclear staining of LT, consistent with an intact nuclear localization signal (NLS).  Original 
magnification = 200X; insets = 600X. 
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Figure 50. Immunohistochemistry of MCV LT in various MCC xenograft tumors and 
metastases 
Shown are paired hemotoxylin & eosin (H&E) stained slides and adjacent sections stained with 
CM2B4, the MCV-LT antibody (LT-IHC), in mice with MCC xenografts: (A) MKL-2 xenograft 
primary tumor, H&E; (B) MKL-2 xenograft primary tumor, LT-IHC; (C) MKL-2 xenograft 
urogenital metastasis, H&E; (D) MKL-2 xenograft urogenital metastasis, LT-IHC; (E) MS-1 
xenograft primary tumor, H&E; (F) MS-1 xenograft primary tumor, LT-IHC; (G) MS-1 xenograft 
subcutaneous metastasis, H&E; (H) MS-1 xenograft subcutaneous metastasis, LT-IHC; I) 
WaGa xenograft primary tumor, H&E; and (J) WaGa xenograft primary tumor, LT-IHC.  MS-1 
cells contain nuclear staining of LT, consistent with an intact nuclear localization signal (NLS).  
Both MKL-2 and WaGa lack an intact NLS, thus LT staining is not restricted to the nucleus.  
Original magnification = 200X; insets = 600X. 
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C.3.5 Combination drug treatments with YM155 act additively, but not 
synergistically, to reduce MCC cell line viability in vitro 
YM155 was tested alone (Figure 51A) and in combination with other chemotherapeutic 
agents to identify a treatment strategy that may kill MCC cells synergistically.  
Bortezomib, docetaxel, carboplatin, etoposide, and topotecan were tested alone or in 
combination with a fixed concentration of YM155 (Figure 51B-I). Bortezomib is a 
proteasomal inhibitor that has been shown previously to efficiently kill MCC cells at sub-
micromolar concentrations (232).  However, primary human fibroblasts, BJ, are also 
efficiently killed by bortezomib treatment (Figure 51B-C).  Docetaxel was previously 
tested in melanoma xenografts with YM155 to induce cancer-specific mitotic 
catastrophe and cell death (415).  Docetaxel treatment does not decrease cell viability 
of MCC cell lines (Figure 51D-E).  Carboplatin, a platinum-based chemotherapeutic, 
also does not decrease cell viability of MCC cell lines (data not shown). Etoposide, a 
topoisomerase type II inhibitor, with or without carboplatin (data not shown), decreases 
cell viability of MCC cell lines at micromolar concentrations (Figure 51F-G).  Topotecan, 
a topoisomerase type I inhibitor, decreases cell viability at sub-micromolar 
concentrations (Figure 51H-I).  However, none of these chemotherapeutic agents 
decrease cell viability of MCC cells in a synergistic manner when combined with 
YM155—the effect is merely additive.  
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Figure 51. Various chemotherapeutics induce MCC cell death in an additive, but not 
synergistic manner, when combined with YM155 in vitro 
CellTiter-GLO assays were performed using multiple MCC cell lines as well as the control 
primary human fibroblast, BJ.  Corresponding EC50 curves are shown for the following 
chemotherapeutic agents and drug combinations: (A) YM155; (B) Bortezomib; (C) Bortezomib + 
3nM YM155; (D) Docetaxel; (E) Docetaxel + 3nM YM155; (F) Etoposide; (G) Etoposide + 3nM 
YM155 (H) Topotecan; and (I) Topotecan + 3nM YM155.   
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C.4 DISCUSSION 
In this study we assessed the sensitivity of four MCV-positive MCCs to YM155.  Three 
of the four xenografts responded to YM155 treatment.  YM155 efficacy is enhanced by 
extending the duration of treatment as well as by increasing YM155 dosage.  However, 
the degree of YM155 efficacy is cell line dependent.  Response to YM155 in vivo 
reflects YM155 response in vitro (Figure 51A); WaGa and MKL-2 xenografts respond to 
YM155 treatment intermediately to MKL-1 and MS-1 when assessing in vivo estimated 
survival data between YM155 double-dose treatment and saline treatment and they also 
have intermediate EC50 values determined from in vitro cell viability data (Figure 51A).  
MKL-1 is the most sensitive to YM155 both in vivo and in vitro, whereas MS-1 is the 
least sensitive to YM155 in vitro and does not respond to YM155 in vivo.   
For MCC xenografts, regression, growth rate, and even metastatic escape are 
highly cell line dependent.  Liver metastasis was only observed with MKL-1 xenografts, 
and metastasis was only observed after survival was significantly prolonged with YM155 
treatment.  While WaGa does not undergo regression or even tumor shrinkage upon 
YM155 treatment, survival was significantly prolonged relative to saline treatment owing 
to a reduced tumor growth rate.  Why MCC xenografts stop responding to YM155 
treatment and what determines overall response to YM155 for a given MCC cell line 
remains unknown.   
Previous studies using MCV-positive MCC cell lines identified bortezomib as a 
potent in vitro chemotherapeutic, but not in vivo (232).  Topoisomerase type I and type II 
 207 
inhibitors were also shown to induce death of MCC cell lines (232). Although we again 
verified in vitro efficacy of bortezomib, etoposide, and topotecan, none of these agents 
act synergistically with YM155 treatment—the effect is only additive.  However, this may 
not exclude the possibility that combination therapy of topoisomerase inhibitors with 
YM155 will prove beneficial in future studies.   
YM155 administered by single daily I.P. injection has a maximum-tolerated dose 
of 4mg/kg.  No toxicity was observed at the 2mg/kg dose (Figure 47B).  In the clinic 
YM155 is administered by continuous intravenous (I.V.) injection and is tolerated up to 
8mg/kg (416).  YM155 has previously been shown to have a 50% clearance by 12 
hours from a single injection (417), whereas continuous injection maintains YM155 in 
the circulation for an extended period of time (416). Continuous injection also seems to 
alleviate the degree of toxicity observed at higher doses of YM155 (400).  Combining 
these facts with the notion that YM155 was tested in our studies using severely 
immunocompromised mice, we are optimistic that YM155 treatment will be met with 
greater success in the clinic.   
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